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This thesis is presented in two parts. The first is concerned with the 
management of patients undergoing repair of hip fracture while the second part 
describes a randomised controlled trial examining analgesic options after total 
hip replacement. 
Musculoskeletal disease has the fourth greatest impact on the health of the 
world’s population (when both death and disability are considered) and is the 
second most common cause of disability globally (1-3). Disability due to 
musculoskeletal disease has risen by 45% over the last 20 years compared to the 
33% average increase seen across other disease groups.  This is likely to increase 
unless action is taken to resolve some of the problems.  This has been recognised 
by The European Parliament Leading Committee on the Horizon 2020 Programme 
(the European Union Research Framework Programme) resulting in the 
identification of rheumatic and musculoskeletal conditions as a priority for 
research over the next 7 years (4). 
Glasgow Royal Infirmary is a tertiary referral centre for orthopaedic and trauma 
surgery undertaking a high volume of both elective and emergency procedures 
each year.  I wished to investigate current standards of care relating to patients 
undergoing emergency surgery and to establish whether by benchmarking our 
practice against national data, we could identify areas for improvement. Hip 
fracture repair was chosen for analysis as it is a common, serious and costly 
condition that occurs in an increasingly elderly, frail and dependent patient 
population (5-7).  Hip fracture is a worldwide concern and a significant public 
health challenge.   
Important patient outcomes such as time to theatre, 30 day mortality and length 
of stay were analysed and compared against national audit data (8).  These data 
compared favourably.  Prior to commencing this work, staff members were 
asked to communicate any opportunities they saw for care to be improved.  
Certain sub-populations were identified by staff as meriting particular attention.  
These were patients admitted to ICU and patients taking warfarin. The sub-
population of patients who were taking warfarin and required admission for 
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repair of hip fracture were particularly frail and resulted in a number of 
management challenges for staff.  A quality improvement endeavour was 
employed in order to standardise management, reduce confusion, expedite time 
to theatre and ensure adequate thromboprophylaxis throughout the peri-
operative period.  This work resulted in the production of a protocol to guide 
management and is subject to ongoing review and audit. 
The role of anaesthesia in the performance of elective total hip replacement 
surgery was also investigated.  Total hip replacement is one of the most 
commonly performed surgical procedures in the United Kingdom, can result in 
improved quality of life, and is considered to be cost effective (9).  In Glasgow 
Royal Infirmary, anaesthesia is most commonly performed using spinal 
anaesthetic with the addition of an opioid.  Spinal opioids, whilst effective, are 
associated with side-effects of which the most serious is respiratory depression.  
Other adverse effects such as pruritus and nausea and vomiting may delay 
recovery and impact upon a patient’s satisfaction with their experience.  I 
carried out a randomised controlled, double blinded trial to assess whether a 
regional anaesthetic technique (ultrasound guided fascia iliaca block) could be 
used as an alternative to spinal morphine.  This technique has not yet been 
assessed clinically in the published literature, though it has shown promise as 
being more reliable when compared to the landmark based technique (10).  A 
non-inferiority design was employed in order to compare these two techniques.  
The primary outcome was 24 hour intravenous morphine consumption.  After 
obtaining the necessary approvals from the West of Scotland Research and Ethics 
Committee and the West of Scotland Research and Development Department, 
recruitment was commenced in May 2011.  Peer review was received from a 
journal of trial methodology and the protocol was published (11).  Further peer 
review and funding was received from the European Society for Anaesthesia and 
Pain Therapy as well as a local peri-operative research fund.  
This study shows that ultrasound guided fascia iliaca block is not non-inferior to 
spinal morphine, or in other words, that ultrasound guided fascia iliaca block is 
unacceptably worse than spinal morphine in the provision of analgesia after hip 
replacement.  Adverse effects were not statistically significantly different 
between groups and reassuringly, there were no episodes of respiratory 
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depression or sedation in either group.  This study has clear implications for 
practice and would suggest that spinal morphine remains an effective 





 NHS GG+C Learning and Education Bursary Scheme 2014-2015, £1250.  
July 2014. 
 Intrathecal opioid versus fascia iliaca block for analgesia after primary hip 
arthroplasty, £3000.  Perioperative Research Trust Fund.  Co-applicant 
with Dr A Macfarlane, Dr K Anderson and Professor J Kinsella.  April 2011. 
 Intrathecal opioid versus fascia iliaca block for analgesia after primary hip 
arthroplasty, 10,000 Euro.  European Society of Regional Anaesthesia and 
Pain Therapy.  Co-applicant with Dr A Macfarlane, Dr K Anderson and 
Professor J Kinsella.  March 2011. 
Publications 
 Kearns RJ, Moss L, Kinsella J.  A review of clinical practice guidelines for 
proximal femoral fracture. Anaesthesia 2013; 68: 159-66 
 Kearns RJ, Macfarlane AJR, Anderson KJ, Kinsella J.  Study Protocol: 
Intrathecal opioid versus ultrasound guided fascia iliaca plane block for 
analgesia after primary hip arthroplasty – a randomised, blinded non-
inferiority trial. Trials 2011; 12: 51.  http://dx.doi.org/10.1186/1745-
6215-12-51 
 Kearns RJ, Macfarlane A, Grant A, Puxty K, Harrison P, Shaw M, Kinsella J.  
Spinal opioid versus ultrasound guided fascia iliaca block for analgesia 
after primary hip arthroplasty: a randmoised, controlled, double blind, 
non-inferiority study, Submitted to The Lancet May 2015.  Under revision.  
Peer reviewed correspondence 
 Kinsella J, Kearns R.  Correspondence: Antibiotics for Community-





Cameron K, Kearns RJ, Kinsella J.  Hip fracture – comparing standards and 
investigating the role of critical care. Anaesthesia 2013; 68(10): 1090-3 
Presentations  
Presented at the Scottish Society of Anaesthetists Annual Conference, Crieff, 
May 2013. 
 Cameron K, Kearns R, Kinsella J.  Hip fracture – a comparison with 
national data. 
 Cameron K, Kearns R, Kinsella J.  The role of the ICU in hip fracture care. 
 Cameron K, Kearns R, Kinsella J. The peri-operative management of 
warfarin in patients admitted with hip fracture. 
Accepted for presentation at the American Society of Anaesthetists Conference, 
San Diego, October 2015. 
 Kearns RJ, Macfarlane A, Anderson K, Shaw M, Kinsella J.  Ultrasound 
guided fascia iliaca block versus spinal morphine for analgesia after total 
hip arthroplasty. Choice and interpretation of statistical approach in a 
non-inferiority study. 
 Kearns RJ, Macfarlane A, Grant A, Puxty K, Harrison P, Anderson K, 
Kinsella J.  Analysis of the primary outcome for the study: Ultrasound 
guided fascia iliaca block versus spinal morphine for analgesia after total 
hip arthroplasty. 
 Kearns RJ, Macfarlane A, Grant A, Puxty K, Harrison P, Anderson K, 
Kinsella J.  Analysis of secondary outcomes for the study: Ultrasound 
guided fascia iliaca block versus spinal morphine for analgesia after total 
hip arthroplasty. 
 Kearns RJ, Shaw M, Kinsella J.  Linear regression modeling as a tool to 




 Kearns RJ, Cameron K, Glennie S, Kinsella J.  The introduction of a 
protocol to guide the management of patients on warfarin requiring repair 



















Definitions / Abbreviations 
 
AAGBI  Association of Anaesthetists of Great Britain and Ireland  
ACC/AHA The American College of Cardiology and American Heart Association  
ACCP  American College of Chest Physicians 
AIC  Akaike's Information Criterion  
ASA  American Society of Anesthesiologists 
AMT  Abbreviated Mental Test score  
APTT  Activated Partial Thromboplastin Time  
BCSH  British Committee for Safety in Haematology 
BMI  Body Mass Index 
BPT  Best Practice Tariff 
CACI  Charlson Age Co-morbidity Index  
CEA  Continuous epidural analgesia 
CFNB  Continuous femoral nerve block 
CI  Confidence Interval 
CLPB  Continuous lumbar plexus block 
COTE  Care of the Elderly 
CT  Computed tomography 
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DALY  Disability-Adjusted Life Year   
DBP  Diastolic Blood Pressure 
DLA  Disability Living Allowance  
DVT  Deep Venous Thrombosis 
ED  Emergency Department 
FFP  Fresh Frozen Plasma 
FNB   Femoral nerve block 
GA  General Anaesthesia 
GP  General Practitioner 
GRI  Glasgow Royal Infirmary 
HALE  Healthy Life Expectancy  
HipPeN The Hip Fracture Peri-operative Network 
Hz  Hertz 
INR  International Normalised Ratio 
LA  Local anaesthetic 
LMWH  Low Molecular Weight Heparin 
LPB  Lumbar plexus block 
mA  milli ampere 
mcg  micrograms 
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MHRA  Medicines and Healthcare products Regulatory Authority 
NHFD  National Hip Fracture Database 
NCEPOD National Confidential Enquiry into Perioperative Outcome and 
Death 
NHS  National Health Service 
NICE  National Institute for Health and Care Excellence 
NNH  Number needed to harm 
NHFS  The Nottingham Hip Fracture Score 
OA  Osteoarthritis 
OR  Odds ratio 
PCA  Patient controlled analgesia  
PCC  Prothrombin complex concentrates 
PE  Pulmonary Embolism 
PFF  Proximal femoral fracture 
PNS  Peripheral nerve stimulator 
POSSUM The Physiological and Operative Severity Score for the enUmeration 
of Mortality and Morbidity  
PT  Prothrombin Time  
QALY  Quality Adjusted Life Years 
QoL  Quality of Life 
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RA  Regional Anaesthesia 
RCoA  Royal College of Anaesthetists 
RCRI  Revised Cardiac Risk Index 
RCT  Randomised controlled trial 
RR  Relative Risk 
RRR  Relative Risk Reduction 
RhA  Rheumatoid Arthritis 
SD  Standard Deviation 
SHFA  The Scottish Hip Fracture Audit  
SAB  Subarachnoid block 
SIGN  Scottish Intercollegiate Guidelines Network 
SBP  Systolic Blood Pressure 
THA  Total Hip Arthroplasty 
UFH  Unfractionated Heparin 
UK  United Kingdom 
US  United States of America 
USG  Ultrasound guided 
VQ  Ventilation-perfusion 
VTE  Venous Thromboembolism 
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WHO  World Health Organisation 
WMD  Weighted mean difference 
 YLL  Years of Life Lost 
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1.1 The ageing population and societal expectations on 
health care delivery 
It has long been established that the world’s population is ageing.  Average life-
span continues to increase and there are now a greater number of older people 
living around the world than at any other time in history.  In around 5 years time 
it is predicted that the worldwide over 65 population will out-number the under 
5 age group for the first time (12). This is due to a combination of factors 
including reduced levels of fertility and increased longevity.  Such population 
growth is expected to continue and even accelerate over the next few decades 
with the over 65 population predicted to increase from 524 million in 2010 to 1.5 
billion by 2050.  Indeed, the over 85 category is the fastest growing demographic 
with numbers projected to rise by 351% between 2010 and 2050 (12). 
 
Figure 1.1-1 - Young children and older people as a percentage of the global population 
1950 - 2050.  Available at: http://esa.un.org/unpd/wpp (12). 
 
In Scotland, a similar picture is seen.  A report published by the Scottish 
Executive in 2007 summarises the demographic changes seen in the Scottish 
people over the past century and predicts what is likely to happen over the next 
30 years (13). In 1900 the average Scottish life expectancy was 40 years, whilst 
in 2004 it was just over 74 years for males and 79 for females.  By 2031, the 
number of people aged over 50 is projected to rise by 28% and the number aged 
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over 75 years by 75% (13). A further report issued by National Statistics for 
Scotland in 2010 further highlights the change in age distribution seen in the 
Scottish population over the last decade (2000 - 2010) (14).  An increase is seen 
in each of the three oldest age groups (+14% in the 45-59 age group, +13% in the 
60-75 and +14% in the >75 age group).  A decrease of 7% is seen in the youngest 
age category of 0 - 15 years (14). 
 
Figure 1.1-2 - The changing age structure of Scotland’s population, 2000 - 2010. 
(15)  Reproduced under the terms of the Open Government License. (C) Crown copyright. Data 
supplied by National Records of Scotland. 
 
Whilst an increase in life-span is a welcome development, ageing does not occur 
without co-morbidity. Although improvements in hygiene and the effective 
treatment of communicable diseases (such as infection and parasites) has done 
much to reduce the death rates of the younger population, there has been an 
increase in the prevalence of non-communicable diseases such as heart disease, 
diabetes, cancer and arthritis. Older people are generally more likely to suffer 
from such chronic, often complex, conditions requiring long-term management 
with consequent increased per capita health expenditure. This population is also 
more likely to be admitted to hospital acutely as a result of such conditions as 
well as other afflictions of ageing such as falls and associated injury.  The 
economic cost associated with chronic conditions is enormous.  A World Health 
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Organisation (WHO) study estimated that the cost of managing just three chronic 
illnesses (heart disease, stroke and diabetes) in 23 low / middle income 
countries would amount to $84 billion over a 9 year period (12).  
In the United Kingdom (UK), a report by the audit commission confirms that 
unscheduled hospital admissions are increasing year on year within the National 
Health Service (NHS) (16). According to a 2012 Royal College of Physicians 
report, 65% of all UK hospital admissions are accounted for by the over 65 
demographic (17).  Each acute admission is estimated to cost in the region of 
£470 (18).   In Scotland, older people have a higher demand for surgical 
procedures.  A Report by the Scottish Executive published in 2006 reported the 
rate of elective admissions in the over 65 years category to be 235 per thousand 
population compared with 90 per thousand population in the under 65 age group 
(19). Similarly for emergency cases, the annual number of admissions for 
patients aged 85 and over increased four-fold between 1981 to 1999 and has 
continued to increase since (19).  
An increase in the older demographic decreases the proportion of people in the 
workplace as well as placing unprecedented demands upon healthcare, social 
care and social security resources. If such increasing demands are to be met, 
societal and economic adaptation must occur.  The need to reconfigure 
healthcare systems to account for this changing demographic has been 
recognised for some time.  In 2002, The Wanless Report suggested that the 
United Kingdom was falling behind other countries in terms of the quality of 
healthcare provided and needed to prepare for the demands of an ageing 
population within a sustainable, publicly funded service (20). These themes have 
continued in the initiatives of subsequent governments.  Such concerns co-exist 
with the inexorable advance of medical technology and the increasing capability 
to treat previously untreatable conditions.  Resources are therefore scarcer than 
ever and more information is required to determine which interventions, in 
which populations, exhibit the most value for money.  The development of the 
economic downturn and world-wide recession serve to highlight that healthcare 
resources are limited and must be used in the most efficient way possible if 
benefits are to be maximised.   
Chapter 1  31 
As well as the successful treatment of illness, it is vital that the disability 
associated with disease is reduced and that the number of people living out their 
older years with independence and acceptable quality of life is maximised.  This 
is challenging in a number of ways.  From a societal perspective, changes in 
lifestyle such as reduction in number of offspring, increased divorce levels, non-
marriage, increase in the proportion of female offspring undertaking full-time 
employment, rise in emigration, and growing financial pressures, have a 
negative impact in the ability to provide traditional family-based care.  This has 
implications for the state in terms of the provision of alternative forms of care.  
In contrast, as our average life expectancy increases, so might our ability to 
work to an older age.  This is not reflected in the current retirement age which 
has remained relatively constant.  While there are many misconceptions about 
ageing, it is recognised that the expertise, experience and skill-set exhibited by 
an older workforce has much to add to the workplace.  Increasing activity into 
old age may also help to prevent cognitive decline (12).  Old age must not be 
seen as a term interchangeable with ill health but should be seen as additional 
years with which to enjoy life and contribute to society (13).  The ability to live 
out one’s later years in a healthy fashion is something to which we can all 
aspire. 
 
1.2 The global burden of disease 
Disability is the common end point of a variety of chronic diseases and can 
greatly influence quality of life.  In this last century, there has been a transition 
from disease-related mortality, to disease-related disability throughout 
remaining years of life.  The ability to accurately and consistently describe the 
diseases and risk factors associated with disability is of great importance in the 
planning of healthcare, future research and allocation of resources. The WHO 
Global Burden of Disease group has performed the largest ever analysis of the 
health effects related to disease and injury on a worldwide scale over the past 
20 years (1-3;21-24). This has resulted in a comprehensive estimate of mortality, 
morbidity and disability by age, sex, and region for a wide range of diseases.   
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The most recent report from this group is formatted as a collection of seven 
articles and was published in The Lancet in December 2012 (1-3;21-24). Each 
report focuses on a different aspect of the enormous volume and scope of data 
collected   
In summary, the findings of this large volume of work with regard to 
musculoskeletal disease specifically are as follows: Musculoskeletal disease has 
the fourth greatest impact on the health of the world’s population (when both 
death and disability are considered) and is the second most common cause of 
disability globally.  Osteoarthritis is the fastest growing health condition as a 
result of the ageing population, obesity and falling levels of physical activity.  
Disability due to musculoskeletal disease has risen by 45% over the last 20 years 
compared to the 33% average increase seen across other disease groups.  This is 
likely to increase unless action is taken to resolve some of the problems.  This 
significant burden of disease has been recognised by The European Parliament 
Leading Committee on the Horizon 2020 Programme (the European Union 
Research Framework Programme).  This programme, which determines European 
Union funding for research from 2014 to 2020, has identified rheumatic and 
musculoskeletal conditions as a priority for research over the next 7 years (4).  
In the United Kingdom (UK), the extent of this problem was depicted in a 
prospective 2 year study performed by the Medical Research Council in 2006.  
This work aimed to determine the onset of disability (defined as requiring help 
from another person at least several times a week and by dependency in 
activities of daily living) in the over 65 demographic in five areas throughout 
England and Wales (25).  Data on those who were eligible to receive a disability 
living allowance (DLA) served as a marker of those who were the most severely 
disabled. DLA was a benefit for people who had personal care needs, mobility 
needs or both before their 65th birthday. The most common condition resulting 
in people receiving DLA was ‘arthritis’, representing 18% of all recipients.  This is 
equivalent to half a million people aged less than 65.  A further 7% of people 
received DLA for muscle / bone / joint disease. This represents an expenditure 
of around £48 million each week for arthritis and muscle  / bone / joint disease 
combined (25).  
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1.3 Femoral pathology in adults. Why is it associated with 
ageing? 
Bone deteriorates in structure, composition and function with increasing age. 
The development of arthritis, osteoporosis and consequent fracture occurs as a 
result of such deterioration, accompanied by the “wear and tear” accumulated 
throughout life.   
1.3.1 Osteoporosis 
Osteoporosis is a disorder of the skeleton characterised by low bone mineral 
density and subsequent bone fragility. Bone is a hard material which is in a 
constant state of flux. Bone formation by osteoblasts is predominant in 
childhood and adolescence, while bone resorption performed by osteoclasts 
increases with age (26). Minerals essential to the formation of new bone include 
calcium and phosphate.  Deficiencies in these minerals, due to inadequate diet 
or poor absorption, impair the formation of new bone and increase the risk of 
osteoporosis.  Bone mineral content decreases by around 4% per decade in males 
after the age of 20, and by 15% per decade in females after menopause (26).  
Secondary causes of osteoporosis include; malignancy, pharmacological agents 
(such as steroids), endocrine disorders, malnutrition, immobility, bone marrow 
dysfunction, renal disease and disorders of the gastrointestinal or biliary tract 
(27).  Work carried out by the WHO in 2004 estimated that the prevalence of 
osteoporosis among post-menopausal, white American women is 14% in those 
aged 50-59 years, 22% in the 60-69 years of age group, 39% in 70-79 year olds and 
70% in those aged 80 years and older (28).  In the UK, around 3 million people 
are thought to have osteoporosis (29).  
Deterioration in bone architecture leads to increased bone fragility and 
susceptibility to fracture.  It is estimated that the lifetime risk of fragility 
fracture related to osteoporosis is around 40% in women over 50 years of age 
(26).  This is particularly common in the bones of the wrist, spine and hip.  
There were an estimated 1.7 million hip fractures worldwide in 1990 and this is 
estimated to rise to 6 million by 2050 (26).  Surgical repair remains the most 
common management strategy for hip fracture with non-operative management 
usually reserved for those considered too frail for surgery.  Osteoporotic 
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fractures are increasingly common with age, result in disability, present a 
significant burden to healthcare systems, and are a major public health 
challenge.  The combined social and healthcare costs associated with the 
management of hip fracture in the UK alone is around £2.3 billion per year (29).  
1.3.2 Degenerative hip disease and osteoarthritis 
Degenerative hip disease occurs mostly as a result of osteoarthritis and 
rheumatoid arthritis. Other less common causes of degenerative hip disease 
include: Paget’s disease, avascular necrosis of the femoral head, Perthe’s 
disease, slipped upper femoral epiphysis and trauma.  Pain resulting from 
degenerative hip disease frequently becomes severe and is difficult to control 
using standard analgesics.  This can result in a loss of functional ability and 
hence independence.   
Osteoarthrtitis (OA) is defined as joint pain associated with functional limitation 
and reduced quality of life (30).  OA describes the degeneration of cartilage and 
bone within a joint with resultant tissue loss.  At the same time, proliferation of 
bone in the form of osteophytes occurs.  While this process aims to repair a joint 
after an insult, it may fail to achieve this and instead result in ongoing joint 
damage. This can culminate in pain and stiffness in a variety of joints most 
commonly knees, hips, hands and spine (31). OA may be considered Primary if 
occurring in the absence of anatomical, traumatic, metabolic, endocrine or 
neuropathic causes, or Secondary if such an abnormality is present (32).  Factors 
associated with the development of OA include genetic factors, female sex, joint 
laxity, occupations involving heavy lifting, elite sports and obesity (32;33).  OA is 
more common in Caucasians than in other ethnic groups such as Asians, Africans 
and Hispanics suggesting a significant genetic component (32). 
OA is common and is the most prevalent cause of walking related disability 
amongst the older population in the US (33).  According to data compiled by the 
US National Arthritis Data Work Group, OA affects 33.6% (12.4 million) of 
patients over the age of 65 (34). This equates to an estimated 26.9 million of all 
US adults in 2005, an increase from around 21 million in 1990 (34).  OA of the hip 
occurs in 88 per 100,000 patient years and increases with age (35).  In the UK, 
OA is thought to affect 8.5 million people (36). 
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Total Hip Arthroplasty (THA) is commonly performed in the treatment of pain 
and disability related to hip joint disease and is considered one of the most 
effective orthopaedic procedures in current practice. From data published in 
2011 by the UK National Joint Registry, 93% of patients undergoing hip 
replacement surgery require to do so as a result of osteoarthritis (37). 
 
1.4 The medical profession and the difficulties with this 
patient group.  
The management and care of elderly patients presents a specific challenge to 
the medical team, including the anaesthetist (5).  Age-related alterations in 
physiology, pharmacokinetics, pharmacodynamics, increased co-morbidity, 
polypharmacy, cognitive impairment and considerations relating to social 
circumstances result in the necessity for a careful and thoughtful management 
plan during any hospital admission. Elderly patients have reduced functional 
reserve when compared to younger patients (38). This can be thought of as a 
reduction in the gap between basal performance level (i.e. when the patient is 
at rest) and maximal performance level.  The requirement for a surgical 
procedure, whether elective or emergent, represents a further significant insult 
from which even the fittest of elderly patients may struggle to compensate.  
Older patients also have an increased incidence of post-operative complications 
(39;40).  Fluid shifts, hypoxia, infection, as well as transient peri-operative renal 
and cognitive impairment may all have more severe consequences in the elderly 
patient.  This can result in a prolonged and more turbulent recovery period.   
In a prospective cohort study of 594,911 American patients undergoing non-
cardiac surgery over the period 1991 to 1999, 30 day all cause mortality was 
found to be significantly increased in the subset of patients aged over 80 years 
(8% versus 3%, p<0.001). 20% of patients over 80 years had at least one post-
operative complication, and those who suffered such a complication had a higher 
30-day mortality than those who did not (26% versus 4%, P<.001) (39). A more 
recent US study analysing prospectively collected peri-operative data for 7696 
patients over the period 2002 to 2005, reported an overall 28% morbidity rate 
and 2.3% mortality rate.  This was increased to 51% and 7% respectively when 
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the over 80 age group were analysed separately. Post-operative morbidity and 
mortality were noted to increase progressively with advancing age. Age was 
statistically significantly associated with morbidity (wound p = 0.021, renal p = 
0.001, cardiovascular p = 0.0004, respiratory p < 0.0001) and mortality (p = 
0.001) (40).  
Careful, thoughtful pre-operative assessment and optimisation of elderly 
patients is paramount if adverse events are to be minimised.  This is emphasised 
in a 2010 document by the National Confidential Enquiry into Peri-operative 
Outcome and Death (NCEPOD) examining peri-operative care in the elderly 
population within the UK (excluding Scotland) (41).  This report aimed to;  
“explore remediable factors in the processes of care of patients aged 
80 or older”  
Investigators reviewed notes relating to all patients aged ≥ 80 years who died 
within 30 days of a surgical procedure.  This was performed over a two month 
period in 2008.  Surgeons, anaesthetists and organisations involved in the care of 
each patient were required to complete a questionnaire examining events 
relevant to the case.  All documents pertaining to each of the 1120 identified 
cases were then anonymised and reviewed by external advisers.  The majority of 
patients (83.4%) were admitted as an emergency and had an American Society of 
Anesthesiologists (ASA) score of 3 or more (84%) signifying severe systemic 
illness.  The most common surgical procedure performed was repair of proximal 
femoral fracture (37.9% of cases).  Of all patients with sufficient data for 
analysis (n=740), around 30% (220/740) died within the first three days of the 
procedure and 52% (385/740) died within one week of the operation.  Of notable 
concern was that only 37.5% of patients (295/786) were considered to have 
received good care with 43.6% (343/786) assessed as having room for 
improvement in either clinical or organisational care.  6.4% (50/786) of patients 
were considered to have received care which was less than satisfactory (41). 
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Figure 1.4-1 - Overall assessment of care, NCEPOD 2010(41).   
Reproduced with permission from NCEPOD. 
 
High quality care of elderly patients often involves complex decision making 
processes highlighting the importance of multi-professional input (41).  The 
NCEPOD report makes a number of recommendations regarding appropriate care 
in this vulnerable patient group.  These include: the involvement of a multi-
disciplinary team, regular input from Care of the Elderly (COTE) physicians, 
recognition that co-morbidity, disability and general impression of frailty act as 
independent markers of risk in the elderly, avoidance of delays to theatre, 
appropriate assessment of nutritional status and cognitive impairment, 
avoidance of hypothermia, management of hypotension, adequate treatment of 
pain,  increased use of level 2 and 3 beds post-operatively, appropriate use of 
peri-operative monitoring including cardiac output monitoring, and necessity for 
consultant involvement (41).  
1.4.1 Frailty 
The concept of frailty is interesting and variably defined with nutritional, 
functional and medical components.  Frailty may be regarded as a state of 
reduced resistance to stressors (42).  This results in general decline and is 
associated with a high level of vulnerability for adverse outcomes such as 
disability, dependency, falls, need for long-term care and death (43-45). There 
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is no “best” definition of frailty and several scales and scoring systems have 
been proposed.  These are outlined in a 2008 review article examining the 
relationship between frailty and cardiovascular disease (44).  Weight loss, self-
reported exhaustion, weakness of grip, slow walking speed, physical inactivity, 
sensory loss, incontinence and depressive symptoms are included variably in such 
definitions (44). A 2004 consensus report from the Interventions on Frailty 
Working Group further refines the frailty phenotype as relating to a 
deterioration in: mobility, strength, balance, motor processing, cognition, 
nutrition, endurance and physical activity (46).  These markers may be used 
alongside the “end of the bed” clinical assessment often used in clinical 
practice.  The prevalence of frailty is therefore difficult to determine in view of 
the different definitions and variable populations studied.  However, early 
recognition of frailty as a risk factor for poor peri-operative outcome can be 
helpful in planning optimal pre-, intra- and post-operative care (41).  A multi-
disciplinary approach involving surgeons, anaesthetists, COTE physicians, nurses, 
physiotherapists, dieticians, occupational therapists, pharmacists, speech 
therapists and social workers is desirable if optimal care and good outcomes are 
to be achieved (5). 
1.4.2 Deprivation and “The Glasgow Effect” 
At this juncture, it is interesting to consider why the health of Scotland and 
more specifically, the population of Glasgow is poorer than that of the rest of 
the UK.  “The Glasgow Effect” is a term used to describe the phenomenon of 
poorer health and higher levels of mortality seen in Glasgow beyond that which 
might be expected due to poorer socio-economic circumstances (47).  Whilst the 
link between deprivation and poorer health related outcomes is well established 
(48), it is now thought that this does not account for all of the differences seen 
in outcomes between populations in different cities.  This concept was 
investigated by Walsh et al in 2010 (49).  These investigators compared rates of 
“income deprivation” (a measure known to be very highly correlated with UK 
indices of multiple deprivation) for small areas (average population size 1600) in 
Glasgow, Liverpool and Manchester.  Liverpool and Manchester were chosen as 
they are cities known to have high levels of poor health, deprivation and have 
the lowest life expectancy of all cities in England(50).  Standardised mortality 
ratios were calculated for Glasgow and compared to those seen in Liverpool and 
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Manchester. Results were standardised for age, gender and income deprivation.  
Despite all cities having almost identical levels of deprivation, premature deaths 
in Glasgow were > 30% higher [SMR 131.4, 95% confidence interval (CI) 128.6–
134.1] with deaths in all age groups around 14% higher (SMR 114.4, 95%CI 113.2–
115.5) (49).  Interestingly, childhood (0–15 years) mortality was significantly 
lower in Glasgow relative to Liverpool and Manchester (SMR 81.3, 95%CI 71.2–
91.3).  Therefore the biggest excess of deaths were seen in adults of working age 
(15-64 years). The additional mortality was seen in both male and females 
(although was more marked in males) and across the entire spectrum of 
affluence and deprivation.  In deaths considered to be premature, alcohol and 
drugs were found to account for around 50%.  When cause of death was 
considered, Glaswegians had significantly higher rates of lung cancer (27%), 
suicide (70%), alcohol related causes (2.3 times higher) and drug related causes 
(2.5 times higher).  The authors calculated that there were more than 4500 
excess deaths in Glasgow over a 4 year period when compared to Liverpool and 
Manchester despite all cities exhibiting almost identical levels of deprivation.  
These findings of poorer health and increased mortality in Scotland, even after 
correction for socio-economic status, have also been noted by other 
authors(49;51;52).    
The reasons for these differences remain unclear.  Walsh et al postulated that 
they may be due to undetected differences in deprivation not captured by the 
indices analysed (which rely on information about benefits claims as well as 
other databases).  They also explore the possibility that the socio-economic 
status of Glasgow has changed in recent years with higher levels of deprivation 
in the past still yielding effects but not being detected on analysis of up to date 
data.  However, their analysis of historical data makes this theory seem unlikely.  
Another theory centres on Glaswegians having more extreme “adverse health 
behaviours” (i.e. smoking, drinking to excess, drug abuse and poor eating habits) 
than English people of similar socio-economic groupings.  However, the authors 
did not have sufficient data to make this conclusion and remarked that further 
analysis would be required to explore this further.  Other postulated theories to 
explain the “Glasgow Effect”include: the breakdown of social and moral norms 
leading to increased instances of “self-destructive behaviours”, genetic factors, 
cultural differences, the effects of migration and the breakdown of the family 
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unit.  Further investigation of these factors is ongoing but as yet, no clear 
explanation for this effect has been found (53-55).   
1.5 Peri-operative risk stratification  
Peri-operative morbidity is associated with prolonged hospital stay, poorer 
surgical outcome and reduced long-term survival.  Systems to estimate peri-
operative risk may be desirable in providing useful information to patients and 
families, obtaining informed consent from patients, planning interventions to 
minimise risk, utilising resources most effectively and allowing comparisons 
between units and countries.  Various scoring systems have been developed to 
this end.  An ideal risk prediction score is accurate, simple, reproducible, cheap, 
devoid of the need for expensive equipment and easily available.  
Existing risk prediction scores include the American Society of Anesthesiologists’ 
(ASA) Physical Status Score (56), the Revised Cardiac Risk Index (RCRI) (57), The 
Charlson Age Comorbidity Index (CACI) (58), The Physiological and Operative 
Severity Score for the enUmeration of Mortality and Morbidity (POSSUM) (59) and 
The Nottingham Hip Fracture Score (60). 
The ASA score is a widely used scoring system consisting of six categories which 
is simple to perform, useful for predicting outcome in a population and valuable 
for audit and research purposes.  Whilst the ASA classification has stood the test 
of time and remains widely used, it has a number of limitations and is not useful 
as a tool for predicting risk in individual patients.  The RCRI is used for the 
estimation of peri-operative risk in patients undergoing non-cardiac surgery (61). 
It should be highlighted that the RCRI is designed for predicting adverse peri-
operative cardiac events and is not a tool for predicting peri-operative morbidity 
and mortality from all causes.  Cardiac events account for only a small 
proportion of post-operative complications thus limiting the role of the RCRI to a 
specific sub-set of patients. The Charlson Age Co-morbidity Index (CACI) is used 
to predict the 10 year mortality for a patient who may have a variety of co-
morbidities.  The CACI relies upon patient self-reporting of co-morbid conditions 
and does not incorporate surgical information, both of which can limit its 
effectiveness as a predictive tool. The Physiological and Operative Severity Score 
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for the enUmeration of Mortality and Morbidity (POSSUM) was developed by 1991 
as a scoring system for surgical audit (59).   
The POSSUM score has been evaluated in orthopaedic surgery using a modified 
equation to allow for orthopaedic operations (62).   An analysis of 2236 elective 
and emergency patients over a 12 month period in a single centre was 
performed.  The POSSUM logistic regression equations yielded an overall 
predicted mortality of 53 patients (versus 51 observed) and a predicted 
morbidity in 254 patients (versus 252 observed).   Given the close correlation 
between predicted and observed events, the authors concluded that the POSSUM 
score was a useful audit tool with which to assess the quality of orthopaedic care 
(62). 
Further to this work, the POSSUM score was evaluated in 1164 patients who had 
sustained a hip fracture over a 21 month period in a single centre (63).  The 
POSSUM score was found to over-predict death overall with 181 predicted versus 
119 observed.   The area under the receiver operating curve was 0.62 indicating 
that the POSSUM score was a poorly predictive test in this patient group (63).  To 
put this into context, the area under the receiver operating curve in the analysis 
of general orthopaedic patients was >0.85 (62).  Possible reasons for this were 
felt most likely to relate to the physiological variables inputted (as the surgical 
data were fairly similar in patients undergoing this type of surgery).  An 
argument was made that as the population sustaining fractured hips is generally 
very elderly, some of the physiological variables considered to put patients “at 
risk” using the scoring system, were more likely to be within a “normal range” 
for this particular population.  Also, the way in which items were weighted was 
felt to be less appropriate for the elderly demographic, with other variable such 
as haemoglobin and albumin considered as being potentially useful as markers of 
risk (these are not included in the POSSUM scoring system).  The authors 
concluded that the POSSUM score was not suitable for risk prediction or 
comparison of outcomes in patients undergoing surgery for proximal femoral 
fracture (63).  Despite its limitations, the POSSUM score (and its variations) 
remain a useful tool for predicting individual patient risk in the peri-operative 
period.   
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1.5.1 The Nottingham Hip Fracture Score 
The Nottingham Hip Fracture Score (NHFS) is a summative assessment tool 
designed specifically to predict post-operative mortality in patients undergoing 
surgical repair of hip fracture.  This provides the anaesthetist with objective 
information which can be used in planning the most appropriate pre-, intra- and 
post-operative management, as well as to inform patients and relatives of 
potential outcomes in this particularly frail group.   
The NHFS score was developed using a prospectively gathered dataset of 4967 
patients undergoing repair of hip fracture in a single centre over a seven year 
period (1999 - 2006) (60).  Univariate logistic regression analysis was performed 
on all potential variables (identified from published research as being potentially 
influential upon outcome) in order to select those which were predictors of 
mortality at 30 days.  An automated, stepwise, forward multivariate, logistic 
regression analysis was then applied to each independent variable in a subset of 
patients (approximately half of the dataset) in order to create the score.   After 
the score had been constructed, its validity was assessed against a further subset 
of patients (the other half of the dataset).  The variables found to be 
independent predictors of 30 day mortality on multivariate logistic regression 
analysis were age (66–85 and ≥86), sex (male), number of co-morbidities (≥2), 
mini-mental test score (≤6 out of 10), admission haemoglobin concentration (≤10 
g/dl), living in an institution and presence of malignant disease.  Calculation of 
the Hosmer–Lemeshow goodness-of-ﬁt statistic showed that there was good 
concordance between observed and predicted deaths at 30 days (Chi2 test, 
P=0.79) (60).  
The Hosmer-Lemeshow statistic divides cases into 10 groups according to 
increasing score values, and compares the predicted with the observed death 
rates.  A lack of difference between predicted and the observed mortality 
indicates good concordance of the score (64). “Goodness-of-ﬁt” tests are 
considered to have more relevance as an evaluation of scoring systems 
concerned with risk. This is because they assess how well the score predicts 
outcome for bands of risk.  When a Receiver Operating Curve (ROC) was 
calculated, the area under the curve was 0.719.  This makes the NHFS superior 
to the POSSUM score when applied to patients with hip fracture (63), though 
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inferior to the POSSUM score when applied to the general orthopaedic population 
(62).  
Variable         Points 
Age 66 – 85 years        3 
Age ≥ 86         4 
Male          1 
Haemoglobin concentration ≤ 10g/dl on hospital admission                         1 
Abbreviated mental test score ≤ 6/10 on hospital admission               1 
Living in an institution         1 
More than one co-morbidity        1 
Active malignancy within last 20 years                1 
Figure 1.5-1 - Calculation of NHFS (60). 
 
Further analysis of the NHFS was performed on data from 6202 patients over a 
ten year period (1999-2009) to evaluate its accuracy in predicting mortality at 
one year (65).  The seven item score (maximum score 10) was calculated for 
each patient and patients subsequently divided into high risk (score > 4) or low 
risk (score ≤ 4) groups.  Survival was signiﬁcantly higher in the low risk compared 
with the high risk group at 30 days [96.5% compared with 86.3% (P<0.001)] and 
at 1 yr [84.1% compared with 54.5% (P<0.001)].  One year survival in patients 
who survived beyond 30 days was also greater in the low risk group compared 
with the high risk group [87.1% compared with 63.1% (P<0.001)].  In the analysis 
of the effects of delay to surgery, a delay of > 48 hours was associated with an 
increased mortality at 1 yr of 31% compared with 26% (P<0.001).  As the 
mortality difference persisted even when those who died early were excluded, 
the authors concluded that pre-operative factors had an ongoing influence on 
mortality risk after hip fracture surgery.  The NHFS is therefore an accurate 
predictive tool in assessing mortality risk at one year after hip fracture surgery 
(65). 
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Figure 1.5-2 - Kaplan-Meier curve showing 1 year post-operative mortality after hip fracture 
surgery.  Low- and high risk groups have an NHFS of ≤ 4 and > 4 respectively (65).   
Reproduced with permission from Oxford University Press, (license no. 3111981497531). 
 
 
Figure 1.5-3 - Kaplan-Meier curve showing 1 year post-operative mortality in patients who 
survived 30 days after hip fracture surgery.  Low- and high risk groups have an NHFS of ≤ 4 
and > 4 respectively (65).   
Reproduced with permission from Oxford University Press, (license no. 3111981497531). 
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Further work from this group applied the NHFS to three geographically distinct 
sites in order to assess its applicability outside of its parent hospital.  Data from 
7290 patients were analysed for the outcome of 30 day mortality (66).  This was 
found to be 6.6% for the complete cohort though the NHFS was found to over-
estimate mortality in the higher risk groups.  Following a revision of the equation 
used to derive the score, the NHFS was found to calibrate well across data from 
all three sites confirming its status as a robust and useful tool for risk prediction 
(66).   
 
 
Table 1.5-1 - Calculated 30 day mortality using original and revised NHFS (66). 
Reproduced with permission from Oxford University Press, (license no. 3111980654030). 
 
The Nottingham Hip Fracture Score therefore provides a disease specific scoring 
system which is validated in the frail population for which it is intended and can 
be used to predict 30 day mortaility, 1 year mortality and functional outcome. 
Identification of high risk patients may allow for specific measures to be taken in 
terms of optimisation, use of invasive monitoring and cardiac output monitoring, 
involvement of senior personnel, expedition of surgery, information provision to 
relatives and use of critical care facilities as well as audit and quality 
improvement work.   
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1.6 Chapter 1 Summary 
 The world’s population is ageing. 
 While mortality levels have fallen, levels of morbidity and associated 
disability are rising. 
 Musculoskeletal disease has the fourth greatest impact on the health of 
the world’s population and is the second most common cause of disability 
globally. 
 This is associated with large costs in terms of health care and social 
support, and is an area of priority for the research community. 
 The elderly population requires special consideration in the peri-operative 
period and presents a number of challenges to health care professionals. 
 A number of scoring systems have been developed to help quantify peri-
operative risk.   
 The Nottingham Hip Fracture Score has been evaluated specifically in 
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Evidence to date – Emergency surgery for 
fractured femur 
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2.1 Burden to the NHS and expected projections  
Hip fracture is a common, serious and costly condition that occurs in an 
increasingly elderly, frail and dependent patient population (5-7).  This is a 
worldwide concern.  There were an estimated 1.6 million cases of hip fracture 
worldwide in 1990 and this is projected to surpass 6 million by 2050 (5;67).  
According to the findings of a recent systematic review examining the worldwide 
distribution of hip fracture, incidence can vary 10 fold between countries.  The 
United Kingdom was classified as a “high risk” country due to its high age-
standardised annual risk of hip fracture (68).  
 
Figure 2.1-1 - Age-standardised annual risk of hip fractures in women (/100,000) according 
to country (68). 
 Reproduced with permission from Springer, (license no. 3111990667214). 
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Data from the National Hospital Discharge Survey in the US estimates that hip 
fracture accounted for around 281,000 hospital admissions in adults over 65 
years of age in 2007 (69).  In the UK it is estimated that 70 000 – 80 000 cases of 
hip fracture occur annually, accounting for 1.5 million bed-days and resultant in-
patient costs of £0.785 billion (70-72). This is projected to rise to around 100 000 
cases in England alone by 2033 with an estimated associated cost of £3.6-5.6 
billion (73).  In Scotland, according to information from the Information Services 
Division, there were around 6266 cases of hip fracture in 2009 (74).  This figure 
has remained relatively constant over the preceding decade despite an ageing 
population. 
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Figure 2.1-2 - Hip fracture incidence in patients ≥ 65 years in Scotland (74). 
 
The vulnerability of this patient group is apparent in its associated prolonged 
length of hospital stay, complex care journey, ongoing care needs and high 
levels of morbidity and mortality (75).  Data from national audit suggest a 
consistent and persistent mortality rate of around 7-10% at one month and 30% 
at one year (8;71;76).  Hip fracture therefore results in significant levels of 
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financial and human expenditure and is a burgeoning public health challenge 
(73;77;78). Outcomes following hip fracture are used as a marker of the quality 
of healthcare across all the relevant disciplines. The peri-operative management 
of hip fracture is an important example of a challenging clinical area where 
evidence is lacking and practice varies (8). 
 
2.2 Emergency surgery – proximal femoral fracture 
Hip fracture is a serious injury which can result in severe pain and requires 
admission to hospital.  The consequences of a fractured hip can be devastating 
resulting in disability, reduced mobility and subsequent loss of independence.  
Many people who suffer this injury are unable to continue living in their own 
home and have to be cared for in alternative accommodation once the acute 
hospital admission is over.   
There is a time-pressure to operate on patients who have suffered a hip 
fracture.  Surgery is the optimal analgesic for these patients and therefore early 
repair has merits on a humanitarian level alone. Surgery remains the mainstay of 
treatment.  As it would be unethical to perform an RCT comparing expedited 
with delayed surgery in this vulnerable patient group, the majority of evidence 
is obtained from cohort studies and is of low quality. This is highlighted in the 
analysis of optimal time to theatre in the 2011 NICE guideline: Management of 
patients with hip fracture (79).  In this analysis, 10 studies with a total of 
193,793 participants were reviewed.  Analyses for 24, 36 and 48 hour time 
periods revealed significant improvements in morbidity (e.g. pressure ulcers), 
increased return to independent living and some evidence for reduction in 
mortality for early surgery.  It should be highlighted that the evidence was 
generally deemed to be of low or very low quality by the NICE assessors.  Despite 
the low quality of evidence, there was no observable benefit from delaying 
surgery and no harm seen with its expedition.  NICE concluded that surgery 
should be performed “on the day of or day after admission” (79).  Surgical delay 
of greater than 48 hours after admission is associated with prolonged hospital 
stay, increased morbidity (e.g. pressure sores, thromboembolic complications, 
pneumonia) and increased mortality (if delay is prolonged) (80;81).  
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2.2.1 Anatomy of the hip joint 
In order to understand the relevant surgical procedures, knowledge regarding 
the anatomy of the hip joint is required. 
2.2.1.1 Bony structure 
The hip joint is a ball-and-socket synovial joint in which the femoral head is the 
ball, and the acetabulum the socket. The adult hip bone is formed by the fusion 
of the ischium, the ilium and the pubis.  The ischium forms the inferior aspect of 
the pelvis and the infero-posterior aspect of the acetabulum (82).  The bilateral 
hip bones are united anteriorly by the pubic symphysis and along with the 
sacrum and the coccyx, form the bony pelvis.  The hip joint connects the axial 
skeleton with the lower limb and is thus essential in the maintenance of posture 
and balance (82;83).  
The proximal end of the femur comprises the femoral head, neck and greater 
and lesser trochanters.  The femoral head is angled anteriorly, superiorly and 
medially at approximately 130 degrees to the femoral shaft and articulates with 
the acetabular component of the hip joint (see Figure 2.2-1). The greater 
trochanter lies on the antero-lateral surface of the femoral neck and is the 
insertion site for the gluteus medius and minimus muscles whereas the lesser 
trochanter lies medially and provides the insertion site for the iliopsoas muscle 
(82;83). 
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Figure 2.2-1 - Anatomy of the hip joint (84). 
Reproduced from Gray’s Anatomy, 20th edition. 
 
2.2.1.2 Musculature of the hip 
Movement at the hip joint occurs due to the actions of 4 different muscle 
groups:  the gluteal, iliopsoas, adductor, and lateral rotator groups.   
Gluteal group:  These include gluteus maximus, medius, minimus and tensor 
fascia lata.  Gluteus maximus originates from the sacrum and ilium and is the 
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main muscle of hip extension, while gluteus medius and minimus are involved in 
abduction and medial rotation.   
Adductor group:  Adductors brevis, longus, magnus, as well as gracilis and 
pectineus originate from the pubis bone and are the main adductors of the hip 
joint.   
Lateral rotator group:  Piriformis, gemelli, quadratis femoris and obturator 
muscles. 
Iliopsoas group:  This includes iliacus and psoas major which comprise the main 
hip flexors.  Psoas major arises from the transverse processes of T1-5 and inserts 
upon the lesser trochanter (after merging with iliacus).  Iliacus is a flat, 
triangular-shaped muscle which originates from the iliac bone, sacrum and 
iliolumbar ligaments.  Iliacus covers the curved, inner surface of the iliac bone 
before merging with psoas major at the inguinal ligament.  It is innervated by 
branches of the femoral nerve and direct branches of the lumbar plexus (82;83).  
2.2.1.3 Innervation of the hip joint 
Sensory innervation of the hip joint is complex and involves several afferent 
nerves. The anteromedial capsule is supplied by articular nerves from the 
obturator nerve with further anterior innervation arising from the femoral nerve.  
Articular branches of the sciatic nerve innervate the posterior compartment and 
articular branches of the nerves supplying quadratis femoris supply the 
posteriomedial component.  Cadaveric studies have demonstrated that articular 
branches of the superior gluteal nerves have a role in the supply of the 
posterolateral component of the hip joint (85). Cutaneous innervation of the skin 
overlying the incision site on the lateral thigh is supplied by the lateral 
cutaneous nerve of thigh and by the lateral cutaneous branch of the subcostal 
nerve.  The ilioinguinal and genitofemoral nerves also provide some sensory 
fibres to the upper aspect of the anterior portion of the thigh (86). 
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2.2.2 Types of femoral fracture 
Hip fractures may be classified as intra-capsular or extra-capsular depending on 
the relationship between the fracture location and the insertion of the capsule 
of the hip joint.   
 
Figure 2.2-2 - Classification of fractures of the proximal femur (hip fractures). 
(87)  This figure is reproduced from SIGN 111 (Management of hip fracture in older people) by kind 
permission of the Scottish Intercollegiate Guidelines Network.  
 
Intra-capsular fractures occur proximal to the attachment of the hip joint 
capsule to the femur and tend to result in minimal blood loss due to the poor 
vascular supply at the fracture site and tamponade by the capsule.  Intra-
capsular fractures can be further divided into displaced or non-displaced 
categories and are generally treated surgically using either implants or femoral 
prostheses.  Undisplaced intra-capsular fractures are usually managed with 
surgical fixation in order to reduce the risk of dislocation at a later stage, while 
displaced fractures require fracture reduction with consequent fixation in order 
to maintain stability and prevent damage to the blood supply of the femoral 
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head.  Surgery for undisplaced fractures generally involves the insertion of 
screws or pins across the fracture site under x-ray guidance.  A 2011 Cochrane 
review of 30 studies involving 6334 patients aimed to determine which of the 
available fixation devices was superior for intra-capsular hip fracture (88).  The 
review concluded that the quality of the evidence was generally poor with only 
one study describing allocation concealment and that there was inconsistent 
reporting of outcomes between studies.  Sliding hip screws were found to result 
in a reduced incidence of avascular necrosis when compared with cancellous 
bone screws.  However, sliding hip screws were associated with longer insertion 
time and higher blood loss. The review concluded that there was no clear 
benefit of one technique over another (88). 
In the case of displaced intra-capsular fractures, internal fixation, hemi-
arthroplasty and total hip replacement can be considered.  Arthroplasty (either 
partial or total) is recommended in guidelines produced by the National Institute 
for Clinical Excellence (NICE) due to the lower re-operation rates, improved pain 
control, and superior functional and quality of life scores seen with these 
techniques (79).  In guidance produced by the Scottish Intercollegiate Guideline 
Network (SIGN), a more conservative approach is suggested for younger, fitter 
patients who are recommended to receive internal fixation whilst older, frailer 
patients should undergo either a hemi-arthroplasty or total hip replacement.  
The reason for this is a concern that the more invasive arthroplasty techniques 
produce better short term outcomes but have a higher incidence of longer term 
problems such as dislocation.  Where either hemi-arthroplasty or total hip 
replacement are being considered, patients with pre-existing joint disease, 
medium / high activity levels and a reasonable life expectancy, are 
recommended to receive total hip replacement rather than hemi-arthroplasty as 
the primary treatment (87). 
Extra-capsular fractures can be per-, inter-, or sub-trochanteric and are usually 
described by their degree of comminution.  Fractures which occur at the base of 
the femoral neck are often around the level of the joint capsule and behave as 
extra-capsular fractures.  Extra-capsular fractures occur in cancellous bone and 
therefore have the potential to generate greater blood loss.  As these fractures 
are outwith the joint capsule, they are unlikely to damage the blood supply to 
the femoral head and are usually repaired using internal fixation techniques such 
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as sliding hip screws or intra-medullary nails (79;87). Conservative management 
with traction and bed-rest is rarely practiced in this country due to an increased 
rate of morbidity, prolonged hospital stay and increased costs (79;87).  
 
2.3 National Audits of proximal femoral fracture  
2.3.1 The National Hip Fracture Database 
The National Hip Fracture Database (NHFD) is a web-based audit of all patients 
admitted with a hip fracture in England, Wales, Northern Ireland and the 
Channel Islands (76).  This audit has collected data for over 200,000 patients 
from 188 hospitals since its inception in 2007, making it the largest audit of hip 
fractures in the world.  The aim of the audit is to allow hospitals to bench-mark 
their service against national data, highlight areas for improvement and optimise 
patient care (76).  As a result of the data generated from this audit, hip fracture 
has become a “Best Practice Tariff” (BPT) initiative for the National Health 
Service (NHS) in England prompting extra payments for trusts meeting all of the 
defined standards for best care. 
The NHFD examines care against six standards set by the British Orthopaedic 
Association / British Society of Geriatricians’ (BOA/BSG) “Blue Book”.  These are 
prompt admission to orthopaedic care, surgery within 48 hours and within 
normal working hours, nursing care aimed at minimising pressure ulcer 
incidence, routine access to ortho-geriatric medical care, assessment and 
appropriate treatment to promote bone health and falls assessment (89).  The 
audit produced initial improvements in all of these standards, although some of 
these have now reached a plateau with some having worsened slightly since the 
audit’s launch.  Ongoing improvements in ortho-geriatric input, bone protection 
medication prescription and falls assessment provide ongoing evidence of the 
audit’s success (76). 
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Table 2.3-1 -  Compliance with BOA/BSG Blue Book standards (76). 
 
The NHFD reports on a number of additional outcomes examining all aspects of 
the patient journey during admission with hip fracture.  These include: age, 
gender, housing status on admission, ASA grade, walking ability, fracture type, 
Abbreviated Mental Test (AMT) score, admission to orthopaedic ward from 
emergency department (ED) in 4 hours, type of anaesthesia, surgery performed 
within 36 hours, surgery performed within 48 hours and during normal working 
hours, reason for delay > 36 hours, presence of pressure ulcers, pre-operative 
medical assessment, bone protection medication, falls assessment, length of 
acute and post-acute stay, discharge destination, re-operation within 30 days, 
return to home at 30 days, 30 day mortality and proportion of patients treated 
conservatively.  As with any major exercise in data collection, the NHFD suffers 
from certain limitations, namely incomplete case ascertainment by hospitals and 
denominator problems due to uncertainty regarding whether all cases are being 
reported.   
The NHFD was not initially designed to examine outcomes relating to anaesthesia 
specifically but does contain an analysis of anaesthetic technique.  In the 2012 
report, 52.7% of patients received a general anaesthetic with 42.4% receiving 
spinal anaesthesia and 29.4% given a supplementary nerve block (76). This has 
since been revised with inclusion of more anaesthetic related data fields (see 
section 2.3.3) 
2.3.2 Scottish Hip Fracture Audit  
The Scottish Hip Fracture Audit (SHFA) was a national audit performed in 
Scottish hospitals during the period 1993 to 2008.  While initially a small project 
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incorporating only four hospitals, the latter two years of the audit (2007 and 
2008) included all 21 mainland Scottish hospitals and was funded by the Scottish 
Government.  Data collection ceased in 2008 when funding was transferred to 
the Musculoskeletal Access Group (MSk).  Data collection in the last two years of 
this audit was performed by dedicated data collectors with telephone interviews 
used to collect data at later time points.  Data relating to 6369 patients from 
Jan 1st 2007 to 31st December 2007 are reported in the 2008 SHFA report.  
Patients under 50 years of age are excluded (71).   
Similar to the NHFD, the SHFA reports on outcomes relating to the processes of 
care in patients sustaining hip fracture and does not specifically examine 
anaesthetic care.  The outcomes reported by SHFD are as follows: percentage of 
patients transferred through the Emergency Department in 2 and 4 hours, 
percentage of patients going to theatre within 24 safe operating hours, discharge 
destination, length of stay, place of residence at 30 and 120 days post 
admission, survival to 30 and 120 days post-admission, return to home at 120 
days for patients admitted from own home, 120 day mobility levels, patients 
living independently at 120 days, pain levels at 120 days and further falls after 
discharge.  A separate report explores in detail the reasons for delay to theatre 
(90).  
It is apparent that there are some significant differences in the standards 
assessed between NHFD and SHFA.  For example, the SHFA audits the standard:  
“98% of medically fit patients who have sustained a hip fracture 
should be operated on within 24 hours of ‘safe operating time’ (i.e. 
between 8 am and 8 pm, seven days a week)”. 
 In contrast, the NHFD audits compliance with;  
“surgery on the day of, or the day after admission”.   
The reason for this variation relates to the different guidelines used to inform 
audit standards.  The NHFD bases its standards mainly upon those set in NICE 
guidelines(79) and the BOA/BSG Blue book (89). The SHFA bases its analysis upon 
The Scottish Government Health Delivery Directorate’s “Time to Theatre” 
targets (91).  
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From 2009, data on hip fracture care has been collected under the Scottish MSk 
Audit. Part of this is a MSk and Orthopaedic Quality Drive of which hip fracture 
care is one of four priority work strands. Data on hip fracture care are collected 
in a one week sample during a rolling 4-week audit pattern. Outcomes were last 
reported from 2012-2013 (92).  This report showed that survival and other 
outcomes remained broadly similar to outcomes from the previous Scottish Hip 
Fracture Audit in 2007 and 2008. Although sample sizes in the current audit were 
small, there was a trend towards hip fracture patients in 2012-13 being less 
likely to be in hospital at 120 days than those in 2007-08.  They were also less 
likely to have returned home (but were more likely to be independent at home), 
and were less likely to be fully mobile.  A longer-term analysis of data revealed 
no difference in overall 30 and 120 day mortality rates between 2008 and 2013. 
The report recommended that all hip fracture patients should follow the 
“Scottish Standard of Care for Hip Fractures”, an evidence based summary of 
best practice recommendations to support early recovery and return to 
independent living (93).  This was published in 2015, after the performance of 
the audit detailed in this thesis. 
 
2.3.3 The Hip Fracture Peri-operative Network 
The Hip Fracture Peri-operative Network (HipPeN) is an initiative aimed at 
linking anaesthetists with an interest in the management of proximal femoral 
fractures in hospital trusts throughout England and Wales for the dissemination 
of evidence-based, best practice and the performance of collaborative 
nationwide audit.  This concept was first outlined at the Age Anaesthesia 
Association meeting held in 2007 and published its first report in 2010 (8). 
The first report from HipPeN provides an introductory study of current national 
management of proximal femoral fractures and examines patient demographics, 
delays in admission to operation, grade of surgical and anaesthetic personnel, 
30-day mortality and method of anaesthesia.  Data for all patients undergoing 
hemi-arthroplasty, dynamic hip screw, total hip replacement or proximal 
femoral fracture operations were accrued manually using specially designed 
data-capture sheets over a two month period.  Twenty two hospitals provided 
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data for 1195 patients over the 59 days study period.  Unfortunately, this 
represented only 13% of the 168 eligible acute hospitals within the NHS in 
England and Wales (8).  
While demographic data were found to be similar to other large scale audits 
(71;76), other variations in practice were seen.  Forty two percent of operations 
were performed after the standard 48 hour post-admission period.  In addition, 
there was a ﬁve-fold variation between hospitals in the delay between admission 
and operation, a 12-fold variation in 30-day postoperative mortality and 
considerable variations in the seniority of attending surgeons and anaesthetists 
present during surgery (8). 
The report highlights the lack of research in this patient group and discusses the 
considerable challenges inherent in performing randomised controlled studies.  
For example, in order to compare general versus regional anaesthesia in terms of 
1 year mortality, around 9000 patients would be required in each group.  As 
many clinical outcomes are dependent on multiple factors (e.g. physiotherapy 
availability, nursing presence etc.), problems concerning which outcomes to 
report are rife in this population.  In addition, the high incidence of cognitive 
impairment has significant implications for the ethical recruitment of patients.   
The second report focuses on the epidemiology of hip fracture, the resources 
required to manage it and its financial implications (73). Data from a 10 year 
period were used to calculate the incidence, bed usage and costs associated 
with hip fracture and projections made regarding the implications for future 
resource management.  Despite noting a decline in the prevalence of hip 
fracture among the ageing population (2.98% since 2002), it was estimated that 
around 100,000 patients annually will require surgery for hip fracture by 2033 in 
England, with a 30 day mortality of 8.9–9.3% resulting in costs of  £3.6–5.6 billion 
(when adjusted for inflation) in total care. 
The third report from HipPeN was an electronic survey of blood transfusion 
practices in patients with hip fracture in the UK and was published as an 
abstract in the journal Anaesthesia (94).  Only 8% of respondents checked a 
haemoglobin level immediately post-operatively in this patient group. The 
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authors concluded that there was a high level of variability in practice which is 
reflective of the controversies in the evidence in this area.   
A fourth report resulted from a survey of UK anaesthetists’ practice in relation 
to the management of hypotension during repair of hip fracture and was 
published as an abstract in the journal Anaesthesia (95).  This survey which 
targeted anaesthetists who regularly anaesthetised for trauma patients and had 
a high response rate again showed significant variation in practice with regard to 
the diagnosis and management of hypotension. 
The Anaesthesia Sprint Audit of Practice (ASAP) was a large scale project 
conducted jointly by HipPeN in conjunction with the Association of Anaesthetists 
of Great Britain and Ireland (AAGBI), The National institute of Academic 
Anaesthesia (NIAA) and the National Hip Fracture Database (NHFD) (96).  This 
large audit carried out over a 3 month period aimed to establish compliance with 
the AAGBI guideline: The management of proximal femoral fracture in hospitals 
throughout England, Wales and Northern Ireland (72). Anaesthesia related 
information was incorporated into the NHFD dataset in order to allow large scale 
data collection. Data from 11130 patients and 182 hospitals were analysed 
resulting in a comprehensive set of data regarding management and outcomes 
(see Section 4.5.1). The data from this audit were not available at the time of 
performing the audit detailed in the forthcoming chapters of the thesis. 
Furthermore, an analysis of outcome by type of anaesthesia was performed using 
data collected as part of the NHFD (97).  By incorporating anaesthesia-related 
outcomes into this large scale and established system of data collection, data for 
around 5000 cases per month was able to be collected.  Data for 65 535 patients 
over a 1 year period were analysed, with 90% of these having data relating to 
anaesthesia.  The authors found no difference in 5 day or 30 day mortality in 
patients receiving general compared with regional anaesthesia, even when 
adjusted for age and ASA.  24 hour mortality was found to be higher in cemented 
when compared with uncemented hemiarthroplasty.  The authors concluded that 
mortality may not be the optimal endpoint with which to assess anaesthetic 
influence on outcome and that further research should focus on the optimal 
performance of general and regional techniques as well as other outcomes such 
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as pain, post-operative confusion, respiratory infection, hypotension and 
mobilisation. 
The Hip Fracture Peri-operative Network is an important agency which continues 
to  explore the advantages of large-scale data collection and audit as a means of 
determining current practice and establishing how variations in practice impact 
upon outcome.   
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2.4 Chapter 2 Summary 
 Hip fracture is a common and serious condition with high levels of 
associated morbidity and mortality. 
 Hip fracture is associated with the utilisation of significant health care 
resources and cost. 
 Expedited surgery is beneficial. 
 A number of national audits have been performed to inform practice and 







Anticoagulation in the peri-operative period. 
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3.1 Thromboprophylaxis 
The term venous thromboembolism (VTE) incorporates deep venous thrombosis 
(DVT) as well as pulmonary embolism (PE).  Thrombus formation is favoured by 
changes in Virchow’s Triad: blood stasis, increased coagulability of blood and 
damage to the vessel wall. The risk of thromboembolic disease is elevated in the 
peri-operative period and in several medical conditions such as malignancy, 
thrombophilia and nephrotic syndrome.   
According to a classification of risk published by the American College of Chest 
Physicians (ACCP), patients admitted with PFF are considered as being in the 
highest risk group for the development of VTE (98).  The rate of VTE detected in 
patients with PFF depends somewhat upon which definition is used.  The rate of 
asymptomatic VTE is significantly higher than that of symptomatic VTE.  If 
venography or ventilation-perfusion (VQ) scanning is performed in all patients 
with a hip fracture, 36% will have a DVT and 6% a PE (72;99;100).  If 
symptomatic DVT is considered, its incidence is thought to lie somewhere 
between 1% and 3% of patients, while the risk of PE is thought to lie between 
0.5% and 3% (72;100;101).  While thromboprophylaxis has the benefit of reducing 
the potential for VTE, this must be balanced against an increased risk of 
bleeding.  This is of particular concern in patients undergoing surgical 
procedures.  Options for thromboprophylaxis include mechanical methods (e.g. 
TED stockings and intermittent compression devices) and pharmacological 
methods such as heparin.   
3.1.1 Mechanical compression devices 
A 2008 Cochrane Review identified 5 studies (487 patients) examining 
mechanical compression devices compared with control with regard to DVT in 
patients admitted with hip fracture (102).  The authors concluded that there was 
a likely benefit of mechanical compression devices in preventing DVT after hip 
fracture and that this intervention was not associated with an increased risk of 
bleeding or blood transfusion.  The American Association of Chest Physicians 
specifies that only intermittent pneumatic compression devices which can record 
and report proper time-wear data should be used and that patients should wear 
these devices for 18 hours per day (103).  Unfortunately, but perhaps 
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unsurprisingly, the use of these devices was found to be limited by poor 
compliance due to blisters / foot sores etc.  Such side-effects are likely to limit 
the effective use of these devices in everyday practice.   
While graduated compression stockings have been found to reduce the incidence 
of DVT in many other surgical settings, they do not appear to be effective in 
patients with hip fracture (102).    
3.1.2 Heparin 
Heparin (in both unfractionated and low molecular weight forms) is licensed for 
VTE prophylaxis in the UK (104). When used for VTE prophylaxis, heparin is most 
commonly given subcutaneously and in a reduced dose to that used in the 
treatment of thromboembolism.  Low molecular weight heparin (LMWH) is 
frequently used in the peri-operative setting as it can be given once daily and 
does not result in a prolonged anti-coagulant effect.  It is recommended that 
LMWH is commenced at least 12 hours prior to the planned operation in order to 
allow adequate time for the anti-coagulant effects to reduce to a level safe for 
neuraxial blockade and surgery.  In patients undergoing surgery for PFF, 
guidelines from the American College of Chest Physicians recommend the use of 
LMWH in preference to other agents, ideally in combination with a mechanical 
compression device (which should be worn for 18 hours per day).  They also state 
that this should be continued for 35 days post-operatively where possible (103).   
A Cochrane Review of 15 studies (1199 patients) analysing thromboprophylaxis in 
patients with hip fracture found that both LMWH and unfractionated heparin 
(UFH) reduced the risk of DVT by 41% and 36% compared with placebo (102).  
However, there was no difference in the incidence of VTE when low molecular 
LMWH and UFH were compared (102).  As LMWH has a favourable side-effect 
profile, it is generally considered the preferred agent.  When heparin was 
compared to mechanical compression devices, no difference was seen in terms 
of DVT, PE or mortality.  This may have been due to a lack of studies making this 
comparison.  While the use of mechanical compression devices is appealing, 
there are significant limitations in terms of poor compliance and the 
development of skin sores / blister etc.  No difference was detected in VTE or 
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bleeding complications when two different LMWHs were compared (Enoxaparin 
versus Dalteparin) (102).    
3.1.3 Aspirin 
The use of aspirin as a thromboprophylactic agent was the subject of one of the 
largest trials to date in this area.  The Pulmonary Embolism Prevention (PEP) 
study (2000) was a multi-national, multi-centre study incorporating over 13,000 
patients undergoing surgery for hip fracture and was published in the Lancet 
(105).  Patients received either 160mg of aspirin daily or placebo.  However, 
patients could also receive other forms of thromboprophylaxis such as heparin if 
deemed necessary.  This study resulted in a positive outcome for the aspirin 
intervention.  PE or DVT was confirmed in 105 (1.6%) of 6679 patients assigned 
aspirin, compared with 165 (2.5%) of 6677 assigned placebo.  This represented 
an absolute reduction of 9 per 1000 and a proportional reduction of 36% (19-50; 
p=0.0003). Despite these positive findings, this study has been criticised for the 
large numbers of patients receiving other concurrent forms of 
thromboprophylaxis such as mechanical compression devices and heparin. The 
implication that only those at lowest risk would have received aspirin alone may 
be a source of significant bias.  Sub-group data also showed that concomitant 
use of aspirin and LMWH did not produce any additional reduction in the risk of 
DVT (event rate 1·4% for aspirin + LMWH versus 1·8% for LMWH alone, p=0·37).  
The thrombosis risk for aspirin alone was 1·7%, 1.6% for unfractionated heparin 
plus aspirin, and 1.8% for LMWH alone.  Aspirin was also associated with an 
increase in bleeding events (excess of 6 bleeds per 1000 patients treated).   
3.1.4 Fondaparinux 
Fondaparinux is a synthetic pentasaccharide anticoagulant which inhibits factor 
Xa and affects the coagulation cascade in a similar manner to heparin. Patients 
taking Fondaparinux do not require to be monitored with laboratory tests (in 
contrast to patients taking vitamin K antagonists such as warfarin).  There is no 
antidote to the actions of Fondaparinux.  The Pentasaccharide in Hip-Fracture 
Surgery study (PENTHIFRA) compared fondaparinux with enoxaparin in patients 
with PFF (106).  This 99 centre, multi-national, randomised, double-blind trial 
included 1,711 patients admitted with PFF (of which 1250 were included in the 
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final analysis).  Patients were excluded if an epidural catheter was planned for 
more than 6 hours postoperatively, if the patient had surgery more than 48 hours 
from the time of admission, or if the serum creatinine level was greater than 2 
mg/dL.  Fondaparinux 2.5 mg daily subcutaneously was commenced 6 to 8 hours 
after surgery and the second dose was given at least 12 hours after the first.  
The group receiving enoxaparin were given a dose of 40 mg subcutaneously at 
approximately 12 hours before surgery and at 12 to 24 hours after surgery.  
Treatment continued for 5 to 9 days.  The use of mechanical compression 
devices, anti-platelet and other anticoagulant drugs was not permitted.  The 
primary outcome was VTE (defined as deep-vein thrombosis, pulmonary 
embolism, or both) up to day 11. Secondary outcomes were total, proximal, or 
distal DVT or symptomatic VTE up to day 11 and symptomatic VTE up to day 49.  
Venography was performed to identify DVT and PE was confirmed by either 
ventilation perfusion scan, pulmonary angiography, helical computed 
tomography CT) scan or autopsy. 
The incidence of VTE was significantly lower in the Fondaparinux group (8.3% vs 
19.1%, P <.001).  However, the risk of symptomatic DVT and fatal and non-fatal 
PE was the same in both groups.  By day 49, the incidence of symptomatic VTE 
was similar in both groups (2.0% in fondaparinux and 1.5% in enoxaparin).  No 
differences in clinically relevant bleeding rates were observed.   
The PENTHIFRA Study had some notable limitations. Firstly, only one dose of 
study drug was required for the patient to be included in the efficacy analysis.  
Secondly, only a minority of patients received the pre-operative dose of heparin.  
In addition, a significant number of the members of the steering committee 
were from the pharmaceutical company and statistical analysis was also 
performed by the sponsor (this was fully acknowledged in the paper) (106).    
Twenty two of the 30 symptomatic VTE events and 11 of the 15 fatal PEs in the 
PENTAHIFRA study occurred in days 11 to 49 prompting the authors to question 
whether Fondaparinux should be continued for longer than one week post-
operatively (106).   
A further study was performed in 2003 in order to investigate the effects of 
prolonging the course of Fondaparinux.  The PENTAHIFRA-plus study enrolled 656 
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participants from 57 centres in 16 countries and randomised them to receive 
either Fondaparinux 2.5mg or placebo for a further 19-21 days after the original 
week of thromboprophylactic treatment (Fondaparinux) (100).  The authors 
found that prolonged thromboprophylaxis with Fondaparinux reduced the 
incidence of VTE from 35.0% to 1.4% resulting in a Relative Risk reduction (RRR) 
of 95.9% (95% CI, 87.2%-99.7%; P<0.001) when compared to placebo.  The 
incidence of symptomatic VTE was also reduced from 2.7% to 0.3% (RRR 88.8%, 
95% CI 67.7-100%).  There were 3 fatal PEs in the placebo group and none in the 
Fondaparinux group.  The Fondaparinux group had a higher bleeding rate than 
the placebo group but there were no differences between the 2 groups in 
clinically relevant bleeding episodes (100).   
Fondaparinux and heparin are both recommended as potential 
thromboprophylactic agents in SIGN guidelines for patients with hip fracture 
(87).  As Fondaparinux has a longer half life (18 hours) than LMWH, 
administration pre-operatively may preclude the use of neuraxial anaesthetic 
techniques for over 24 hours and as such, SIGN recommend Fondaparinux as 
being used in the post-operative period only (87).  Fondaparinux is the preferred 
agent post-operatively and it is recommended that this be continued for 28 days 
post-operatively.  Fondaparinux may also be considered as an alternative agent 
in patients in whom heparin is contraindicated (e.g. patients with heparin 
induced thrombocytopaenia).  The higher cost of Fondaparinux may limit its 
clinical use. 
3.1.5 Dabigatran 
This drug works via the direct inhibition of thrombin and as with Fondaparinux, 
does not require laboratory monitoring.  It has a peak time to anticoagulant 
activity of 2 – 3 hours and an elimination half life of 12 – 14 hours in patients 
with normal renal function.  There is no antidote to Dabigatran.  It has recently 
been approved by NICE as being suitable for use as a thromboprophylactic agent 
in patients undergoing total hip or knee replacement (107).   
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3.1.6 Rivaroxaban 
This drug is a direct inhibitor of factor Xa and inhibits both the extrinsic and 
intrinsic components of the coagulation cascade.  As with Dabigatran, 
Rivaroxaban has a rapid onset of action and similar elimination half life.  
Rivaroxaban has been approved by NICE as suitable for thromboprophylaxis after 
total hip and knee replacement operations (108). 
3.2 Warfarin in the peri-operative period 
Warfarin is a synthetic coumarin derivative that exerts its action by inhibiting 
the synthesis of vitamin K dependent clotting factors (II, VII, IX and X) in the 
liver.  The formation of clotting factors is dependent upon the carboxylation of 
their precursor proteins.  During this carboxylation reaction, vitamin K is 
oxidised to form vitamin K 2,3-epoxide.  Warfarin prevents the reduction of 
vitamin K 2,3-epoxide back to its original state resulting in reduced levels of 
vitamin K and subsequent reduced levels of clotting factors (109).  Warfarin has 
an oral bioavailability of 100%, is predominantly protein bound (99% to albumin) 
and is metabolised in the liver.  Its metabolites are excreted in the urine and 
faeces with an elimination half life of 35 to 45 hours.  This is prolonged in the 
elderly and in patients with renal impairment (109).  Warfarin is commonly used 
as an anticoagulant drug for patients with conditions such as; atrial fibrillation, 
thromboembolic disease, prosthetic valves and cerebrovascular disease.  The 
average daily dose of warfarin required to achieve therapeutic anticoagulation is 
around 5mg, though there is large inter-individual variation (1 – 15mg).  This is 
due to genetic variability in drug metabolism.  Intra-individual variability in 
response may also occur as a result of dietary content of vitamin K and drugs 
causing interactions with warfarin.   
3.2.1 Monitoring of warfarin therapy 
The response to warfarin treatment is monitored using a laboratory test known 
as the Prothrombin Time (PT).  This is the time take for the blood to clot after 
the addition of tissue factor and measures the activity of the extrinsic and 
common pathways within the clotting cascade. The normal range for this 
measurement is 10-14 seconds.  This measurement is standardised in each 
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individual laboratory to an International Normalised Ratio (INR).  The normal 
range for INR is 0.8 - 1.2 for a patient on no anticoagulant.  Each patient is 
assigned a target INR range.  This can range from 2 to 4 depending on the 
indication for warfarin therapy.   
3.2.2 Management strategies for warfarin in the peri-operative 
period 
Anti-coagulated patients present a challenge to the peri-operative team.  While 
the patient is fully anti-coagulated, they should be at lower risk of 
thromboembolic phenomena.  However, they are at higher risk of bleeding 
during surgery.  The impact of this will depend on the indication for anti-
coagulation and the type of surgery being performed.  Options for the 
management of warfarin in patients undergoing invasive procedures include: 
withholding warfarin and waiting for INR to self-correct, or the administration of 
pharmacologic compounds such as vitamin K, fresh frozen plasma (FFP) and 
prothrombin complex concentrates (PCC).   
3.2.2.1 Cessation of warfarin alone 
When warfarin is withheld in a patient with an INR of 2–3, it will take around 4 – 
5 days for the INR to drop below 1.5 (110).  However, there is inter-individual 
variation in the time taken for the effects of warfarin to be reversed.  In 
patients in whom warfarin is withheld, an initial increase in INR may occur due 
to the stress response and prolonged periods of fasting.  This makes cessation of 
warfarin alone an impractical option for reversal in patients who are actively 
bleeding or who require to undergo time-dependent surgery (such as repair of 
hip fracture).   
3.2.2.2 Vitamin K 
Vitamin K is a fat soluble vitamin essential for the formation of clotting factors 
and which is depleted by the actions of warfarin.  The administration of vitamin 
K therefore reverses the effects of warfarin.  The onset of vitamin K is at least 4 
– 6 hours after intravenous administration and 24 hours for oral administration 
(111;112).  It is thought that excessive doses of vitamin K may result in a state of 
warfarin resistance which can persist for up to one week.  This has resulted in a 
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call for lower doses (1 – 2.5mg to be given) in cases where immediate reversal is 
unnecessary.  Doses of 1mg vitamin K have been reported to result in reversal of 
warfarin within 24 – 27 hours with the avoidance of a prolonged time to return to 
therapeutic INR (110;113).  Vitamin K can be associated with anaphylactic 
reactions when given intravenously and should be given as a slow infusion.  Oral 
vitamin K, while slower in onset, is well absorbed from the gastrointestinal tract 
and does not cause the same adverse effects as the intravenous preparation 
(110). 
3.2.2.3 Fresh Frozen Plasma 
Fresh Frozen Plasma (FFP) will reverse the effects of warfarin rapidly and 
without causing later resistance to warfarin.  Its effects dissipate within 8 – 12 
hours of administration and it should be administered within 4 hours of the 
procedure to obtain optimal effect. FFP has to be thawed prior to its use and 
this can result in delays of around 45 minutes.  Risks of FFP administration 
include: anaphylactoid reactions, alloimmunisation, transfusion related lung 
injury, fluid overload and transmission of infection. 
3.2.2.4 Prothrombin Complex Concentrates 
PCC contain high concentrations of clotting factors II, VII, IX and X and can be 
used to rapidly reverse the effects of warfarin.  PCC is more rapid and effective 
at reducing INR than FFP (114) and smaller volumes of concentrate are effective 
thus reducing the risk of fluid overload (115).   Risks of PCC are those of 
immediate allergic reactions, heparin-induced thrombocytopenia for the 
preparations containing heparin) and thromboembolic complications. The 
primary safety concern with PCC has been their association with thrombotic 
events such as stroke, myocardial infarction, deep vein thrombosis, pulmonary 
embolism and disseminated intravascular coagulation (111).  Transfusion related 
lung injury has not been reported.   
3.3 Guidelines for the management of warfarin in the 
peri-operative period 
Guidelines differ in their approach to this issue.  For example, a recent SIGN 
guideline (SIGN 129: Antithrombotics; indications and management, 2012) 
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examined the use of warfarin in the peri-operative period (116).  In low risk 
procedures such as dental extractions, no change in warfarin therapy is 
recommended.  However, in patients undergoing more invasive procedures, 
warfarin reversal is usually required.   
In procedures where the risk of bleeding is considered significant, SIGN 129 
makes the following recommendation: 
“Decisions regarding interruption of warfarin therapy for other 
surgical and invasive procedures, and whether bridging therapy is 
advisable, should be made on an individual basis dependent upon the 
perceived risks of bleeding and thrombosis associated with 
continuation of anticoagulation and discontinuation of 
anticoagulation, respectively, and the nature of the proposed 
procedure (116).”  
Recommendations from other relevant guidelines are as follows:  A guideline by 
the British Committee for Safety in Haematology (BCSH) in 2011 recommends: 
 “For surgery that requires reversal of warfarin and that can be 
delayed for 6-12 h, the INR can be corrected by giving intravenous 
vitamin K. For surgery that requires reversal of warfarin and which 
cannot be delayed for vitamin K to have time to take effect the INR 
can be corrected by giving Prothrombin Complex Concentrate (PCC) 
and intravenous vitamin K. PCC should not be used to enable elective 
or non-urgent surgery (117).” 
The 2005 AAGBI guideline; Blood transfusion and the anaesthetist: blood 
component therapy recommends the following approach:  
 “Vitamin K +/- prothrombin complex concentrate (PCC) is 
recommended to reverse warfarin. Fresh Frozen Plasma (FFP) is 
indicated when there is severe bleeding or when PCC is unavailable 
(118).” 
 
SIGN guideline 111; the management of hip fracture in older people states:  
“Withholding warfarin combined with administration of oral or 
intravenous vitamin K (1 – 2.5mg) is recommended if reversal of the 
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anticoagulant effects of warfarin to permit earlier surgery is deemed 
appropriate (87).”  
The 2011 AAGBI guideline; management of hip fracture states;  
“Hospital guidelines concerning the peri-operative management of 
patients taking warfarin should be followed; in general, the 
International Normalised Ratio (INR) should be < 2 for surgery and < 
1.5 for neuraxial anaesthesia. Small amounts of vitamin K may be 
used to ‘reverse’ the effects of warfarin; supplemental peri-
operative anticoagulation with heparins is usually indicated. 
Prothrombin complex concentrates rapidly reverse the effects of 
warfarin but are expensive and rarely indicated. Warfarin should be 
recommenced 24 h after surgery, although some departments 
recommence it later on the day of surgery. 
The advice of haematologists should be sought if in doubt about the 
peri-operative management of patients on chronic anticoagulant 
therapy. Regular anticoagulant medication requires that the 
anaesthetist balance the attendant risks of neuraxial and lumbosacral 
plexus blockade (i.e. haemorrhage and neuropraxia) against the 
benefits of these procedures for the elderly (72).” 
The NICE guideline; the management of hip fracture in adults, 2011 states (79): 
 “INR should be corrected promptly to avoid undue delay to theatre” 
The differences seen between guidelines reflect the lack of high quality 
evidence in this area. 
 
3.4 Management of warfarin in patients undergoing repair 
of proximal femoral fracture 
Warfarin is currently the most commonly prescribed anticoagulant drug in the UK 
(119).  It is estimated that around 1 - 1.5% of the UK population are treated with 
warfarin (119). This figure rises with age and around 5% of people admitted with 
hip fracture are thought to be taking the drug (72).  
In a retrospective audit of 57 patients in a single centre undergoing repair of hip 
fracture, patients receiving either cessation of warfarin or pharmacologic 
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management were compared.  The authors found that the delay to theatre was 
4.4 days in the group receiving cessation of warfarin, and 2.4 days in the group 
receiving pharmacologic therapy (p<0.01) (120).  In a prospective audit of 90 
patients admitted with hip fracture in two hospitals, the authors compared their 
standard management of warfarin cessation in the first 45 patients, with the 
subsequent 45 patients treated with 1mg Vitamin K intravenously. In patients 
receiving standard treatment, the mean time to achieve INR < 1.5 was 158 hours 
compared with 63 hours in the patients receiving vitamin K.  This translated into 
an improvement in mean time to theatre from 91 hours to 38 hours.  These 
results were statistically significant (121).  
3.4.1 The role of bridging therapy 
A further important consideration is the risk of thromboembolism while warfarin 
is being withheld.  A risk assessment may be performed in order to stratify 
patients into high or low risk categories.  In those considered to be at high risk 
of thromboembolism, bridging therapy with an alternative anticoagulant is 
usually considered necessary.  Heparin is mainly used in this situation.  Heparin 
may be administered as either unfractionated heparin (UFH) or as low molecular 
weight heparin (LMWH).     
LOW RISK 
• AF with normal heart valves and no previous embolism or stroke. 
• Single episode of venous thromboembolism > 3 months ago. 




• AF with previous stroke, embolism, valve disease or any type of valve replacement. 
• Metal mitral valve, any 'ball and cage' valve, or pre-1990 metal aortic valve. 
• Artificial valve plus previous embolism. 
• Any valve replaced within previous 2 months. 
• Arterial embolism or venous thrombosis within previous 3 months. 
• Prior recurrent venous thrombosis. 
• Prior venous thrombosis and known high risk thrombophilia. 
• Patient with target INR of 3-4. 
Table 3.4-1 - Thomboembolic risk stratification for patients taking warfarin (122). 
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3.4.1.1 Unfractionated Heparin 
Unfractionated heparin (UFH) is a naturally-occurring glycosaminoglycan with a 
molecular weight range of 5,000-35,000 Daltons.  UFH potentiates the effect 
anti-thrombin and inhibits the coagulation cascade at several points.  It prolongs 
the laboratory measurement of the intrinsic coagulation pathway, the activated 
partial thromboplastin time (APTT), when given in therapeutic doses.  UFH is 
administered either by intravenous (IV) injection or by subcutaneous injection.  
Intravenous administration has an immediate effect and short plasma half-life 
(30 minutes to two hours) while subcutaneous injection has a delayed onset (two 
hours) but more prolonged effect (around 10 hours). There is wide variability 
among patients in response to a given dose of heparin.  The anticoagulant effect 
(APTT ratio) of unfractionated heparin therapy must therefore be monitored at 
least daily and the dose adjusted to achieve the target therapeutic range.  This 
should in turn minimise the risks of bleeding and thrombosis.  UFH has a short 
half-life after intravenous administration (30 - 120 minutes), and cessation of 
therapy results in reversal over a few hours.  Protamine sulphate can be given if 
immediate reversal is required.  The advantages of UFH relate to its relatively 
rapid onset and offset times and its reversibility.  Disadvantages include its 
inter-individual variability and the practicalities of frequent blood monitoring 
with possibility of over or under-shooting target APTT (109). 
3.4.1.2 Low Molecular Weight Heparins 
Low molecular weight heparins (LMWH) are manufactured from UFH and consist 
of short chains of polysaccharide with an average molecular weight of <8,000 
Daltons.  LMWH have better availability than UFH when administered by the 
subcutaneous route.  They have an onset time of round 1 hour with peak 
anticoagulant activity at 5 hours and a half life of 3 – 5 hours.  In contrast to UFH 
the anti-Xa effect predominates over the anti-thrombin effect.  The APTT is 
therefore not used to monitor the effects of LMWH.  The anti-Xa level can be 
used to monitor LMWH but its predictive value in terms of efficacy against 
thrombosis and bleeding risk is sub-optimal.   As LMWH is excreted by the 
kidney, the dose should be reduced in patients with renal failure (109).   
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In a meta-analysis of 12 studies involving 4971 patients, LMWH was associated 
with a statistically significant increase in the risk of major bleeding in patients 
with a creatinine clearance of 30 mL/min or less compared with those with a 
creatinine clearance of greater than 30 mL/min (5.0% vs 2.4%; odds ratio, 2.25 
[95% CI, 1.19 to 4.27]; p = 0.013) (123).  Reduced doses of LMWH or the use of 
UFH may therefore be more prudent in patients with a creatinine clearance of 
<25ml/min. 
In general, decisions regarding bridging therapy warrant an individualised 
consideration of risks and benefits taking into account the perceived risk of 
thrombosis and the likelihood and consequences of surgical bleeding.  For 
example, the consequences of bleeding after neurosurgery could be catastrophic 
making this one of the higher risk surgeries from a bleeding perspective.  On the 
other hand, a patient undergoing a procedure with a relatively low risk of 
bleeding may be at greater risk from harm by thrombosis and thus merit bridging 
therapy.    
In a non-randomised cohort study of 1024 patients (mainly with AF), warfarin 
was withheld on 1293 occasions to allow various procedures to be performed.  
Bridging therapy was instituted in only 8.3% of cases.  Six patients (0.6%, 95% CI 
0.2-1.3) had a “major” bleeding episode, while 17 patients (1.7%, 95% CI 1-2.6) 
had a “non-major” bleeding episode.  Four of the 6 patients with major bleeding 
and 10 of the 17 with non-major bleeding had received bridging therapy.  This 
resulted in an overall bleeding rate of 13% in bridged patients.  
Thromboembolism occurred in 7 patients in the first 30 days post-operatively 
(0.7%, 95% CI 0.3-1.4).  None of these patients had received bridging therapy, 
and two of the seven would have been considered at high risk for thrombosis 
(124). 
In a second cohort of 345 patients with AF undergoing invasive procedures, 
warfarin was withheld and bridging therapy (UFH or LMWH) given to those 
considered at high risk of thromboembolism.   The incidence of 
thromboembolism was 1.1% in the first 3 months post-operatively and did not 
differ significantly between those who had received bridging therapy and those 
who had not.  The three month post-operative incidence of major bleeding was 
2.7% and was not different between groups. The authors concluded that the 3-
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month cumulative incidence of thromboembolism and bleeding among patients 
with AF in whom anticoagulation was temporarily interrupted for an invasive 
procedure was low and was not significantly influenced by bridging therapy 
(125).   
 A meta-analysis of 34 studies (only one of which was a randomised controlled 
trial) over the period 2001 – 2010, examined the use of heparin bridging therapy 
in elective surgery.  Thromboembolic events occurred in 73 of 7118 bridged 
patients and 32 of 5160 non-bridged patients (pooled incidence 0.9% versus 0.6%, 
odds ratio 0.8; 95% CI 0.42-1.54) in the eight studies comparing these two 
groups.  The authors concluded that there was no significant difference between 
groups for the occurrence of thromboembolism.  The risk of bleeding was 
increased in the group receiving bridging anticoagulation (odds ratio 5.4, 95% CI 
3-9.74) while the risk of major bleeding was also increased with an odds ratio of 
3.4 (95% CI 1.52-8.5).  When full therapeutic doses of bridging heparin were 
compared with prophylactic doses, there was no increase in thromboembolic 
events (odds ratio 0.3, 95% CI 1.27-4.08).  However, there was an increase in 
bleeding episodes (odds ratio 2.28, 95% CI 1.27-4.08) (126).  The studies 
analysed in this meta-analysis were not of high quality and included only one 
RCT.  This could have resulted in the introduction of bias as patients at higher 
risk of thromboembolism would have preferentially received bridging therapy.  
Caution should therefore be exercised in the interpretation of these data (126). 
A further study of 328 patients examined the use of sub-therapeutic doses of 
LMWH (e.g. 40mg enoxaparin or 3800IU Naroparin) once daily in patients 
considered to be at low risk for VTE and given twice daily in those considered to 
be high risk.  The overall incidence of VTE was 1.8% and this was not 
significantly different between those in the low (0.54%) and high risk groups 
(3.4%).  The overall risk of bleeding was 2.1% and was not significantly different 
between low and high risk groups (127).   
This approach may be considered a reasonable compromise between the risks of 
bleeding and VTE in surgical patients.   
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3.5 Chapter Summary 
• Patients suffering hip fracture are at high risk of developing venous 
thromboembolism and should be prescribed thromboprophylaxis both pre- 
and post-operatively.   
• Both low molecular weight heparins and Fondaparinux are recommended 
for this purpose by SIGN.  Mechanical compression devices may also be 
used but are limited by adverse effects such as skin trauma.  Graduated 
compression stockings are not recommended. 
• Patients taking warfarin present a particular challenge in the peri-
operative period, and the risks of thrombosis while warfarin is stopped 
must be weighed up against the risks of bleeding.   
• The use of small doses of vitamin K is recommended to expedite reversal 
of warfarin and allow early surgery in patients with hip fracture.  
• Evidence regarding the use of bridging therapy is lacking and there is 
considerable variation in practice in this area.   
• A reasonable compromise could be to use sub-therapeutic dose 
enoxaparin in those deemed low risk for VTE with higher dose enoxaparin 
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Clinical Practice Guidelines and their role in the 
management of hip fracture
 4.1 Clinical Practice Guidelines  
Guidelines are designed to assist clinical decision making by summarising 
evidence and forming recommendations.  Health care professionals working in all 
disciplines are expected to practice according to current policies and guidelines 
from a variety of sources.  Robust, evidence-based guidelines should lead to the 
most effective therapy, result in improved outcomes and reduce unnecessary 
variations in practice.    
4.1.1 Problems with guidelines – volume of information 
Evidence-based medicine should manifest as the integration of best research 
evidence with clinical expertise and patient values (128).  However, the quality 
of published evidence is variable and is being produced at such a rate that 
remaining “up to date” is nigh on impossible. Pubmed has reached the 20 million 
citation mark (129) and one new citation is added to Medline each minute of 
every day (130).  It is therefore not feasible to expect a practicing clinician to 
attain and maintain an in depth knowledge of anything other than a small 
fraction of the available medical literature.  The volume of literature (which is 
of variable quality) needs to be summarised so that where evidence of 
superiority of a particular approach exists, clinicians can be advised of that 
benefit. This leads many of us to rely on others to read, evaluate and summarise 
on our behalf.   
The number of guidelines being produced is equally vast with local health 
boards, learned societies, governing bodies and government agencies within 
local, national and international spheres all contributing to the plethora of 
information.  This has the potential to create duplication and the risk of 
contradictory or conflicting advice (131-133).  In performing a review of 
guidelines relating to all stages of the management of a patient with proximal 
femoral fracture, Carthey and colleagues identified 75 relevant guidelines and 
trust-wide policies (134).  Carthey et al go on to highlight the 80 plus guidelines 
produced by the Royal College of Anaesthetists (RCoA) and Association of 
Anaesthetists of Great Britain and Ireland (AAGBI) alone.  This is in addition to 
the further 15 bodies also identified as producing guidelines relating to 
anaesthesia, and the 1000 plus guidelines produced by NICE (each of which may 
Chapter 4  82 
be several hundred pages long).  Indeed, even identifying all relevant 
recommendations from the vast number of available sources is intensely time 
consuming.  When one considers the actual dissemination and realisation of 
these guidelines, it becomes clear that this is in reality profoundly difficult. 
4.1.2 Problems with guidelines - methodology 
While there is compelling evidence that guideline implementation has in some 
cases resulted in improved outcome (135;136), the issue of quality control has 
been brought into question (135;137).  In a review of 279 guidelines published 
over a 12 year period, only 43% were found to adhere to set methodological 
standards (135;138) and in a 2009 evaluation of all guidelines produced by the 
American College of Cardiologists, a majority of recommendations were found to 
be based on expert opinion or consensus with only 11% of recommendations 
fitting into the Class A category (recommendation based on evidence from 
multiple randomised trials or meta-analyses) (135;139). This, in such a high 
profile field of medicine, is perhaps surprising. 
Concerns regarding variability in guideline methodology and integrity have 
resulted in the formation of tools designed to further assess quality and 
applicability.  The Appraisal of Guidelines Research & Evaluation (AGREE) 
Instrument seeks to provide a framework for assessing the quality of guidelines 
to ensure that recommendations are both internally and externally valid and 
feasible for practice.  Refinement in the form of the AGREE II instrument has 
provided a validated and internationally agreed tool to assess methodological 
rigour and transparency of published guidelines. In essence, AGREE II aims to 
provide the busy clinician with a degree of reassurance that a guideline can be 
trusted (140).  A recent appraisal of peri-operative guidelines using the AGREE 
assessment found that guidelines issued by government funded organisations 
were of the highest quality (141).  This evaluation tool has been adopted by 
organisations throughout the world. 
The way in which recommendations are graded is also a source of some concern. 
Traditionally, recommendations were graded in relation to the strength of the 
supporting evidence, using study design as the dominating criterion for quality 
without relating this to clinical relevance or importance.  This is considered by 
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many to be impractical and a serious limitation of guidelines.  Clinical groups, 
including the Scottish Intercollegiate Guideline Network (SIGN), have adopted 
the GRADE (Grades of Recommendation, Assessment, Development and 
Evaluation) approach to evaluate evidence (142).  The GRADE system is designed 
to separate the quality of evidence (very low, low, moderate, or high quality) 
from the level of recommendations (strong or weak). Achieving such clarity 
mandates a thorough evaluation of methodology, synthesis of a comprehensive 
evidence base and interpretation of relevance and applicability to the target 
population. An assessment of risks and benefits, as well as the likely clinical 
impact of the intervention is also made. 
Do it    A judgement that most well-informed people would make. 
Don’t do it  A judgement that most well-informed people would make. 
Probably do it  A judgement that requires full and careful consideration of   
              patients’ values and preferences when offering an    
   intervention. 
Probably don’t do it  A judgement that the majority of well-informed people would  
   make but a substantial minority would not.    
Table 4.1-1- Summary of GRADE recommendations (142). 
 
In the GRADE system, a recommendation with a high quality evidence base, such 
as a well performed randomised controlled trial, may be downgraded to a lower 
level of recommendation if the treatment effect is thought likely to be small or 
if the evidence is thought not to be applicable to the target population.  The 
strength of recommendation made reflects the likelihood of a new study coming 
to a different conclusion. Therefore, a study with a lower score would both lead 
to a weaker level of recommendation as well as identifying areas for further 
research.  It should be noted that although GRADE has the potential to increase 
consistency between guidelines, it is also subject to operator subjectivity and is 
not without potential error.  
The NHS Evidence accreditation scheme provides a further useful quality 
assurance process (143).  Only guidelines with this seal of approval are used in 
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the development of NICE guidelines. Although such quality assurance processes 
are welcome, there are many highly useful and widely adopted guidelines which 
may not have been produced using such stringent conditions. For example, 
publications such as the AAGBI Safety Guidelines provide succinct, practical 
advice relating to anaesthetic emergencies such as local anaesthetic toxicity and 
malignant hyperpyrexia and have proven invaluable to anaesthetists at all stages 
in their careers (144;145).  
In order to improve consistency, the policy of leading journals is to ask that 
guidelines are introduced in an agreed and unified way describing:  The clinical 
problem to be addressed, the mechanism by which the statement was 
generated, a review of the evidence for the statement (if available) and a 
statement on practice itself. 
Where more than one group or society has issued statements on the same topic, 
it is recommended that the following questions are answered in order to 
minimise confusion and improve transparency: 
‘What other guideline statements are available on this topic?  
Why was this guideline developed?  
How does this statement differ from existing guidelines?  
Why does this statement differ from existing guidelines?’ 
4.1.3 Problems with guidelines – conflict 
Even when strictly defined methodological processes are followed, guideline 
producers may come to surprisingly different conclusions.  An interesting 
example may be found in the use of thromboprophylaxis in the intensive care 
unit.   
SIGN guideline 122: Prevention and Management of Venous Thromboembolism, 
published in 2010, states the following in relation to intensive care patients; 
 “There are insufficient data to support the recommendation of 
routine use of heparin thromboprophylaxis in such patients”  
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and  
“Other forms of thromboprophylaxis, including mechanical measures, 
have not been adequately studied in the ICU setting (104).”  
This is contradictory to the NICE guideline; venous thromboembolism- reducing 
the risk, also published in 2010 which recommends that clinicians;  
“offer VTE prophylaxis to patients admitted to the critical care unit 
according to the reason for admission taking into account: any 
planned interventions and the use of other therapies that may 
increase the risk of complications (99).” 
In making these recommendations, SIGN and NICE appraise different 
publications.  SIGN review two systematic reviews (incorporating nine 
randomised controlled trials [RCTs] and 11 cohort studies) (146;147), an RCT in 
patients within in a neurosurgical ICU (148), and an RCT in trauma patients 
(149).  NICE’s recommendation is derived primarily from one large RCT in 
medical ICU patients (150), and supported by a further RCT in septic patients 
(151).  As illustrated in this example, the interpretation of evidence even when 
performed by eminent organisations may culminate in very different conclusions.  
This is particularly prevalent in areas in which there is a dearth of literature and 
the studied populations are heterogeneous.  Conflict therefore often arises 
because the original research was not sufficiently robust to allow definitive 
guidance to be produced. Such conflict within guidelines has the disadvantage 
that it leads to confusion and may result in a degree of clinician dissatisfaction 
and disillusionment.  
4.1.4 Problems with guidelines - applicability 
Guidelines are generally focused on single conditions and can perform poorly 
when applied to more complex cases (152). The very presence of guidelines 
relating to coexisting medical conditions has been demonstrated to reduce 
clinician adherence to guidance for the underlying condition (153).  Elderly 
patients, who often have several co-morbidities and in whom complex decisions 
must be made, are frequently under-represented in guidelines (154;155).  The 
perceived lack of ability of guidelines to provide patient centred 
recommendations (which is arguably most apparent in the cohort of patients in 
whom guidance is most needed) remains a source of criticism.    
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4.1.5 Problems with guidelines - adherence 
Despite efforts to improve the quality and reliability of guidelines, it is known 
that rates of clinician adherence to CPG vary between 20 - 100% (153).  
Adherence may be influenced by a number of factors including peer opinion and 
beliefs regarding consequences of non-compliance (156;157).  A meta-analysis of 
existing literature on clinical adherence suggests six categories to describe why 
clinicians deviate from a published guideline (158).  These categories have 
subsequently been verified in other clinical settings (159;160).  A more detailed 
analysis of why clinicians deviate from guidelines has recently been published 
(134). 
Lack of awareness  Inability to remain up to date with all published   
    literature 
Lack of familiarity  Inability to recall specific information from a guideline 
    despite being aware of its existence 
Lack of agreement  Clinician disagreement with a specific guideline or   
    guidelines in general 
Lack of outcome expectancy   Disbelief that following a guideline will lead to            
                                          improved outcome 
Lack of self-efficacy  Lack of confidence in ability to perform a behaviour  
                resulting in failure to adhere to a recommended   
    practice 
Inertia of previous practice Lack of motivation to change 
External barriers  Guideline deemed to be difficult to follow, conflicting  
    guidelines.  Patient preferences in conflict with  
    recommendations.  Financial and resource related   
    constraints 
Table 4.1-2 - Barriers to clinician adherence to guidelines adapted from Cabana et al (158). 
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4.1.6 Problems with guidelines – accessibility and reliability 
Policies and guidelines are often stored on the hospital intranet.  Having such 
documents available in an online format allows them to be accessed more 
conveniently than if they were in a library and should also allow for more 
reliable mechanisms for updating documents.  However, the amount of 
information on such servers can be vast and the identification of the necessary 
piece of information can be difficult.  Equally, while having electronically 
modifiable information should allow for updates where relevant, it can also 
allow the presence of multiple different versions of the same guideline (and 
permit out of date versions to continue in circulation. 
4.2 A comparison of clinical practice guidelines for 
proximal femoral fracture 
The following section provided the basis for an article published in the journal 
Anaesthesia, February 2013:68;159-166. The article was written by me with 
contributions from my co-authors Dr Laura Moss (clinical physicist and honorary 
lecturer, University of Glasgow), and Professor John Kinsella (Professor of 
Anaesthesia, University of Glasgow).  
 
4.2.1 Background 
In 1990, the Institute of Medicine proposed that clinical guidelines be developed 
in order to bridge the gap between evidence and practice, reduce variations in 
healthcare, assist clinical decision-making, improve patient care and decrease 
costs (161).  While opinion and consensus amongst practitioners with years of 
clinical wisdom undoubtedly is of huge value in providing guidance to those with 
less experience, the paradigm shift of recent years has led away from eminence 
and towards evidence as the basis for best practice. Increasingly, guidelines may 
be referred to as examples of customary or best practice (162).  In common with 
all healthcare professionals, anaesthetists are faced with complex patients in 
whom several clinical guidelines may apply. This creates a number of challenges 
in an increasingly time and resource-pressured environment. The peri-operative 
management of patients admitted with hip fracture is an important example of a 
challenging clinical area where evidence is lacking and practice varies (8).  
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Hip fracture is a common, serious and costly condition that occurs in an elderly, 
frail and dependent patient population (6;7).  It is estimated that 70,000 – 
80,000 cases of hip fracture occur each year in the UK (70;71).  This is projected 
to rise to around 100,000 cases in England alone by 2033, with an estimated 
associated cost of £3.6 – 5.6 billion (73).  The vulnerability of this patient group 
is illustrated by the associated prolonged length of hospital stay, complex care 
journey, ongoing care needs and high levels of morbidity and mortality (75).  
Data from national audits suggest a consistent and persistent mortality rate of 
around 7–10% at one month and 30% at one year (8;71;76).  Hip fracture 
therefore results in signiﬁcant levels of ﬁnancial and human expenditure, 
accounts for the useage of a huge amount of health resource and is a burgeoning 
public health challenge (73;77;78). 
Several guidelines designed to standardise and improve care for patients with 
hip fracture group have been created over the last ﬁve years (72;79;87;89;163).  
A review of guidelines relating to the management of hip fracture exploring the 
similarities, differences and conﬂicts encountered was performed. 
4.2.2 Methods 
The PubMed, Medline, Embase and Cochrane databases were searched for papers 
in the English language published from 1996 to September 2012 using the search 
terms ‘clinical practice guidelines’, ‘practice policies’, ‘protocols’ and 
‘consensus statements’, and combining these with ‘femoral fracture’ and ‘hip 
fracture’. Current local and national (UK) guidelines relating to the peri-
operative management of hip fracture were accessed via the former NHS 
National Library of Guidelines (164) and NHS Evidence websites (165).  The 
websites of relevant government organisations, professional societies, and 
guideline publishers were reviewed for publications of interest and reference 
lists examined. 
4.2.3 Results 
Five clinical guidelines issued over a ﬁve-year period in the UK were identiﬁed. 
These were: the British Orthopaedic Association/British Society of Geriatricians 
(BOA/BSG2007) (89), the Scottish Intercollegiate Guideline Network (SIGN 2009) 
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(87), the National Institute for Health and Clinical Excellence (NICE 2011) (79), 
the Association of Anaesthetists of Great Britain and Ireland (AAGBI 2011) (72), 
and the British Orthopaedic Association (Standards for Trauma; BOAST 2012) 
(163).  Guidelines ranged in length from one to 664 pages.  
4.2.4 General recommendations and timeline 
All guidelines highlighted the high levels of comorbidity and frailty apparent 
within this patient group, advising a thorough assessment of any factors that may 
have caused the fall as well as level of physical and cognitive function.  
Recommendations relating to general aspects of management such as delivery of 
adequate patient information, multidisciplinary management, the beneﬁts of 
orthogeriatric input, a dedicated trauma team and theatre list and consultant-
delivered care were common to all guidelines.  General care issues including 
pressure area protection, nutritional assessment and supplementation, adequate 
hydration, and coordinated rehabilitation with supported discharge were also 
consistently acknowledged.  Recommendations regarding timing of surgery were 
addressed in all guidelines.  A four-hour time period from hospital to 
orthopaedic ward admission was speciﬁed in BOA/BSG 2007, NICE 2011 and 
AAGBI 2011 publications.  This was reduced to two hours in SIGN 2009, and was 
not speciﬁed in the updated BOAST 2012 guideline.  All guidelines emphasised 
the advantages of expedited surgery with all but SIGN 2009 setting a standard of 
surgical repair on the day of or day after surgery and within daylight hours.  This 
was reduced to 24 hours in the SIGN 2009 guideline. 
4.2.5 Analgesia 
Both SIGN 2009 and AAGBI 2011 advise early analgesia in the pre-hospital setting 
while the remaining guidelines focus on management in the emergency 
department.  Guidelines generally recommend the use of regular oral 
paracetamol, the avoidance of non-steroidal anti-inﬂammatory drugs and regular 
assessment of pain at rest and movement taking into account the potential for 
the decreased capacity to express pain in the elderly population. The BOA/BSG 
2007 guideline speciﬁed that oral or intramuscular opioids should be used in 
preference to the intravenous route, with codeine and tramadol also considered 
as useful agents.  This is in contrast to the SIGN 2009 and AAGBI 2011 guidelines 
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which advise the careful titration of intravenous morphine and the avoidance of 
oral opioids and codeine due to adverse effects such as constipation peri-
operative cognitive dysfunction and delirium. There was a lack of cited evidence 
in this area. 
The use of peri-operative peripheral nerve blockade was discussed in SIGN 2009, 
NICE 2011 and AAGBI 2011. All three guidelines, after considering the same 2002 
Cochrane review (166), concluded that peripheral nerve blockade should be 
considered as an adjunct for both pre- and postoperative analgesia.  The NICE 
2011 guideline speciﬁed further that peripheral nerve blockade should only be 
added if analgesia was inadequate after the administration of paracetamol and 
titration of systemic opioid analgesia. 
4.2.6 Anaesthesia 
The conduct of anaesthesia was discussed in all guidelines with the exception of 
BOAST 2012. Conclusions from both SIGN 2009 and NICE 2011 were based on the 
results of a 2004 Cochrane meta-analysis of 22 studies (167), with an additional 
paper on cost-effectiveness included by NICE (168).  Whilst SIGN 2009 made a 
consensus recommendation that regional anaesthesia should be considered for 
all patients unless contraindicated, NICE 2011 considered that patients should be 
offered a choice between regional and general anaesthesia after a patient- 
centred consideration of the risks and beneﬁts.  The AAGBI 2011 publication 
included another more recent meta-analysis that included 18,715 patients from 
34 randomised controlled trials, 14 observational studies and eight reviews 
(169).  The recommendation of this guideline was that regional anaesthesia be 
the preferred technique. The importance of patient-centred, multidisciplinary 
decision-making and considerate anaesthesia (regardless of technique) was 
highlighted. Other recommendations by AAGBI 2011 included: consideration of 
peripheral nerve blockade in all cases, low doses of local anaesthetic and use of 
the lateral position to reduce haemodynamic compromise with neuraxial block, 
the use of fentanyl in preference to morphine or diamorphine for spinal 
anaesthesia and avoiding the combination of general and spinal anaesthesia. 
Pragmatic guidance relating to the administration of general anaesthesia was 
also given. 
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4.2.7 Anticoagulation and antiplatelet therapy 
Guidelines differed in their approaches to this issue.  Recommendations are 
summarised in Table 4.2-1. It should be noted that guidelines on the peri-
operative management of anticoagulation not speciﬁc to patients undergoing 
proximal femoral fracture repair are also available. 
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Not mentioned Surgery should not be delayed. General 
anaesthesia recommended in patients 
taking dual antiplatelet therapy. Transfuse 



































Aspirin may be withheld during inpatient 
stay, unless indicated for unstable angina or 
recent / frequent transient ischaemic 
attacks. Clopidogrel generally not stopped 
on admission. Surgery should not be 
delayed. Platelets should not be 
administered prophylactically. Higher than 




















Table 4.2-1 - Summary of guidance for the management of anticoagulant / anti-platelet drugs in patients undergoing repair of proximal femoral fracture. 
  
4.2.8 Cardiac murmur and anaemia 
The presence of an undiagnosed systolic murmur is a common dilemma in this 
patient group. This is highlighted in the 2001 NCEPOD report (170), and this 
document is therefore included in the analysis. Guidance is summarised in Table 
4.2-2. 
Guidance related to anaemia is summarised in Table 4.2-3.
 Source Indications for pre-operative echocardiography 
BOA / BSG 2007 (89) If an echocardiogram can be obtained without causing delay, the information may be useful. 
The absence of echocardiography should not lead to delays in fixing the fracture. 
 
SIGN 2009 (87) 
 
Echocardiography should be performed if aortic stenosis is suspected, to allow confirmation of diagnosis, risk stratification 
and any future cardiac management. 
The need for echocardiography, based on clinical history, physical examination and ECG findings should not delay surgery 
unduly 
Rapid access to an echocardiography service is recommended for appropriate patients to avoid unnecessary delay to 
surgery 
Older people with hip fracture do not require routine additional cardiac investigation such as echocardiography before 
surgery. 
 




AAGBI 2011 (72) 
 
Echocardiography may be indicated:  
(i) to establish left ventricular function if the patient is breathless at rest or on low-level exertion  
(ii) to investigate the severity of an ejection systolic murmur heard in the aortic area, particularly if signiﬁcant aortic stenosis 
is suggested by two or more of:  
- a history of angina on exertion 
- unexplained syncope or near syncope 
- a slow rising pulse 
- an absent second heart sound 
- left ventricular hypertrophy on the ECG without hypertension (although clinical signs of aortic stenosis can be difﬁcult to 
elicit). 
“Awaiting echocardiography” is an unacceptable reason to delay surgery. 
A majority of clinicians favour proceeding to surgery with modiﬁcation of their technique towards general anaesthesia and 
invasive blood pressure monitoring, with the proviso that patients should undergo echocardiography in the early 
postoperative period. 
 




NCEPOD 2001 (170) 
 
An asymptomatic cardiac murmur may indicate significant cardiac disease and should be investigated with pre-operative 
echocardiography. 
Table 4.2-2 - Summary of guidance for the management of cardiac murmurs in patients undergoing repair of proximal femoral fracture
   
Source Perioperative management of anaemia 
BOA / BSG 
2007 (89) 
Transfusion may be required as a drop in haemoglobin concentration of 2-3 g.dl-1 over the peri-operative period can be 
anticipated in most patients 
In the absence of reliable evidence to guide the use of blood transfusion after hip fracture surgery, practice varies 





Comments on paucity of evidence in this area 










Pre-operative transfusion should be considered for a haemoglobin concentration <9 g.dl-1, or <10 g.dl-1 with a history of 
ischaemic heart disease 
If haemoglobin concentration is 10–12 g.dl-1, two units of blood should be crossmatched  
If haemoglobin concentration is within normal limits, a grouped sample is sufﬁcient 





Identify and treat correctable co-morbidities immediately so that surgery is not delayed 
 
Table 4.2-3 - Summary of guidance for the management of anaemia in patients undergoing repair of proximal femoral fracture. 
  
4.2.9 Discussion 
Consider the care of an elderly patient arriving in hospital at 11:00am, who 
spent three hours in the emergency department, received oral opioids, was 
found to have an asymptomatic murmur and was investigated with an 
echocardiogram before being operated on the following afternoon. The 
management of this patient would be compatible with the BOA/BSG 2007, NICE 
2011 and BOAST 2012 guidelines, whilst various aspects of the same patient’s 
management would be contrary to AAGBI 2011 (in at least two aspects) and SIGN 
2009 (in at least three aspects).  It is also relatively easy to select other 
examples that are completely compatible with the SIGN 2009 and AAGBI 2011 
guidelines but are contrary to the other guidelines. 
So why do guidelines differ?  Timing undoubtedly plays a major role. It is clearly 
impossible that a guideline published ﬁve years ago could appraise the same 
literature as one published several years later.  Conversely, the authors of a new 
guideline might ﬁnd that there is no recent evidence to review and be forced to 
analyse studies that are out of date and are not representative of current 
practice.  Whilst this situation might seem surprising in view of the continuing 
increase in volume of medical literature (130), it is not infrequently encountered 
(as illustrated in the review of anaesthetic technique for proximal femoral 
fracture repair).  Furthermore, guidelines can vary in the literature reviewed, 
even when they are published around the same time. This may relate to 
different search strategies and criteria, or could reﬂect differing perspectives, 
objectives and intended readership. 
For example, although the AAGBI 2011 and NICE 2011 hip fracture guidelines 
were published in the same year, they differ in the literature reviewed on 
anaesthetic technique.  While both guidelines include the 2004 Cochrane review 
by Parker and colleagues (167), the AAGBI document also considers a larger more 
recent meta-analysis by Luger et al (169).  The reasons for this are not clear 
though may reﬂect the differing timescales in which guidelines are created, as 
well as the slightly later publication date of the AAGBI guideline.  The AAGBI 
guideline is clinician driven and patient-centred, placing a greater emphasis on 
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the practical issues surrounding the patient journey, whilst NICE must balance an 
over-arching responsibility for the fair and optimal use of resources with that of 
current best practice and clinical will and is accountable to Government. This 
may at times create an interesting counterpoise.  Differences in guidelines may 
result in fundamental differences in practice and are an important phenomenon. 
Barriers to compliance with guidelines are well documented in a recent article 
by Carthey and colleagues (134).  The exponential increase in the number of 
published guidelines brings with it a notable variability in guideline quality, an 
issue actively addressed by the AGREE (Appraisal of Guidelines for Research and 
Evaluation) collaboration (140;171). The AGREE II tool is designed to “assess the 
quality of practice guidelines across the spectrum of health, provide direction on 
guideline development, and guide what speciﬁc information ought to be 
reported in guidelines” (140). Despite laudable intentions, such tools are not 
infallible and have limitations.  The AGREE II instrument is one of the most well-
validated tools for guideline methodological assessment and incorporates 23 
items within six domains: scope and purpose, stakeholder involvement, rigour of 
development, clarity of presentation, applicability and editorial independence 
(140).  Within this process, methodological processes are systematically 
assessed.  However, the quality of the literature assessed and the 
appropriateness of the conclusions reached are not independently evaluated.  
This is a potential weakness and leaves open the possibility for unanswered 
questions on a guideline’s clinical validity. Equally, while allowing for a degree 
of comparison to be made between different guidelines on a topic, there is no 
watershed mark by which a guideline on a particular topic can universally be 
considered acceptable or clinically apt.  Although AGREE II is undoubtedly a 
welcome addition to guideline development processes, it may not yet be 
adequate to fully determine the utility of an individual clinical guideline. Thus, 
even guidelines produced by organisations granted the AGREE seal of approval 
are not immune to criticism (172;173).  
This raises further questions regarding the medicolegal implications of 
guidelines. In correspondence following a much debated editorial on NICE 
guidance of CardioQTM monitoring (174),  Ghosh and colleagues suggested that 
clinicians might fear claims of negligence if they did not follow guidance 
produced by high-proﬁle organisations such as NICE. They also considered that 
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the incorporation of guidelines into the Commission for Quality and Innovation 
(CQUIN) framework is likely to result in additional ﬁnancially motivated 
pressures to comply (173;175).  In reply to recent similar criticisms (176), NICE 
responded by clearly stating that guidelines are “not in any way mandatory” and 
are designed to help “healthcare professionals and patients make informed 
choices” (177).  Despite these reassurances, the quasi-legal status of guidelines 
is a matter of understandable anxiety and uncertainty amongst practicing health 
care professionals.  In a case of medical litigation, the main question that must 
be answered is whether or not a doctor has provided a standard of ‘reasonable 
care’ as required by law. This is judged by taking into account the circumstances 
surrounding a particular situation and balancing the differences inherent in 
medical practice against the interests of the patient. Traditionally, the standard 
of care in law has been determined according to the Bolam test (178).  This is 
based upon the principle that a doctor does not breach the legal standard of 
care and thus is not negligent if their practice is upheld by a responsible body of 
professionals with expertise within the same clinical ﬁeld. However, this 
principle has been criticised as relying unduly upon medical testimony with 
insufficient attention to the interests of the patient. More recently, there has 
been a move towards the requirement for an explanation of the logic underlying 
the standard of care deemed acceptable by the ‘body of medical opinion’. This 
is known as the Bolitho test.  As a result, the Courts enquire in increasing detail 
about the analysis of events, supporting evidence base and risk analysis of 
potential other courses of action (179).  Although accepted practice will be 
established in the Court by the invitation of expert testimony, guidelines may be 
increasingly referred to by expert witnesses, as well as the judge, as evidence of 
customary and accepted best practice. 
On a superﬁcial level, it might seem reasonable to suggest that a competent 
clinician should follow all of the recommendations in an evidence-based 
guideline, all of the time.  This assumes that the guideline is completely up to 
date, uses only completely robust evidence and is entirely applicable to the 
patient in question. Unfortunately, or perhaps fortunately, the medical 
literature is expanding rapidly at a rate far exceeding that possible for guideline 
production. The process by which guidelines are formed is hugely resource and 
labour intensive and cannot at present be repeated for every new piece of 
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evidence that is produced in a clinical field. Even once a guideline is accepted as 
being fit for purpose, its timely implementation in the clinical setting can create 
signiﬁcant challenges in terms of resources, cost, staff training and ultimately 
acceptance and reliable implementation by the clinical team. 
The presence of conﬂicting, out-of-date or methodologically ﬂawed guidelines 
could have far-reaching and serious consequences though are hard to avoid in 
reality. Equally, the presence of guidelines containing polarised advice could 
highlight that the area under investigation is one in which there is clinical 
uncertainty (and likely low levels of clinical evidence) and thus aid both 
defendant and claimant on the same issue. Until these issues are resolved, if 
they ever are, guidelines should serve as a source of reference regarding best 
practice and not be legally binding. Despite this, it is certainly plausible that 
high-quality, peer-reviewed guidelines produced by a professional group (such as 
the AAGBI) may be seen as consistent with the tenets of both Bolam and Bolitho, 
and thus realise a greater importance as a source of reference during court 
proceedings. As discussed recently, it would seem reasonable that clinicians 
should be prepared to justify their reasoning when making any major deviations 
from relevant guidelines (180).  
Advances in technology have the potential to provide solutions to some of the 
issues described above. The SIGN guidelines are now being published in 
electronic rather than paper-based formats to allow them to be read on mobile 
devices (181) and NICE has also taken measures to improve user-friendliness by 
creating ‘pathways’ mapping all sources of guidance on a particular topic and by 
enhancing its website (182).  It is hoped that these measures will help to 
increase awareness, accessibility and utility of guidelines providing useful 
information where needed at a clinical interaction. Similarly, the Artiﬁcial 
Intelligence in Medicine research ﬁeld recognises the inherent challenges (and 
potential advantages) of managing multiple, complex clinical guidelines and is 
currently active in the development of methodologies and systems to aid in this 
task (183;184).   Although many advances have been made in the technology 
supporting the computerisation of guidelines, further investigation into which 
populations to target, the optimal types of system to use and most importantly 
effects on patient outcomes and overall cost-effectiveness are needed.  The 
recognition that poorly programmed systems may result in harm due to poor 
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training, human error or improper use of software is also important and 
highlights the need for caution when such technologies are introduced into 
practice (183). Development and validation of the necessary technology 
represents only one of the barriers to its successful integration into the clinical 
environment. If the promise of its considerable potential is ever to be realised, 
advances must be made not only within the technical domain, but in the social, 
educational and cultural change that must accompany it. 
4.2.10 Competing interests 
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4.3 Chapter 4 Summary 
 The use of clinical guidelines has a number of advantages but is also 
associated with significant limitations. 
 Processes for formulating guidelines must be robust and open to 
evaluation by external parties. 
 Making guidelines up to date and user-friendly is essential if they are to 
continue playing a meaningful role in clinical care 
 Guidelines for the anaesthetic management of hip fractures vary. 
 Reasons for this include: the date of guideline creation, nature of 
organisation creating the guideline and methodology used to create the 
guideline. 
 Guidelines are useful aids with which to inform practice and clinicians 
should be prepared to justify any major deviations from relevant 
guidelines. 
 Guidelines are not currently legally binding though they may be used to 
guide opinion in court. 
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A one year retrospective audit of the management 
of patients with hip fracture in Glasgow Royal 
Infirmary 
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A significant proportion of the following chapter was performed as 
part of an intercalated BSc degree project for which I was principle 
supervisor.  The concept for the audit and quality improvement 
intervention was mine.  Under my direction and close supervision, 
Miss Katherine Cameron (KC, 3rd year medical student) performed the 
data collection and analysis informing this work. Ongoing data 
collection, analysis and quality improvement work are being 
performed by myself. 
 
5.1 Rationale 
As the SHFA had ceased reporting 4 years ago, prior to the commencememt of 
this work (71), and in keeping with recommendations for large scale data 
collection by HipPeN (8), we wished to study the management of patients 
admitted with proximal femoral fracture (PFF) in Glasgow Royal Infirmary over a 
one year period.   We aimed to establish current practice, allow comparison 
against national data and identify possible areas for improvement.   
The analysis performed was based mainly on the outcomes reported by HipPeN 
as these related more specifically to anaesthesia and peri-operative care (8). 
This was felt to be most relevant to our clinical practice and potential area of 
influence. Other outcomes of interest were compared against those reported in 
NHFD and SHFA where possible (71;185). 
5.2 Methods 
Ethical approval was sought from the West of Scotland Research Ethics Group 
and was deemed unnecessary as the intervention was considered to be one of 
service development. 
Data for patients admitted between 1st August 2011 and 31st July 2012 were 
obtained by RK from the Bluespier Database (an orthopaedic theatre 
management system).  Data for each patient (Table 5.2-1[a]) were collected by 
KC using Clinical Portal, North Glasgow laboratories’ database, case notes and 
hospital admission records. The database was cross-checked for accuracy by a 
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second investigator (RK).  All data were stored using an encrypted storage 
device.  Data for comparison were extracted directly from the first report from 
the NHS Hip Fracture Per-operative Network (HipPeN) (8).  
After consultation with clinical staff from a number of disciplines, patients 
admitted to ICU and patients taking warfarin were felt to be sub-groups meriting 
a more detailed analysis.  Patients admitted to the Intensive Care Unit (ICU) 
were identified using the WardWatcher database. Patients on warfarin were 
identified using Clinical Portal, laboratory results and clinic letters (Data fields 
collected as outlined in Table 5.2-1[b & c]). Case notes of patients taking 
warfarin were subject to further analysis resulting in the production of individual 
management timelines.  Results for patients taking warfarin are discussed in 
detail in Chapter 6. 





Date of surgery 
Delay to theatre 
Death at 30 days 
Length of stay 
Type of anaesthetic 
Grade of surgeon 
Grade of anaesthetist 
 
(b) Specific data for patients admitted to ICU 
Reason for admission 




Predicted hospital mortality score 
 
(c)  Specific data for patients taking warfarin 
INR on admission 
Time to reduce INR to < 1.5 
Time to theatre 
Method of warfarin reversal 
INR on day of surgery 
Prophylactic bridging therapy 
Time to restart warfarin post-operatively 
 Time to achieve therapeutic INR 
  
Table 5.2-1 - Data fields 
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Figure 5.2-1 – CONSORT diagram of patient identification 
 
Data were recorded and analysed using Microsoft Excel.  Statistical analysis was 
performed using Minitab v15. Data were reported as Mean (SD) or Median (IQR) 
where appropriate. Tests of two proportions, Chi-square and Fishers exact tests 
were utilised dependant on the distribution of the data and statistical 
significance was assumed at the level of p < 0.05.  For some outcomes, the 
national audits being used for comparison did not mention assessment of 
normality.  In the case of our data being non-normally distributed, no statistical 
comparison could be made as we did not have access to the raw data from 
national audits.  
5.3 Results 
5.3.1 Benchmarking data from GRI against national data 
Three hundred and ninety three surgical repairs of PFF were performed at GRI 
between August 2011 and July 2012. A comparison of data from GRI and HipPeN 
(2010) is shown in Table 5.3-1. 
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Variables GRI HipPeN p value 
Patients (n) 393 1195  
     Male 120 (30%) 319 (27%) 
0.140* 
     Female 273 (70%) 876 (73%) 
Age / years. Median (IQR) for 






     Male 72 (61-83) 78 (13) † 
     Female 80 (73-87) 83 (10) † 
ASA Grade    
       I 16 (4%) 30 (3%) 
0.146* 
      II 107 (26%) 351 (29%) 
     III 235 (60%) 619 (52%) 
     IV 35 (10%) 119 (10%) 
 Method of Anaesthesia    
     General Anaesthetic (GA) 216 (55%) 596 (51%) 
0.063* 
     Regional Anaesthetic (RA) 177 (45%) 579 (46%) 
Grade of Surgeon    
     Consultant 158 (41%) 416 (38%) 
<0.001* 
     Registrar 93 (25%) 252 (23%) ° 
     ST 3-7 82 (21%) 406 (37%) ° 
     ST 1-2 34 (9%) 22 (2%) 
     SHO 15 (4%) §  0 § § 
Grade of Anaesthetist    
     Consultant 368 (94%) 683 (58%) 
<0.001¶      Registrar 20 (5%) 260 (32%) ° 
     Trainee Grades 5 (1%) 235 (20%) ° 
Table 5.3-1 - Comparison of data between GRI and HipPeN 
Values are n (%) unless stated otherwise 
*Denotes chi-square analysis. † Denotes GRI data not normally distributed and therefore not 
suitable for comparison with HipPeN data. § Denotes data incompatible for statistical comparison 
removed from analysis due to values of 0. ¶ Denotes Fishers exact test (used due to small sample 
size). ° Denotes HipPeN data estimated from graphs 
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Ninety three patients (24%) underwent surgery on the same day as their hospital 
admission, with 190 (48%) being operated on within one calendar day, 64 (16%) 
within two calendar days and the remaining 46 (12%) thereafter (Range 0-22 
days). The median length of stay was 15 days (IQR 8 - 30 days, Range 1 - 207 
days). 
Thirty day mortality was 6.1% (22/393). Results for thirty day mortality from 
national audits are listed for comparison: NHFD (8.1%), SHFA (9%) and HipPeN 
(9%).  This did not reach statistical significance (p = 0.179). Mortality and length 
of stay data were compared with results relating to patients in GRI from the 
SHFA in 2008 and are tabulated (Table 5.3-2). 
Variables GRI (2008) GRI (2011/12) p value 















15 (18-30) § 
Table 5.3-2 - Comparison of data: SHFA 2008 versus GRI 2011-12 
Values are n (%) unless stated otherwise. ‡denotes test of two proportions.  § denotes data not 
suitable for comparison as not normally distributed and no access to raw data. 
 
The Scottish Index of Multiple Deprivation (SIMD) 2012 was used to stratify 
patients for levels of deprivation (186).  Two hundred and fifty one (64%) 
patients admitted for hip fracture repair were living in the 25% most deprived 
areas of Scotland. 
5.3.2 Patients admitted to Intensive Care Unit 
Demographic data for patients admitted to ICU / HDU are shown in Table 5.3-3.  
During the period 1st August 2011 and 31st July 2012, seventeen patients (4.3%) 
were admitted to the GRI ICU / HDU following surgery for hip fracture. Eleven 
patients had been admitted to ICU in the 4 year period 2007-2011 (2007 was the 
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time point at which WardWatcher began and hence the period from which 
reliable data could be obtained).  
The mean length of stay in the ICU was seven days (SD = 11), median APACHE 
score was 19 (IQR 15-23), and median predicted hospital mortality was 15.9% 
(IQR 9.6-29.2). Actual hospital mortality was 29% (5 patients). “Surgery plus co-
morbidity” (41%) was the most common reason for admission to ICU with 
cardiovascular disease constituting the majority of co-morbid conditions (13, 
76%). Four patients required organ support (24%), three required ventilation and 
three underwent invasive cardiovascular monitoring.  Renal replacement therapy 
was not required in any patient. 
Variables All GRI ICU 
Patients (n) 393 17 
Sex    
Males 120 (30%) 9 (53%) 
Female 273 (70%) 8 (47%) 
 
Age (SD) 76 (14) 76 (9) 
Males 70 (16) 74 (9) 
Female 78 (12) 83 (6) 
 
ASA   
1 16 (4%) 0 
2 107 (26%) 1 (6%) 
3 235 (60%) 13 (76%) 
4 35 (10%) 3 (18%) 
 
Length of stay 
median (IQR) 
15 (8-30) 29.5 (22.5-
42.5) 
 
30 day mortality (n, %) 22 (6.1%) 3 (17.6%) 
Table 5.3-3 - Demographic data for all patients compared with the sub-group of interest 
(patients admitted to ICU) 
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5.4 Discussion 
5.4.1 Glasgow Royal Infirmary versus National Data 
In this comparison of data obtained from patients in a single Scottish hospital 
(GRI) with data reported by the HipPeN group (English and Welsh hospitals), 
gender split was not significantly different with females accounting for around 
70% of all operations (p=0.140). Although age distribution was not suitable for 
statistical comparison, the mean age for patients in GRI was 76 years, lower than 
that reported by HipPeN (81 years). Overall, ASA score distribution was not 
significantly different (p = 0.146). However, when higher ASA grades were 
analysed separately, a greater proportion of GRI patients had ASA III and IV 
status (70% in contrast to 62% in HipPeN).  
The performance of high quality RCTs for hip fracture surgery is associated with 
significant challenges, including issues with eligibility criteria and informed 
consent. This has resulted in a lack of high quality evidence from randomised 
controlled trials (RCTs) (80). One proposed solution is the collection of large 
amounts of high quality data via large collaborative audits.  Such audits aim to 
collect data on outcomes of interest as well as relevant information on potential 
sources of bias and confounding factors (such as co-morbidity data) and adjust 
appropriately (8). National databases such as HIPPeN, SHFA and NHFD have done 
much to advance our knowledge regarding the management of these patients.   
In GRI, 72% of patients received surgery on the day of, or day after admission. 
Unfortunately, for logistical reasons, data could not be collected on number of 
hours to theatre, and this is a major limitation of this audit.  HipPeN reported a 
median time to theatre of 47h, with 11 of the 22 included hospitals reporting a 
mean time >48 hours (8). Several meta-analyses have concluded that 
unnecessary delay is more likely to increase morbidity (80;81;187-189). Most 
guidelines therefore recommend expedited surgery (72;79;87;89;163). Timing of 
surgery is discussed further in Chapter 7. 
The median length of stay within the study period in GRI was 15 days.  This 
represents a 4 day reduction when compared to the data reported for GRI by the 
SHFA in 2008.  Length of stay was not reported by HipPeN. Reducing the length 
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of hospital stay is considered to be one of the most important areas for 
improvement both in terms of patient outcomes and reducing costs.  The NHFD 
estimate that each additional day in hospital results in an increased spend of 
£248 (76).  It should be noted that length of stay is a relatively crude marker of 
care which can be affected by a number of wide-ranging factors outwith the 
realm of medical fitness for discharge.   
Morbidity and mortality after hip fracture is high and 30-day mortality persists at 
around 7-10%.  Thirty day mortality is the most frequently studied and reported 
measure of hip fracture outcome (75).  Large studies employing multiple logistic 
regression methods have resulted in the acceptance that male sex, advanced 
age, an ASA grade of III or IV, and multiple co-morbidities are associated with 
higher mortality rates (60;65;66;190). The thirty day mortality rate in GRI was 
6.1%, lower than that reported by HipPeN, NHFD and SHFA, though this was not 
statistically significant (p = 0.179). Comparison with data collected for GRI by 
the SHFA in 2008 also showed a reduction in both 30 and 90 day mortality, 
though, this did not achieve statistical significance (p = 0339 and p=0.226 
respectively). Whilst these reductions are not statistically significant, any 
potential reduction in patient mortality may be considered beneficial. 
Our data showed that over half of patients undergoing hip fracture repair 
received a general anaesthetic.  There was no statistically significant difference 
in the method of anaesthesia used in GRI compared with that HipPeN (p = 
0.063).  This was unexpected as regional anaesthesia is recommended by SIGN 
guidelines, commonly referenced in our institution.   While there is some 
evidence that regional anaesthetic techniques may reduce post-operative 
confusion, respiratory complications and financial cost (72;87;187), there is a 
counter-argument that general anaesthesia may confer greater haemodynamic 
stability.  A 2004 Cochrane review concluded that there was insufficient high 
quality evidence to rule out clinically important differences between the two 
methods (167). Type of anaesthesia remains an area of clinical variability and 
uncertainty. Both SIGN and AAGBI recommend that regional anaesthesia should 
be performed in preference to general anaesthesia where possible (72;87), 
whereas NICE adopt a more conservative approach in advocating a decision after 
full discussion with the patient (79).  
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GRI and HipPeN data differed significantly in the grade of both surgeon and 
anaesthetist (p = <0.001). A higher percentage of consultant surgeons operated 
in GRI than was seen in data from HipPeN, though the difference was small (3%). 
At GRI, 94% of anaesthetics were performed by consultant anaesthetists, 
compared to an average of 58% in data reported by HipPeN. This represents the 
most significant difference in our findings (p<0.001).  This is likely to be due to a 
new departmental policy, where consultant anaesthetists provide resident 
anaesthetic cover for weekend trauma lists. This commenced in March 2011, just 
before the study period. Published literature relating to the professional grade 
of both surgeon and anaesthetist is sparse and any available is of “low quality”, 
as reported by NICE (79).  Guidelines generally recommend involvement of senior 
staff due to the high risk nature of this patient population.   
Using SIMD 2012 data (186), 64% of our patients were found to be living in the 
25% most deprived areas of Scotland. Comparable socio-economic data was not 
reported by HipPeN. Scotland has been reported to have poorer public health 
and higher general mortality than the rest of the UK (191).  It is possible that the 
Glasgow Effect may offer some explanation as to why our patients showed a 
trend towards being younger and less fit than was reported nationally. Whilst 
level of deprivation was not discussed in the HipPeN data, it is interesting to 
consider as a confounding factor which may affect patient outcomes.  We 
speculate that GRI patients, whilst chronologically younger than the 
demographic reported in HipPeN data, may be “physiologically” older.  This 
could potentially explain some of the differences observed in both age and ASA 
score. 
 
5.4.2 Subgroups of interest - Intensive Care Unit: 
Patients admitted with hip fracture are already a high risk group.  We wished to 
examine subgroups of patients admitted with hip fracture who were felt to be at 
the higher end of the spectrum of risk.  It was considered that such an analysis 
may identify areas where care might be improved and / or resources targeted.  
Groups identified as meriting more detailed analysis were; (i) patients admitted 
to ICU and (ii) patients who were taking warfarin.  The cohort of patients 
admitted to ICU was of interest in order to identify the frequency of admission, 
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the level of care required, their length of stay in critical care facilities, and the 
potential impact on future resources.  During the audit period, our ICU changed 
from being a 10 bed unit ICU to a 20 bed combined ICU and HDU.  We were 
interested to see whether this increase in bed availability had affected the 
number of patients admitted following hip fracture and whether this demand 
was likely to increase. As this is a frail patient group, it could be argued that 
critical care facilities are under-utilised and that patients may benefit from an 
area where enhanced post-operative care tailored to this patient group could be 
offered. 
GRI patients undergoing hip fracture repair and admitted to ICU post-
operatively, had higher ASA grades and an increased length of stay when 
compared with the main cohort. Thirty-day mortality was also higher (Table 3.4-
3).  Of the 17 GRI patients, most required only basic levels of ICU care such as 
post-operative monitoring due to concerns regarding co-morbidities.  These 
patients did not require organ support and were discharged within a short time-
frame. These data also showed that the use of ICU has increased substantially in 
recent years, which we speculate may be explained by the recent expansion of 
ICU to include high-dependency beds.  It could certainly be argued that the 
majority of patients undergoing hip fracture repair could benefit from enhanced 
levels of care post-operatively.  We predict that the demand for critical care 
beds will rise.  Further work is required to evaluate whether a designated 
orthopaedic higher dependency area would be both beneficial and cost 
effective.   
5.5 Limitations 
Data published by HipPeN and used for comparison in this analysis was obtained 
from a published paper with no access to raw data.  This meant that some values 
were incompatible for statistical analysis and formal comparison.  Data reported 
by HipPeN were collected over a 2 month winter period, whereas data from GRI 
were collected over a full year. Data concerning time to surgery could not be 
collected in hours, as this was not reported in the available data and case-note 
analysis was not practical.  Obtaining case-notes was a major barrier in the 
performance of this work due to secretarial shortages resulting in long delays 
and difficulties in obtaining notes.  The lack of precise data regarding time to 
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theatre meant that this was incompatible for comparison with times reported in 
the relevant literature. These factors may impact on the credibility of our 
results.  
5.5.1 Anaesthesia Sprint Audit of Practice  
Since the performance of this analysis, a further publication from the HipPeN 
collaborators in conjunction with the Association of Anaesthetists of Great 
Britain and Ireland (AAGBI), National institute for Academic Anaesthesia (NIAA) 
and National Hip Fracture Database (NHFD) has been published.  This 
Anaesthesia Sprint Audit of Practice (ASAP)(96) was performed following the 
publication of the AAGBI guidelines on the peri-operative management of 
patients with hip fracture and analysed care against the standards set in this 
document(72).  Data were obtained for 11,130 patients (67.5% of all hip fracture 
operations in England and Wales) over a 2 month study period.  The main 
findings from this report are discussed.  The grade of most senior anaesthetist 
and surgeon was found to be a consultant or specialist in over 90% of cases 
denoting a significant improvement from the initial HipPeN report.  Only 44% of 
patients received spinal anaesthesia with inter-hospital variability noted to be 
high ranging from <10% to >80%.  The doses of bupivacaine used were greater 
than the recommended <10mg level in 79.5% of cases and only 22% of patients 
received spinal fentanyl in keeping with recommendations.  Nerve blocks were 
performed in 56% of cases indicating that this technique is increasing in 
popularity though again this varied significantly between hospitals (range 8%-
92%). The incidence of intra-operative hypotension was high with 90% of patients 
experiencing a blood pressure reduction of >20% from pre-operative values and 
77% suffering a systolic BP of < 100mmHg.  Hypotension was less prevalent in 
patients receiving a spinal and has been identified as an area requiring further 
research.  The incidence of Possible Bone Cement Implantation Syndrome was 
reported as 19% though severe reactions involving hypoxia / hypotension (2.7%) 
or cardiovascular collapse (0.5%) were less common (96).   
The results of this large scale audit have helped to define current practice and 
increase the evidence behind creating a consensus as to what defines best 
practice.  This work has identified areas where practice is variable and where 
more research and large scale data collection may be required.  The impact of 
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the institution of these standards upon patient outcomes has yet to be defined 
and this is the focus of ongoing work from ASAP and NHFD. 
5.6 Conclusions 
Outcomes for patients undergoing repair of hip fracture in GRI were satisfactory 
when compared with those reported by HipPeN in 2010.  Areas of statistically 
significant differences include demographics (with GRI patients appearing 
younger yet with a higher level of comorbidity) and professional grade of 
anaesthetist and surgeon, which is representative of the importance placed on 
the peri-operative care of these patients in GRI.  Although not statistically 
significant, mortality in GRI was lower than reported in national data and was 
shown to have decreased since 2008. The use of the intensive care unit for 
patients with hip fracture is increasing and this represents an area where further 
work is required.  The collection of accurate data is challenging without a 
dedicated data collection system as utilised by the NHFD.  Whilst the MSk group 
continue to collect data in Scotland, this is not a continuous process and cannot 
provide the level of data currently collated by the NHFD in England, Wales and 
Northern Ireland.   
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5.7 Chapter 5 Summary 
• Current practice in Glasgow Royal Infirmary was analysed by comparing 
relevant outcomes to those reported in national data. 
• Patients in Glasgow Royal Infirmary exhibited a trend towards being 
younger and having higher number of co-morbidities than was reported in 
national data. 
• Data were found to be in keeping with standards reported in  national 
data and data previously reported for GRI via the Scottish Hip Fracture 
Audit. 
• A significantly higher proportion of care is delivered by consultants at 
Glasgow Royal Infirmary than is reported in national data. 
• Ongoing collection of quality data on a national basis is important if 
continuedimprovement in care is to be achieved. 
• Patients admitted to intensive care, and patients taking warfarin were 
analysed separately after being identified as sub-groups of particular 
interest by members of the multi-disciplinary team. 
• The use of the intensive care unit is increasing. This may be due to an 
expansion in high dependency level beds.  Patients admitted to the 
intensive care unit did not require high levels of organ support.  
 
 Chapter 6 
 
An audit of the management of patients taking 
warfarin and admitted with hip fracture in 
Glasgow Royal Infirmary 
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6.1 Rationale and methods 
Using the database of 393 patients undergoing hip fracture repair within a one 
year period in Glasgow Royal Infirmary (Chapter 5), the management of patients 
taking warfarin was further examined.  This sub-group of patients had been 
identified as being particularly challenging to manage by both medical and 
nursing staff working in this area.  Management strategies were found to be 
variable and unpredictable constituting a significant clinical problem.  While 
local guidelines are available to guide the reversal of warfarin in surgical 
patients, strategies are focused upon the immediate reversal of warfarin (i.e. in 
patients with ongoing haemorrhage) and in the management of patients 
undergoing elective surgery.  As patients undergoing hip fracture repair require 
expedited surgery, they lie somewhere in between these two scenarios and 
therefore are not specifically catered for in these guidelines. 
Patients taking warfarin were identified by undertaking a review of Clinical 
Portal and the North Glasgow Laboratories database.  Data collected were: INR 
results, mention of warfarin in admission or discharge documentation, mention 
of warfarin in GP referral letter or mention of a diagnosis consistent with the use 
of warfarin (e.g. atrial fibrillation). This initial review was performed by a 
medical student (KC) and yielded 47 patients.  A further review using Clinical 
Portal was performed by an anaesthetic consultant (RK).  Of the initial 47 
patients, 19 were taking warfarin at the time of admission and were therefore 
suitable for analysis.  Case notes were requested for these 19 patients and were 
successfully retrieved for 13 patients.  The other 6 sets of notes were 
unavailable despite frequent requests  
Time-lines were created for each patient in order to describe each patient’s 
journey through the peri-operative period in a graphical form.  Clinical 
interventions (e.g. administration of agent to reverse warfarin, date of surgery 
and time for INR to become therapeutic post-operatively) were plotted against 
the patient’s INR level in order to give a detailed depiction of the sequence of 
events.  A written account of particular issues in each case accompanied the 
time-line to provide further relevant information. 
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Figure 6.1-1 - Example of patient timeline 
 
6.2  Analysis of results 
Nineteen patients were on warfarin (4.8%). However, only 13 sets of patient 
notes could be located for review despite multiple attempts. 
Demographic data are shown in Table 6.2-1. Indications for warfarin therapy 
were atrial fibrillation (10, 77%), mechanical heart valve (1, 8%), pulmonary 
embolism (1, 8%) and superior vena cava occlusion (1, 8%). Two patients (15%) 
were operated on within 24 hours, three (23%) within 36 and seven (54%) within 
48 hours. Care was discussed with the on-call haematologist in two cases (in the 
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Variables All GRI Warfarin 





Males 120 (30%) 5 (38%) 





Males 70 (16) 70 (7) 





1 16 (4%) 0 
2 107 (26%) 1 (8%) 
3 235 (60%) 12 (92%) 
4 35 (10%) 0 
 













Table 6.2-1 - Demographic data for GRI all patients versus warfarin sub-group 
 
Table 6.2-2 provides a summary of warfarin management. The most common 
intervention for reversing warfarin was intravenous Vitamin K, administered to 
10 (77%) of patients in a cumulative dose ranging from 0.5–13mg. Two patients 
were managed by withholding warfarin (15%), and one patient received fresh 
frozen plasma (FFP) (8%). No INR results were available on the day of surgery in 
5 cases (38%).   
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Variables   
Admission INR (median, IQR)                                                           2.2( 1.74-2.78)  
 
Time to reduce INR to <1.6/h  (median, SD) 
 




Total dose of Vitamin K / mg (median, range) 
 










Time from admission to theatre / h (median, IQR) 
 




Time to re-start warfarin postoperatively / h (median, IQR) 
 




Time from warfarin re-start to therapeutic INR / h (median, IQR) 
 
  80 (42.4-109.2) 
 
 
Table 6.2-2 - Results for patients on warfarin 
 
Twelve sets of notes were available for review of thromboprophylaxis. Two 
patients received no thromboprophylaxis.  Of the remaining ten patients, three 
(27%) received unfractionated intravenous heparin infusion, and seven (63%) 
received enoxaparin (six 40mg, and one 20mg).  Post-operatively, five patients 
(45%) received 40mg of enoxaparin until therapeutic INR was reached, and one 
patient received 130mg of enoxaparin daily for 8 days in combination with 
warfarin therapy. No INR checks were made on this patient until day 8.  One 
patient was given Fondaparinux (2.5mg) for 3 days followed by enoxaparin 40mg 
thereafter. All three patients given unfractionated intravenous heparin had 
significant problems with bleeding requiring blood transfusions. Notes and 
prescription charts were either incomplete or missing in 72% of cases.  
Chapter 6  121 
None of the patients taking warfarin were dead at 30 days. One patient died at 
38 days post surgery.  The remainder were still alive at the time of data 
collection. (November 2012). 
6.3 Discussion 
The quality of evidence for the peri-operative management of warfarin is poor 
and consequently, guideline recommendations are often vague and conflicting.  
The lack of concrete guidance has been discussed since 2005 (120;121;192), with 
recent reviews reiterating and defining the discrepancies (132).  Although 
certain authors have made suggestions for new local policies based on audit 
findings, these have omitted guidance on thromboprophylaxis and restarting 
warfarin (121;192).   
In GRI, 4.8% of patients admitted with hip fracture were on warfarin, similar to 
figures reported elsewhere.  Data collection for patients admitted with hip 
fracture was incomplete in that only 13 of 19 sets of case notes were available 
for review.  This is unacceptable if accurate data are to be collected and quality 
is to be assured. It is likely that the availability of notes was affected by the 
transition between a paper-based and electronic patient record which occurred 
around the same time.  This means that any conclusions based on these data 
should be treated with caution. However, we believe there are some issues 
which merit review. 
Both quantitative and qualitative (through timeline) analysis revealed 
inconsistencies in patient management.  Six patients (46%) were delayed to 
theatre beyond 48 hours, though inadequate reversal of anticoagulation was only 
responsible for this in two cases. The majority of patients (77%) underwent 
warfarin reversal with Vitamin K, though the dose range was wide (0.5 - 13mg) 
with many patients requiring repeated doses.  Four patients did not have an INR 
check on the day of surgery which is a potential safety issue.  Re-commencing 
warfarin therapy was sub-optimal with only 4 patients (30%) re-established 
within 24 hours of surgery. The prescription of thromboprophylaxis was variable. 
It should be noted that the finding of 19 patients on warfarin was a small 
number (though in keeping with what would be expected over a one year period) 
and the availability of only 13/19 sets of notes limited the value of the study. 
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Since this study, better electronic records have been introduced which have 
improved data availability and will increase the reliability of any findings. 
Several common themes permeated the management of this patient group: 
confusion regarding best-practice management, lack of clear protocols, sub-
optimal communication between members of the healthcare team and variability 
in care. 
While these data have clear limitations in terms of the small number of cases, 
the retrospective nature of the data collection and missing data, they are 
consistent with the clinical concern that this is an area in which practice varies 
and where management could be improved.  In particular, strategies for the 
reversal of warfarin and the time taken to reintroduce warfarin are variable and 
remain a source of confusion for staff.  The development of an evidence based 
protocol to standardise management was felt to be of benefit in an attempt to 
expedite time to theatre and prevent prolonged periods without anticoagulation 
in the post-operative period. 
6.4 Design of a protocol to direct management in patients 
on warfarin undergoing surgical repair of hip fracture 
The initial audit identified clear areas for improvement in the sub-group of 
patients taking warfarin and admitted for surgical repair of hip fracture.  These 
included standardising the process of warfarin reversal, reducing time from 
admission to theatre, standardising the process for the re-introduction of 
warfarin, reducing the time to achieve therapeutic INR post-operatively and 
improving compliance with thromboprophylaxis.  These findings supported the 
initial concerns expressed by clinical staff.  After liaising with relevant staff, it 
was concluded that it would be beneficial to design a protocol specific to the 
needs of this complex and vulnerable patient group to guide staff in their 
management. Staff were enthused that their concerns had been listened to and 
that an intervention to improve care and aid in the management of a challenging 
clinical area was being planned.  They were reassured that they would be 
consulted during the process and that their feedback would influence the 
production of the final protocol. 
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It was proposed that the most suitable intervention to aid improvement in all of 
these areas would take the form of a structured protocol. The protocol was 
intended to standardise practice, reduce confusion and empower staff to 
manage these complex patients in a safe and timely manner.  A multi-
disciplinary focus group was assembled with representation from anaesthesia, 
haematology, orthopaedics, intensive care medicine, cardiology, stroke 
medicine, care of the elderly and orthopaedic nursing. The protocol was 
discussed and refined within this group before being shown to ward staff for 
further feedback. The protocol was produced in a flowchart style using a colour 
coding scheme in order to ensure that it was clear and easy to follow.  It was 
reviewed by all disciplines prior to its implementation in order to ensure that it 
was unambiguous and would be practical to implement. All feedback was 
considered and changes made accordingly. The protocol was approved for 
clinical use by the Glasgow Royal Infirmary Thrombosis Committee and was 
displayed in the clinical areas used by ward staff so that it was easy to access at 
the point of care.  This protocol was endorsed by the NHS Greater Glasgow and 
Clyde Thrombosis Committee.  The protocol is displayed in Figure 6.4-1.  
Following endorsement by the Thrombosis Committee, education in protocol 
implementation was delivered to both anaesthetic and orthopaedic department 
personnel.  Haematology staff were also made aware of the protocol.  Nurse 
practitioners working on the relevant wards were recruited to be “local 
champions” and continue educating other staff about the use of the protocol.  
These champions were encouraged to liaise with the protocol authors to 
highlight any problems or areas where they felt change may be merited.  
As the use of the protocol was anticipated to be relatively rare (around 20 cases 
per year from audit data), it was considered optimal to evaluate the impact of 
the protocol after a period of six months.   
  
Figure 6.4-1 - Protocol for the management of warfarin in patients admitted with fractured neck of femur.
  
6.4.1 Re-audit results  
There were 28 patients identified as taking warfarin over the 18 month period 1st 
October 2013 and 31st May 2015.   
 Pre-protocol Post-protocol P value 
Patients (N) 13 28  
Warfarin indication (N,%):   
                                              AF 
                                           AVR 
                                  CVA + PE 
                                  AF + DVT 
                                  AF + CVA 










AF                    20 (80%) 
AF + MVR      1 (3.5%) 
AF + TIA         1 (3.5%) 
AF + CVA        1 (3.5%) 
MVR/CABG   1 (3.5%) 
CVA                 2 (7%) 
DVT                 1 (3.5%) 
TIA                  1 (3.5%) 
 
Admission INR (median, IQR)  2.2 (1.7-2.8)  2.5 (2.2-3.5) 0.38 
Hrs post admission to INR<1.6 
(mean, SD) 
31.3 (17.7) 29 (16) 0.43 
Intervention:    
                  Warfarin stopped 
                                           FFP 













Dose of Vit K (median, range) 2 (0.5-13) 5 (0-10) 
(23/28 got 5mg as their 




Patients going to theatre within 
48 hours (N, %) 
7 (58.3%) 20 (71.4%) 0.66 
Time to theatre / hrs  45 (34-68.63) 40 (23.4-51.9) 0.44 
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(median, IQR) 
INR on day of surgery  
(median, IQR)  
1.55 (1.17-1.6) 1.35 (1.2-1.5) 0.31 
Patients restarted on warfarin by 
24 hrs (N, %) 
4 (33.3%) 9 (32.1%) 1 
Time to restart warfarin / hrs 
(median, IQR)  
66.5 (24-149.5) 28 (24-46) 0.32 
Time from starting warfarin to 
INR therapeutic (mean, SD) 
normal 
80 (42.4-109.2) 120 (65-163.3) 0.43 
Thromboprophylaxis 
administered pre-op (N, %) 
10 (83.3%) 





 (10 clexane 40mg) 
0.41 
Thromboprophylaxis 







2.5mg for 3 das 
then clexane 
40mg) 
27 (96.4%)  
(15 clexane 40mg, 2 
clexane 20mg) 
0.009 
Length of stay (median, IQR) 20 (11.7-33.7) 20 (14.4-33.6) 0.38 
 
 
Table 6.4-1 - Comparison of data before and after introduction of warfarin protocol 
 
From these data, the following points were noted: 
 The protocol has standardised the method and dose of warfarin revrersal. 
 The protocol has standardised the prescription of post-operative 
thromboprophylaxis. 
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 Reversal of INR was consistently achieved with a standardised dose of 
vitamin K. 
 There was a trend toward more rapid reversal of INR and lower INR on day 
of surgery though this was not statistically significant. 
 There was a trend towards increased number of patients going to theatre 
within 48 hours. 
 There was a trend towards a reduction in the median time to restart 
warfarin. 
 There was a trend towards an increased mean time to reach therapeutic 
INR.  This did not reach statistical significance (p=0.43), though the 
numbers for comparison were small.  We hypothesise that this may be due 
to the larger dose of vitamin K resulting in a period of relative warfarin 
resistance.  However, this dod not affect length of stay and as such, was 
felt to be acceptable by the GRI Thrombosis Committee.   
 There was a trend towards increased length of stay in the post-protocol 
group. Again this did not reach statistical significance (p=0.38). This may 
have been due to the increased time taken to achieve therapeutic INR 
though reasons for delay to discharge are often multi-factorial. 
 There were no thromboembolic complications noted. 
 The data were difficult to interpret in view of the low numbers of 
subjects. 
 Ongoing data collection has seen an improvement in the availability of 
necessary data now that the electronic patient record is more 
established. 
These data have been under ongoing review by the GRI Thrombosis Committee.  
It has been recommended that the protocol be introduced on a city-wide basis 
and work is currently ongoing to achieve this.
  
Chapter 6 Summary 
 Data collection for patients taking warfarin and admitted with hip 
fracture was incomplete in that only 13/19 sets of case notes were 
available for review.  This is unacceptable if accurate data are to be 
collected and quality is to be maintained. It is likely that this was 
affected by the transition between a paper-based and electronic patient 
record which occurred around the same time. This should be taken into 
consideration when interpreting the results presented prior to the 
introduction of the protocol.  
 Ongoing data collection as part of a quality improvement initiative to 
assess the performance of the protocol has seen an improvement in the 
availability of necessary data now that the electronic patient record is 
more established.  A local (or potentially national) database designed 
specifically to collect real-time information on patients undergoing hip 
fracture repair would be beneficial in ensuring accurate data collection, 
quality control and reliability of information.   
 Management of patients in GRI suffering hip fracture and taking warfarin 
was variable and inconsistent. 
 In light of our results and a lack of national and local guidance, a quality 
improvement venture into the peri-operative management of warfarin was 
commenced.  
 A new hospital protocol has been produced.  This has undergone 
consultation by a multi-disciplinary group and has been approved by the 
Glasgow Royal Infirmary Thrombosis Committee.  
 The protocol has been implemented and is subject to ongoing audit with 
the ultimate aim of improving patient outcomes.
 PART 2 
Chapter 7 
Elective total hip arthroplasty - evidence to 
date 
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7.1 Total Hip Athroplasty 
7.1.1 Epidemiology and burden of disease 
Total Hip Arthroplasty (THA) is a surgical procedure which is performed to 
relieve pain and improve function in patients with disorders such as degenerative 
or inflammatory arthritis.  In Scotland, 7168 primary THA were performed during 
the period 2008 – 2009 (193), an increase from a mean of 6486 procedures per 
annum in the period 2005-2008. In England and Wales, 71,672 primary THA were 
performed in 2011 (37).   
 
Whilst the number of procedures continues to increase, there has been a 
reduction in the median length of in-patient stay which has decreased from 10.3 
days in 2001 to 6.2 days in 2009 in the Scottish population (193).  In addition, 
same day admissions have increased from 2% in 2001 to 35% in 2009 (193). These 
improvements are in part due to fast-track admission pathways and peri-
operative care packages including early mobilisation and physiotherapy (193).  
Despite improvements in patient throughput, the performance of primary THA 
remains a major expenditure within the NHS.  The insertion of an artificial hip 
joint is an expensive treatment with components alone costing between £400 
and £2000.  Data collated by NHS Scotland’s Information Services Division 
calculates the total cost of THA to lie in the region of £8000 and £14,000 
depending on the complexity of the surgery and presence of post-operative 
complications (194).  The performance of THA remains a high volume 
intervention associated with significant financial outlay. 
 
The median age of a Scottish patient undergoing hip replacement is 68 years and 
this is considered likely to rise as the population ages (193;195).  This elderly 
patient group commonly suffers co-morbidities such as ischaemic heart disease, 
hypertension, chronic obstructive pulmonary disease, chronic kidney disease, 
diabetes mellitus and peripheral vascular disease.  Such co-morbidities are 
associated with increased peri-operative risk and post-operative complications 
Chapter 7  131 
 
resulting in a necessity for careful, well planned anaesthesia and peri-operative 
care (196-198).    
Surprisingly, UK-wide data collected by the UK National Joint Registry shows that 
the mean age of a patient undergoing THA has actually remained fairly constant 
at around 67 years since 2003. Similarly stable are the numbers of patients in 
the over 80 category (14%) and under 50 category (6%) (37).  Over the past 8 
years, patient body mass index (BMI) has increased from 27.4 to 28.5 and there 
has been an increase in the number of patients with a BMI of between 30 and 39. 
In addition, the number of patients deemed to be “fit and healthy” according to 
the American Society of Anaesthesiologists’ (ASA) criteria has decreased. 
According to the ASA grading system, only 15% of patients undergoing a primary 
hip replacement in 2011 were considered to be Grade 1 or “fit and healthy” pre-
operatively, compared with 37% in 2003. The proportion of fit patients 
undergoing THA is notably higher in independent, when compared with NHS, 
hospitals (12% graded as ASA 1 in NHS hospitals compared with 23% in 
independent hospital). As the percentage of patients within each age bracket 
has not changed significantly since 2003, this suggests that the reduction in 
fitness and increase in BMI is not solely attributable to an ageing patient cohort 
(37).  
Retrospective data for over 2 million patients collected via the USA National 
Hospital Discharge Survey (NHDS) from 1990 to 2004 reports that the highest 
proportional increase in THA procedures was seen in the 45 – 64 year age group 
(199).   These patients were found to have increasing levels of morbidity 
including obesity, hypertension and ischaemic heart disease (199).   In 
comparison with Scottish data, the mean length of stay in the US population 
undergoing THA fell to a mean of 4.5 days in the most recent time period (199).  
However, the number of patients discharged home was found to be in decline 
with increasing numbers of patients being discharged to “skilled care”, a more 
economical way of providing ongoing care outwith the acute hospital setting.  
Data from both the UK and US demonstrate increasing rates of THA performance, 
alongside increasing levels of co-morbidity and obesity.  While US data highlights 
the increased performance of THA in a younger population, this change is not yet 
apparent in the UK population.   
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7.1.2 Surgical procedure  
The performance of THA essentially involves replacing both parts of the hip joint 
(acetabulum and femoral head) with prosthetic implants (cup, head and stem) in 
order to allow a full range of motion in multiple planes.  The “head” replaces 
the femoral head while the “cup” replaces the bony hip socket.  More than sixty 
different hip prostheses, produced by 19 companies are currently available for 
THA (200).  Prostheses may be cemented, cementless, or “hybrid” (uncemented 
socket, cemented stem).  Of the 71,672 primary THA performed in England and 
Wales in 2011, 38% were cemented THA, 41% were cementless and 19% were 
hybrid with the remainder classified as resurfacing procedures.  This reveals a 
trend towards an increasing use of cementless prostheses as well as a reduction 
in metal on metal devices following a Medical Device Alert from the Medicines 
and Healthcare products Regulatory Agency (MHRA) (200;201).  This alert 
highlighted that metal on metal devices over 36mm in size were associated with 
increased wear and consequent need for revision surgery when compared with 
other devices. There were further concerns that such “wear” could also result in 
traces of metal being found in the systemic circulation. The MHRA now 
recommend that patients with these implants are reviewed yearly on a lifelong 
basis (201). 
A number of techniques for total hip arthroplasty have been described with the 
current most prevalent techniques being the posterior and lateral approaches. In 
a Cochrane review update published in 2006, investigators compared lateral and 
posterior approaches for primary THA.  The review concluded there was 
insufficient quantity and quality of evidence to recommend one approach over 
another and no firm conclusions were able to be  drawn (202).  
7.1.3 Outcomes in total hip arthroplasty 
While the success of operations such as THA were traditionally judged using 
measures such as morbidity, mortality and post-operative complication rates, 
the focus has now shifted toward an evaluation of patient-centred outcomes. 
The assessment of health-related quality of life using validated scoring systems 
can provide a useful insight into multiple domains of patient experience (203).  
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As well as the obvious physical changes of having this surgery, psychological and 
social effects upon the patient’s daily life are also considered.  
A 2004 systematic review of 74 papers published between 1980 and 2003 and 
performed by the WHO Collaborating Centre for Public Health Aspects of 
Osteoarticular Diseases examined quality of life indices after hip or knee 
replacement. The majority of the studies reported outcomes within 6 to 12 
months (though follow up varied from 7 days to 7 years).  All studies, using a 
variety of tools, showed improvements in physical parameters such as pain and 
mobility after joint replacement surgery.  Age was not found to be an obstacle 
to effective surgery and patients seemed to derive more benefit when 
undergoing hip rather than knee arthroplasty (203).  Psychological and social 
effects were more variable but were generally more favourable when compared 
with patients who had not undergone surgery. Patients with poorer pre-
operative health related quality of life were also more likely to derive benefit 
(203).   
A further Italian study published in 2011 examined 250 patients who were under 
70 years of age and had undergone primary THA over an 11 year period (1985 to 
1996).  The study aimed to establish functionality and quality of life after THA 
and identify possible related outcome predictors.  This study followed up 
patients for a mean period of 16 years. This longer term follow up was felt to be 
important as many THA are now being performed in younger patients with 
corresponding longer life expectancies. The main finding was that of worsened 
indices of hip functionality and physical quality of life compared with age-
matched healthy controls, and increased indices of functionality and quality of 
life compared with individuals who had similar pathologies but had not 
undergone operative intervention.  Levels of surgical satisfaction were found to 
be high (204). 
It has also been proposed that timely performance of THA may lengthen lifespan 
in comparison to patients in whom the procedure is delayed (205).  In a study of 
28,469 Medicare patients with OA and Rheumatoid arthritis (RA) undergoing THA 
in 1996, six year survival was improved in the operative group compared with 
matched controls.  However, this benefit was not seen in the first three post-
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operative months (in which mortality was higher in the operative group).  
Protective effects of THA were diminished at five years when the groups 
appeared to converge.  The operative group were generally fitter with 30% less 
prevalence of co-morbid disease than the control group, but despite controlling 
for this and other relevant variables (age, sex, socioeconomic group), the 
protective effects of operative intervention were still present (205).  
Similarly, a large study published in 2011 examined 44,558 Danish patients 
undergoing THA in the 11 year period 1995 – 2006 and compared their mortality 
rates with matched members of the general population (1:3 ratio, n=133,674) 
(206). A slightly increased mortality rate was detected in the first 30 days post-
operatively (adjusted mortality rate ratio 1.4 [95% CI 1.2 to 1.7]) with a 
subsequent reduction to a lower risk at the 90 day time point (adjusted 
mortality rate ratio 0.8 [95% CI 0.7 to 0.9]). Patients undergoing THA had a 
higher incidence of death related to myocardial infarction and venous 
thromboembolism than control patients at 90 days, indicating that 
thromboprophylaxis plays an important role in the peri-operative period.  There 
was a reduced mortality risk in the longer term (up to 12.7 years), though the 
authors recognised that his may partly be due to the selection bias inherent in 
the identification of appropriate patients for surgery. Younger patients and 
patients without co-morbidity had an increase in short-term mortality, although 
the absolute risk among these patients was small compared with older, less fit 
patients. This indicates that although THA is a relatively low risk procedure 
which is associated with short and long term mortality benefits in most, the risks 
may appear comparatively heightened in individuals who are otherwise “low 
risk” in terms of their age and co-morbidity status (206). 
7.1.4 Cost effectiveness of total hip arthroplasty 
While generally considered to be one of the most successful operations 
performed within the NHS, there is little information about the cost-
effectiveness of THA.  This was addressed in a recent report from the Exeter 
Primary Outcomes Study (EPOS).  This longitudinal study examined 1589 patients 
who underwent THA with an Exeter implant during the period 1999 – 2002.  
Patients were followed up for a ten year period with the reported cost-
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effectiveness analysis occurring at the five year time point. Patients were 
compared with “no surgery” controls in terms of costs of care and quality of life 
(9). 
The SF-36 tool was used to evaluate patient outcomes in this study.  SF-36 is a 
multipurpose health survey of 36 questions that yields an eight-scale profile of 
functional health and well-being, as well as measures of physical and mental 
health.  Patient outcome scores (SF-36) were collected annually and the 
difference between pre-operative scores and those collected at five years, was 
calculated. The gain in Quality Adjusted Life Years (QALY) was estimated using 
the patients’ own individual SF-36 score as an estimate of what their quality of 
life (QoL) would have been without surgery.  Clearly this has some limitations in 
that a person’s QoL may have improved, or indeed decreased, for any of a wide 
number of reasons whether surgery had been performed or not.  Analysis was 
performed for only 938 patients due to incomplete datasets.  This study found 
that each patient gained a mean of 0.8 QALYs over 5 years after undergoing 
THA, while the mean cost of hospital stay was around £5000. Cost per QALY was 
found to be around £7000 with older patients incurring higher costs.  This was 
still deemed to be cost-effective when compared with NICE thresholds which 
currently sit at around £20,000 - £30,000 per QALY gained, though this is 
currently undergoing further analysis and consideration (207;208).  
THA is a commonly performed procedure which can result in improved quality of 
life as well as other long term outcomes.  The optimisation of care provided 
during THA is therefore of interest to both patients and health care 
professionals.  The role of the anaesthetist is to provide optimal anaesthesia 
during surgery and analgesia in the post-operative period whilst minimising 
adverse effects.  We wished to investigate methods of providing pain control in 
patients undergoing THA by comparing a method in common use (spinal 
morphine) with a technique which has not been fully investigated in this setting 
(ultrasound guided fascia iliaca block. 
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7.2 Chapter 7 Summary 
 Total hip arthroplasty is increasing in frequency. 
 Length of stay associated with total hip arthroplasty is decreasing. 
 The number of patients with high BMI and other co-morbidities is 
increasing, leading to increasing challenges in the peri-operative period.  
 Total hip replacement may result in improved quality of life and long-
term outcomes.  
 Total hip arthroplasty is considered to be a cost-effective intervention. 
 The role of the anaesthetist is to provide optimal anaesthesia and post-
operative analgesia whilst minimising sde-effects. 
 
 Chapter 8 
Anaesthesia for Total Hip Arthroplasty 
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Anaesthesia for THA is commonly performed using general anaesthesia (GA), 
regional anaesthesia (RA) or a combination of the two. The aim is to provide 
adequate anaesthesia and optimal analgesia whilst minimising side effects, thus 
facilitating rapid mobilisation and recovery. 
8.1 Subarachnoid block 
Subarachnoid blockade (SAB) is a form of RA which can be used to provide both 
anaesthesia and post-operative analgesia in patients undergoing THA.  This 
involves the injection of local anaesthetic into the cerebrospinal fluid via a 
specially designed needle under strict aseptic conditions.  Opioid drugs are 
frequently added to the spinal or “intrathecal” injection of local anaesthetic 
(LA) in order to prolong post-operative pain relief.   
8.1.1 Spinal opioids 
Spinal opioids have been used since 1979 to provide pain control after surgery.  
In a 17 nation European survey, morphine was the most commonly used spinal 
opioid in all countries except the UK (209).  Due to its widespread international 
use, spinal morphine has been extensively investigated.  Spinal morphine with 
post-operative PCA morphine is a commonly used regime for many surgical 
procedures.  
Morphine is more hydrophobic than other opioids and hence has a greater degree 
of rostral spread and a longer duration of action (171). This is beneficial in terms 
of producing long-lasting, effective analgesia but has the associated 
disadvantage of an increased potential for adverse events including respiratory 
depression.  Other side-effects of spinal morphine include: nausea, vomiting, 
pruritus, urinary retention and sedation.  These may be uncomfortable for the 
patient and delay mobilisation, recovery and eventual discharge (210;211).  
There are three recent meta-analyses examining the use of spinal morphine:  
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A meta-analysis published by Meylan et al in 2009 examined 27 studies (1205 
patients) published from 1985 - 2007 in which patients received a general 
anaesthetic accompanied by spinal morphine at doses ranging from 100 - 4000μg 
(without local anaesthetic) (212).  The primary aim was to quantify the analgesic 
effect with secondary objectives stated as quantification of the harmful effects 
of spinal morphine and an evaluation of dose-responsiveness.  Group sizes ranged 
from 10 to 47 patients and the mean quality score of the studies was 3/7 using a 
modified Oxford Score (a seven-point scale evaluating randomisation, 
concealment, blinding and drop-outs) (213).  Surgical procedures were cardiac 
(13 studies), abdominal (five studies), hysterectomy (four studies), spine (three 
studies), thoracic (one study) or cardiac and thoracic (one study).   
When all trials were combined, there was a significant reduction in post-
operative 24 hours morphine consumption (weighted mean difference [WMD] -
16.9mg, 95% CI -23.7 to -10.1; eleven RCTs). Intrathecal morphine significantly 
reduced pain intensity at rest at four hours after surgery (WMD -1.9cm, 95% CI    
-2.9 to -0.8; five RCTs), at 12 hours after surgery (WMD -0.8cm, 95% CI -1.4 to -
0.1; seven RCTs) and at 24 hours post surgery (WMD -1.0cm, 95% CI -1.7 to -0.4; 
eight RCTs). There were also significant reductions in pain intensity on 
movement at 12 hours after surgery (WMD -2.0cm, 95% CI -3.1 to -1.0; four RCTs) 
and at 24 hours after surgery (WMD -1.7cm, 95% CI -2.7 to -0.8; four RCTs). 
Spinal morphine was associated with a significant reduction in the duration of 
hospital stay (WMD -0.49 day, 95% CI -0.89 to -0.09; eight RCTs).  There was a 
statistically significant reduction in the incidence of post-operative respiratory 
complications such as pneumonia.  Six cases of respiratory depression (using a 
variety of definitions) were reported in three trials, occurring only in patients 
who had received spinal morphine at doses of between 300μg and 4000 μg. The 
authors concluded that the risk of respiratory depression was significantly 
increased in patients receiving spinal morphine (OR 7.86, 95% CI 1.54–40.3).  
When all studies analysing respiratory depression as an outcome were combined, 
the number needed to harm (NNH) was calculated to be 84. The incidence of 
pruritus and urinary retention was increased in patients receiving spinal 
morphine, though sedation and nausea and vomiting occurred only with the same 
frequency as that seen in controls (212).  
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Surprisingly, there was no demonstrable statistically significant relationship 
between adverse effects and dose leading Meylan and colleagues to state: 
“The published literature does not allow the establishment of a dose–
response relationship with confidence, and hence the minimal effective 
dose of intrathecal morphine when used alone in patients undergoing 
major surgery remains unknown.”   
Meylan et al suggested that lower doses of spinal morphine should be further 
investigated.  They also stated that due to uncertainty surrounding the optimal 
dose, risks of respiratory depression and requirements for post-operative 
monitoring that there were: 
“..important logistic and financial issues. These are likely to 
challenge the use of intrathecal morphine in settings where limited 
resources do not allow for appropriate postoperative surveillance.”  
They further concluded that: 
“In view of all these caveats, the most radical, and perhaps most 
appropriate, conclusion would be that this analgesic intervention that 
reduces postoperative morphine consumption but not morphine-
related adverse effects, that only slightly improves postoperative 
pain intensity, that significantly increases the risk of pruritus, and 
that is associated with a finite risk of respiratory depression should 
be abandoned.” 
It is of note that this meta-analysis concentrated only on patients who received 
lone spinal opiate (without local anaesthetic), and who also received a general 
anaesthetic.  Studies of patients undergoing total hip arthroplasty were not 
included for review in this meta-analysis. 
A further meta-analysis of 28 RCTs (1314 patients) was also published in 2009 
(214).  This meta-analysis exhibited no overlap with the previously described 
work by Meylan et al due to the different inclusion criteria (Meylan et al 
included only trials examining the use of spinal opioids without local 
anaesthetic) (212).  Gehling et al investigated the use of spinal morphine in 
doses ranging from 25 - 2500μg co-administered with local anaesthetic in 
patients undergoing spinal anaesthesia without general anaesthesia in order to 
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assess the frequency of side-effects (214).  A wide variety of surgeries, including 
orthopaedic procedures, were included (22 studies).  Methodological quality was 
assessed using the recommendations of McQuay and Moore, a method scored on 
a 1 to 5 scale derived using appraisals of randomisation, blinding and 
withdrawals.  A score of 5 points indicated a high quality trial. In the assessment 
of methodological quality, 25 trials (89%) recorded a score of 3 or higher with six 
trials recording the maximum score of 5 points.  
Compared with placebo, patients receiving spinal morphine had a higher 
incidence of nausea (RR 1.3, 95% CI 1.1-1.5; 24 RCTs), vomiting (RR = 1.6, 95% CI 
1.1–2.2; 19 RCTs) and pruritus (RR = 2.0, 95% CI 1.6–1.2.4; 25 RCTs), though they 
found no difference in rates of urinary retention.  Spinal morphine at doses of 
<300μg did not have a significant impact on the risk of respiratory depression 
(risk difference RD< 300μg = -0.005, 95% CI -0.034 to 0.023). Therefore, in patients 
receiving a dose of spinal morphine of less than 300μg, the incidence of 
respiratory depression was not increased when compared with placebo. Higher 
doses of spinal morphine (>300μg) were associated with a trend towards an 
increased incidence of respiratory depression, though this was not statistically 
significant.  This meta-analysis was limited to an examination of side-effects and 
did not evaluate analgesic efficacy (214). 
A more recent meta-analysis published in 2012 by Popping et al, evaluated the 
effects of spinal opioid at doses of 50 - 2000μg (administered in combination 
with local anaesthetic) in patients undergoing surgery, again without general 
anaesthesia (215).  A total of 65 randomised controlled trials (3338 patients) 
examining both analgesic efficacy and adverse effects of spinal opioids were 
included. The studies were published over the period 1983 to 2010.  Twelve of 
these were also included in the Gehling meta-analysis (214), though none 
overlapped with the studies included in the meta-analysis by Meylan (212).   
Almost half of these studies involved patients undergoing orthopaedic 
procedures and the median quality score was 3/7 using the Modified Oxford 
Scale.  Again, unpublished work was excluded leaving room for publication bias 
though no language restrictions were imposed.  
The authors concluded that spinal morphine in doses of 50 - 1000μg, significantly 
reduced 24 hour post-operative morphine consumption (WMD -12 mg, 95% CI -18 
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to -5; 7 RCTs).  Duration of analgesia was also increased though there was no 
evidence of a dose-response relationship.  Respiratory depression was more 
common in patients receiving spinal morphine with a calculated Number Needed 
to Harm (NNH) of between 38 and 59 depending on which definition of 
respiratory depression was used.  Spinal morphine increased the risk of: nausea 
(NNH 9.9), vomiting (NNH 10), urinary retention (NNH 6.5) and pruritus (NNH 
4.4), although again, there was no dose-response relationship elicited.  While a 
dose-response effect was not detected during the meta-analysis process, the 
authors commented that this may be due to other confounders which were not 
accounted for.  When trials evaluating dose-responsiveness as an outcome were 
evaluated independently, a relationship between dose and response was 
identified in some of the reported outcomes.  However, these studies were 
generally small, containing a total of only 338 patients (216-219).  
In one such dose-finding study by Rathmell et al, the use of spinal morphine for 
hip and knee surgery was examined.  There was no increased incidence of 
respiratory depression or hypoxaemia in patients receiving up to 0.3mg of spinal 
morphine.  This included elderly patients who had also received “significant 
doses of PCA morphine (219).”  A further prospective, randomised controlled 
trial performed in elderly patients (>65 years) undergoing THA, compared doses 
of 0 - 200μg of spinal morphine.  The authors concluded that 100 μg was the 
optimal dose as it provided effective analgesia while minimising side effects 
(218). 
Unfortunately, studies investigating the use of spinal opioids are generally 
inadequately powered to detect the incidence of respiratory depression.  As 
respiratory depression is rare, an accurate estimate of its incidence of would 
necessitate the design of a trial containing very large numbers of patients and 
would be difficult and impractical to undertake.  Despite this, it would seem 
reasonable to consider that a lower dose of spinal morphine may increase the 
chance of avoiding respiratory depression (214;218-222).  Equally, it would also 
seem reasonable to state that there is no effective dose of spinal morphine that 
can completely and with absolute certainty, preclude the occurrence of 
respiratory depression.  Further research on the minimal effective dose of spinal 
morphine is merited in order to try and clarify this issue further.  In view of the 
rare yet significant risk of respiratory depression, patients receiving spinal 
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opioids usually receive intensive monitoring and supplemental oxygen in the 
post-operative period.  This has implications relating to adequate staffing levels, 
education and training and associated costs.   
 
8.2 Peripheral Nerve Blockade  
Peripheral nerve blockade is another form of regional anaesthesia technique 
which is growing in popularity for the provision of post-operative pain relief.  
This technique has the advantage of providing targeted analgesia to the 
operative limb as well as avoiding the sympathetic block, associated hypotension 
and documented side-effects of spinal anaesthesia (223).   In THA, peripheral 
nerve blockade improves pain scores and reduces morphine consumption (224).  
This may have advantages in the post-operative period.   
The femoral, obturator and sciatic (via the nerve to quadratus femoris) nerves 
are generally thought of as providing the majority of innervation to the hip joint.  
The lateral cutaneous nerve of thigh provides cutaneous innervation of the skin 
overlying the incision site on the lateral thigh.  There is also variable innervation 
received from the sacral plexus as well as cutaneous innervations from the 
ilioinguinal, iliohypogastric and genitofemoral nerves.  In order to provide 
complete analgesia after hip surgery one must, in theory, block all of these 
nerves.  However, there is no consensus that one nerve block in particular is 
largely superior to others for analgesia after hip arthroplasty (225).    
A review of the pertinent anatomy and nerve localisation techniques is included 
for each of the relevant nerve blocks.  A systematic literature review of studies 
examining each of these nerve blocks is performed in turn.   
 
8.3 Femoral Nerve Block and “3 in 1 block”  
The femoral triangle is an area occupying the upper, medial part of the anterior 
thigh.  The femoral triangle is bordered by the inguinal ligament proximally, the 
sartorius muscle laterally and the lateral edge of the adductor longus muscle 
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medially.  The fascia lata forms the roof of the triangle with the floor comprised 
of the iliopsoas and pectineus muscles.  The femoral triangle houses the femoral 
vein, femoral artery and femoral nerve alongside the deep inguinal lymph nodes 
(83).   
The femoral nerve is the largest branch of the lumbar plexus and is comprised of 
the nerve roots L2, L3 and L4.  It enters the thigh beneath the inguinal ligament 
and lies on the iliopsoas muscle, lateral and deep to the femoral sheath which 
contains the femoral vessels.  At the femoral crease, the nerve is covered by the 
fascia iliaca and separated from the femoral artery by part of the psoas muscle.  
It then divides into superficial and deep branches early in its course through the 
femoral triangle.  Superficial branches include the intermediate and medial 
cutaneous nerves of the thigh as well as nerves to the sartorius and pectineus 
muscles.  Deep branches of the femoral nerve include those supplying the rectus 
femoris and the vasti muscle groups as well as the saphenous nerve (83).  The 
performance of a femoral nerve block therefore results in anaesthesia of the 
anterior thigh and most of the femur and knee joint. The block also supplies 
anaesthesia to the skin on the medial aspect of the leg below the knee joint as a 
result of the distribution of the saphenous nerve. 
 
Figure 8.3-1 - Anatomy of the femoral triangle. 
Reproduced from Gray’s Anatomy, 20
th
 Edition ((84). 
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8.3.1 Femoral Nerve Block – Technique using peripheral nerve 
stimulation 
The femoral nerve can be blocked in the following way: the patient is positioned 
supine with their legs extended and intravenous access is obtained.  Aseptic 
precautions are employed and the patient is attached to routine monitoring in 
accordance with standards set by the Association of Anaesthetists of Great 
Britain and Ireland (AAGBI) (226).  The skin is prepared with antiseptic solution 
and the skin anaesthetised with 1-2ml of a short-acting local anaesthetic such as 
lignocaine 1%.  The femoral crease is identified at a point 1-2 cm distal to the 
inguinal ligament and the femoral pulse palpated.  A stimulating needle 
connected to a peripheral nerve stimulator (PNS) is inserted slightly laterally to 
the pulse and advanced in a sagittal and cephalad plane.  The PNS is initially set 
to 1mA at a 2 Hz frequency until quadriceps contraction in elicited.  The 
stimulation current is subsequently reduced until the quadriceps contraction 
ceases.  Values > 0.3mA are generally accepted as being adequate (though it is 
now recognised that values over 0.2mA do not always exclude intraneural 
injection) (227).  Local anaesthetic is subsequently injected with frequent 
aspirations to detect intravascular needle placement (228). 
8.3.2 Femoral Nerve Block – Ultrasound Guided technique 
The use of ultrasound to locate peripheral nerves has grown in popularity over 
recent years and is now a well established and accepted method of nerve 
localisation. The advantages of this technique include: real time visualisation of 
the nerve, needle and local anaesthetic injection (229;230).  Ultrasound also 
allows the operator to detect abnormal anatomy, potentially further increasing 
the success and safety of this technique (231;232).  Compared to nerve 
stimulation or landmark techniques of nerve localisation, ultrasound has been 
shown to increase success rates, reduce block onset time, increase block 
duration, reduce volumes of local anaesthetic and increase patient satisfaction 
(233-238).  
Femoral nerve block may be performed using ultrasound guidance (USG) in place 
of peripheral nerve stimulation.  The patient is prepared in the same way as 
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described for the landmark technique and an 8-14 Hertz (Hz) ultrasound probe is 
placed in the femoral crease.  The nerve fibres are seen lying inferiorly to the 
fascia iliaca and lateral to the femoral artery.  They are commonly visualised as 
forming a “pennant” shape with the base of the pennant abutting the femoral 
artery medially, and the tip extending laterally.   
The femoral nerve is not a single nerve at this point, and is comprised of 
multiple nerve fibres. The femoral bundle may be approached using both in-
plane and out of plane techniques.  Using the in-plane approach, the needle is 
inserted in a direction along the long-axis of the ultrasound probe and is 
visualised longitudinally as it approaches the nerve.  In the out of plane 
technique, the needle is inserted perpendicularly to the long axis of the 
ultrasound probe and is visualised only as a “dot” or by the detection of tissue 
disturbance.  Local anaesthetic is injected in the same way as described 
previously (239). 
 
Figure 8.3-2 - Sonographic image of femoral nerve, femoral artery and fascia iliaca 
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Continuous FNB using a perineural catheter is a development of the traditional 
single-shot FNB.  This can be achieved by locating the femoral nerve using either 
PNS or USG, and advancing a specially designed catheter to lie adjacent to the 
nerve.  This is usually preferred to lie along the long axis of the nerve. A local 
anaesthetic infusion can then be infused during the post-operative period. 
8.3.3 “3 in 1” Block 
The “3 in 1” block is a modification of the femoral nerve block and was first 
described by Winnie in 1973 (240).   In this technique, a larger volume of 
injectate is used and pressure is applied distal to the needle insertion point in 
order to encourage proximal spread via the fascial conduit containing the 
femoral, obturator and lateral cutaneous nerve of thigh (all of which arise from 
the lumbar plexus). Although previously claimed to force solution cranially to 
the lumbar plexus, this technique can be inconsistent in providing anaesthesia of 
the three nerves arising from the lumbar plexus (86;241). 
 
8.4 Femoral and “3 in 1 nerve blocks” – literature review 
A systematic literature review of femoral and “3 in 1” nerve blocks was 
performed by a single author (RK).  Studies were identified using the following 
methodology;  MEDLINE, EMBASE and the Cochrane Register of Controlled Clinical 
Trials were searched using the search strategy displayed in Figure 8.4-1.  
Inclusion criteria were: randomised controlled trials (RCTs) published between 
1990-2013, performed in human adults, undergoing total hip arthroplasty and 
published in the English language.  At least one of the following outcomes 
required to be recorded for a study to be included: pain scores, analgesia 
consumption, or adverse effects.  Studies were excluded if they examined 
patients undergoing hip and knee arthroplasty as one group with no separation of 
results.  References of retrieved articles were for searched for other articles of 
relevance not identified in the original search.  
The potential performance of a Cochrane Review was discussed with a senior 
academic clinician within the University of Glasgow.  It was felt that this would 
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not be appropriate to undertake as part of a higher degree in view of the 
requirement to commit to ongoing review and updating of results. 
1. exp Arthroplasty, Replacement, Hip/      
2.  exp Nerve Block/                      
3. exp Femoral nerve/              
4. 2 AND 3  
5. (continuous adj femoral).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol 
supplementary concept, rare disease supplementary concept, unique 
identifier] 
6. (three adj one).mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary 
concept, rare disease supplementary concept, unique identifier]   
7.  4 OR 5 OR 6 
7.  1 AND 7 
Figure 8.4-1 – Search strategy 
 
8.4.1 Quality Scoring 
Quality scoring was performed by a single reviewer (RK) using the Jadad scoring 
system (242).  This is a 3 question, 5 point system with superior validity and 
reliability evidence compared with other scoring systems (243).  The Jadad score 
assigns one point for each of the following basic questions: 
 Was the study described as being randomised? 
 Was the study described as being double blind? 
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 Was there a description of withdrawals and dropouts? (The article should 
describe the number of withdrawals and dropouts, in each of the study 
groups, and any reasons given).  
 
Additional points are given if: 
 The method of randomisation was described in the paper, and was 
appropriate. 
 The method of blinding was described, and was appropriate. 
 
Points are deducted if: 
 The method of randomisation was described, but was inappropriate. 
 The method of blinding was described, but was inappropriate. 
 
The maximum score using this system is 5, with scores of 3 or more considered 
to represent studies with satisfactory methodological quality. 
8.4.2 Results 
58 citations were identified of which eight met inclusion criteria (Figure 8.4-2). 
Study characteristics and outcomes are displayed in Table 8.4-1.  The 
methodological quality of the studies was generally poor with only one study 
achieving a Jadad score of 4 and none scoring the full 5 points.  Studies were 
generally from Europe or the USA (One study from each of France, Switzerland, 
Turkey, Denmark, Belgium [2 studies], and USA [2 studies]).  All studies had been 
approved by the relevant Institutional Review Boards or Local Research Ethics 
Committees.  The trials reviewed included a total of 656 patients.  
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Blocks performed at the end of 
surgery.  Pain scores and 
morphine consumption were 
lower in the first 4 post-
operative hours only. No 
reduction in post-operative 
pain scores at rest or 
movement at 48 hours. 
Median (range) 24 hour 
morphine consumption was 
15mg (0-32mg) in PCA group, 
18mg (1-87mg) in FNB group 
and 8mg (0-21mg) in LPB 
group.  No difference in level 
of mobility, post-operative 
nausea, sedation, or length of 
stay. LPB group noted to have 
more complete sensory block 
in proximal thigh and 
accompanying lower pain 
scores in first 4 hours. This 
was postulated to be due to 
the innervation provided by the 
more proximal ilioinguinal, 
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iliohypogastric and 
genitofemoral nerves which 
would be covered by a more 
proximal approach to the 
lumbar plexus and missed by 
the more distal FNB. Epidural 
diffusion of LA occurred in 4 
out of 15 cases in the LPB 
group. The authors concluded 
that neither FNB nor LPB 
should be used routinely for 











3 in 1 block 
(40ml 0.5% L-







Prolonged time to first 
analgesia in the “3 in 1” group.  
Mean (SD) 24 hour morphine 
consumption 8.6mg (±7.7) in 
sham block group and 7mg 
(±6.2) in block group.  Patients 
in both groups also received 
significant amounts of IV 
fentanyl peri-operatively (mean 
235µg). 
Pain scores and analgesic 
consumption not significantly 
different between groups.   
 
























Improved pain scores and 
reduced analgesic 
consumption in the “3 in 1” 
group.  Tramadol used for 
post-operative analgesia –
results not clear over what 
time period the reported 
amount was administered.  






















CFNB (40ml 0.25% L-
Bupivacaine + 1 in 
200,000 adrenaline then 


















Both CFNB and CEA 
continued for 48 hours. No 
significant differences between 
analgesia, rehabilitation or 
length of hospital stay, though 
there was a trend towards 
improved analgesia in both 
regional anaesthetic groups. 
PCA group used mean 30mg 
(SD ± 9mg) IV morphine in 24 
hours.  Other groups received 
IV propacetamol and IM 
piritramide.  Continuous FNB 
associated with fewest side 
effects prompting the authors 
to recommend this technique.  
It was not clear how this study 
was powered and the authors 
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conceded that a larger study 
may have yielded statistically 

























ropivacaine then 0.2% 
ropivacaine at 
0.15ml/kg/hr for 48 hrs). 
 
 
CLPB (local anaesthetic 













Continuous FNB significantly 
inferior to continuous LPB 
when compared for: pain 
scores during physiotherapy 
(though not at rest), opioid 
related side effects, post-
operative ambulatory distance 
and patient satisfaction. 
Continuous FNB only slightly 
superior to the group receiving 
PCA opioids alone though it 
was noted that both regional 
anaesthetic techniques were 
associated with a reduced 
level of post-operative 
delirium.  Hydromorphone 
used for post-op analgesia – 
median (95% CI) 6mg (5-7mg) 
in CFNB group, 4.3mg (3.3-
5.3mg) in CLPB group and 
9.4mg (1.1-7.7mg) in PCA 
group.  This equates to 
anywhere between 28mg - 
60mg IV morphine in 24 hours. 




















CFNB (20ml 1.5%  
mepivacaine +2.5μg/ml 
adrenaline bolus then 
0.2% ropivacaine 6ml/hr 
infusion with 4ml bolus 





CLPB (local anaesthetic 














CFNB provided non-inferior 
analgesia when compared with 
CLPB.  However, CFNB 
resulted in greater quadriceps 
muscle weakness and 
adversely affected patients’ 
ability to ambulate. This has 
implications in terms of the 
reduction in functional ability to 
perform post-operative 
physiotherapy and may 
predispose to falls.(250;251) 
Patients in this study received 
Oxycontin 10mg bd in addition 
to oral paracetamol and 
celecoxib during the study 
period.  It is possible that this 
may have “blunted” any 
differences between the 
groups.  In addition to this 
regular analgesia, patients in 
the CFNB group received 
median (10-90th percentile) IV 
hydromorphone of 2.8mg (1-
7.4) and 2.2 (1.2-7.6) in the 
CLPB group.  This equates to 
approximately 14.6-18.6mg IV 
morphine.  This must be 
added to the regular oxycontin 
received which would equate 
Chapter 8  156 
to 30mg morphine daily if a 




































clonidine 1 µg/mL and 
sufentanil 0.1 µg/ml) 







clonidine 1 µ/mL and 
sufentanil 0.1 µg/ml) plus 
patient controlled bolus 























At 48 hours, pain relief on 
movement was significantly 
better in the 5ml patient 
controlled bolus group than in 
the continuous infusion group 
(p=0.01). Pain scores at rest 
and at other time points were 
not significantly different 
between the 3 groups. 
Bupivacaine consumption was 
significantly less in the patient 
controlled groups than in the 
continuous infusion group 
(p<0.001). Side effects were 
comparable in the three 
groups. Satisfaction scores 
were significantly higher in the 
5ml patient controlled group 
than in the other groups 
(p<0.01).  IV propacetamol 
and IM piritramide used for 
post op analgesia.   
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clonidine 1 µg/mL and 
sufentanil 0.1 µg/ml) plus 
patient controlled bolus 













Nicomorphine 0.1mg prn 
 
 
“3 in 1” block + lateral 
cutaneous nerve of thigh 
block (20ml 0.5% 
bupivacaine and 20ml 
2% lignocaine with 
epinephrine + 5ml 1% 









consumption was just 
statistically significantly 
superior in the “3 in 1” block 
group (p=0.049).  
Nicomorphine was used for 
analgesia.  The difference was 
small and was not felt to be 
clinically significant.  The 
addition of the lateral 
cutaneous nerve of thigh block 
may have had an effect on the 
results.  This study was of 
poor methodological quality. 
Table 8.4-1 - Study characteristics and outcomes – Femoral Nerve Block 
CEA = continuous epidural analgesia, CFNB= continuous femoral nerve block, CLPB = continuous lumbar plexus block, FNB = femoral nerve block, , GA = general 
anaesthesia, IT morphine = intrathecal morphine, LA = local anaesthetic, LCNT = lateral cutaneous nerve of thigh block, LPB = lumbar plexus block,  PACU = post-
anaesthesia care unit, PCA = patient controlled analgesia, PNS = peripheral nerve stimulator, RCT = randomised controlled trial, SAB = subarachnoid block, THA = total 
hip arthroplasty.
 8.4.3   Discussion – femoral nerve block and “3 in 1” block 
Single shot femoral nerve block in isolation is not useful after hip arthroplasty.  
This may be because the approach is too distal to provide clinically useful 
anaesthesia of the relevant nerves (244).  Continuous femoral nerve block 
catheters, whilst a promising concept, have not achieved superior analgesia 
when compared with: continuous epidural analgesia or PCA morphine (247) and 
continuous lumbar plexus block (248;249).  Continuous femoral nerve block 
(CFNB) catheters may also result in a greater degree of quadriceps weakness and 
ability to ambulate (249).  One study suggested a preferable analgesia profile at 
48 hours and decreased use of local anaesthetic using a patient controlled CFNB 
bolus of 5 ml with 30 minutes lockout than with a basal infusion technique (253).  
However, other studies have been unable to find a clinically relevant difference 
between the use of different methods of local anaesthetic administration (255). 
 
8.5 Lumbar (or Psoas) Plexus Block  
The lumbar plexus is formed from the ventral rami of L1-L4 with contributions 
from T12 and L5.  Peripheral nerves arising from the plexus are: iliohypogatric, 
ilioinguinal, lateral femoral cutaneous, femoral and obturator nerves. However, 
the exact location of the lumbar plexus remains controversial. Some authors 
believe that the plexus lies between the psoas and quadratus lumborum muscles 
(256). Further studies on the lumbar plexus place it within the psoas muscle 
(257;258).  A posterior approach is commonly used to block the nerves of the 
lumbar plexus.  The femoral, lateral cutaneous nerve of thigh and obturator 
nerves can be blocked successfully using this approach.  This is therefore a 
useful technique for patients undergoing hip arthroplasty.  As the plexus sits 
near or within the psoas muscle, it is considered a “deep plexus” block.  
Consequently, needle placement occurs in a non-compressible area of the body 
and hence, any bleeding caused during block performance may result in 
retroperitoneal haematoma.  Other potential adverse events include: epidural, 
intrathecal injection, intravascular injection and renal trauma.  
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8.5.1 Lumbar plexus block – Technique using peripheral nerve 
stimulation 
The lumbar plexus block is traditionally performed with the patient in the lateral 
position.  A line is drawn across the superior aspect of the iliac crest and the 
point at which this line is found to intersect a line drawn superiorly from the 
posterior superior iliac spine, is the point of needle insertion. This is 
approximately 5cm lateral from the midline.  The depth of needle insertion is 
aided by contact with the L4 transverse process, and whilst this varies between 
individuals, the distance from this point to successful stimulation of the lumbar 
plexus is relatively consistent at less than 2cm.  On contacting the L4 transverse 
process, the needle should be walked off caudally and in a slightly medial 
direction (256).  Successful needle placement is determined by quadriceps 
femoris twitch (i.e. stimulation of the femoral nerve).  
More recently a refinement of the above approach, as originally described by 
Winnie, was suggested by Capdevilla et al using a slight modification of the 
traditional landmarks (257).  Patients are again placed in the lateral position 
with the operative side uppermost. The needle is inserted at the junction of the 
lateral and medial two thirds of a line between the spinous process of L4 and a 
line parallel to the spinal column passing through the posterior superior iliac 
spine.  This was determined from results obtained in the CT imaging study 
performed by Capdevilla et al where the lumbar plexus was found to lie at this 
distance consistently and independently of sex or BMI (257).  The needle is then 
advanced perpendicular to the skin until contact with the transverse process of 
L4 is obtained. The needle is withdrawn 0.2 cm and advanced under the 
transverse process until quadriceps femoris muscle twitches are elicited.  It was 
noted in the same imaging study that the depth at which the lumbar plexus was 
found is higher in males and with increasing BMI. The authors postulated that the 
perpendicular (rather than medial) direction of the injection reduces the risk of 
spinal or epidural injection, whilst injecting at a point more medially than in the 
original technique, reduces the chance of failure (257).   
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Figure 8.5-1 - Estimation of the point of puncture of continuous psoas compartment block 
by using the preliminary computed tomography studies. PSIS = posterior superior iliac 
spine. *Point of puncture (257). 
Reproduced with permission from Wolters Kluwer Health, licence no. 3576090503546. 
 
In a prospective, randomised, controlled study of 60 patients the Winnie 
technique was compared with the newer Capdevila technique with the nerve 
blocks performed by a single, experienced operator (259). A second operator, 
who was blinded to the block technique, assessed sensory and motor function at 
time intervals up to 45 minutes after block insertion.  No differences were found 
in block procedure time, pain scores, 24 hour morphine consumption or time to 
first morphine analgesia. Bilateral anaesthesia indicating epidural spread was 
found in 10 patients in the Capdevila group and 12 patients in the Winnie group 
(p=0.8), with block heights reaching T4 at their highest.  Seven patients also 
suffered associated haemodynamic instability. This was a higher incidence than 
previously reported.  The authors concluded that the newer technique proposed 
by Capdevila et al did not offer superior efficacy or safety and that bilateral 
anaesthesia may in fact be due to spread of local anaesthetic from the psoas 
muscle rather than direct epidural injection (259). 
It is possible to use ultrasound guidance in the performance of the lumbar plexus 
block, though this is technically difficult due to the depth at which the nerves 
are found.  
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8.5.2 Lumbar (psoas) plexus block – literature review 
Studies were identified using the following methodology; PUBMED, EMBASE and 
the Cochrane Register of Controlled Clinical Trials were searched using the 
search strategy as detailed in Figure 8.5-2.  Inclusion criteria were: RCTs 
published between 1990-2013, performed in human adults, undergoing total hip 
arthroplasty and published in the English language.  At least one of the following 
outcomes required to be recorded for a study to be included: pain score, 
analgesia consumption or adverse effects. Studies were excluded if they 
examined patients undergoing hip and knee arthroplasty as one group with no 
separation of results.  References of retrieved articles were for searched for 
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1. exp Arthroplasty, Replacement, Hip/      
2.  exp Nerve Block/                       
3. (lumbar adj plexus).mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary 
concept, rare disease supplementary concept, unique identifier] 
4. (psoas adj compartment).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol 
supplementary concept, rare disease supplementary concept, unique 
identifier] 
5.  2 AND 3 
6.  2 AND 4 
7.  (continuous adj lumbar).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol 
supplementary concept, rare disease supplementary concept, unique 
identifier] 
8.  (continuous adj psoas).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol 
supplementary concept, rare disease supplementary concept, unique 
identifier] 
9.  5 OR 6 OR 7 OR 8 
10.  1 AND 9   
Figure 8.5-2 - Search strategy 
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8.5.3 Results 
90 citations were identified, of which 14 met inclusion criteria (Figure 8.5.3) 
Study characteristics and outcomes are displayed in Table 8.5.1   
The methodological quality of the studies was generally good with only two 
studies achieving a Jadad score under 3, and three scoring the full 5 points.  
Studies were from USA (6 studies), Brasil (2 studies), Italy (2 studies), France (2 
studies), India (1 study) and Switzerland (1 study).  All studies had been 
approved by the relevant Institutional Review Boards or Local Research Ethics 
Committees.  The included trials reviewed a total of 831 patients. 
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Figure 8.5-3 - Consort diagram of included studies 
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CFNB provided non-inferior 
analgesia when compared with 
CLPB.  However, CFNB 
resulted in greater quadriceps 
muscle weakness and 
adversely affected patients’ 
ability to ambulate. This has 
implications in terms of the 
reduction in functional ability to 
perform post-operative 
physiotherapy, and may 
predispose to falls (250;251). 
Patients in this study received 
Oxycontin 10mg bd during the 
study period.  It is possible that 
this may have “blunted” any 
differences between the 









CLPB - 15ml of 2% 
mepivacaine with 
epinephrine (5 µg/ml) 





This study found that varying 
the volume and concentration 
(though not the dose) of local 
anaesthetic had no effect on 













ropivacaine infusion at 
12ml/hr plus bolus of 4ml 
(4mg) ropivacaine, 
lockout 30 mins 
 
 
CLPB - 15ml of 2% 
mepivacaine with 
epinephrine (5 µg/ml) 
bolus, then 0.4% 
ropivacaine infusion at 
3ml/hr plus bolus of 1ml 
(4mg) ropivacaine, 
lockout 30 mins 
 
N.B. oxycodone or IV 
morphine administered 








quadriceps muscle strength at 
1 day post-op (primary 
outcome). Secondary 
outcomes including abductor 
and hip flexor strength, and 
breakthrough opioid 
requirements were also 
equivalent.  No patients 
sustained a fall during the 
study period. The authors 
concluded that dose rather 
than volume or concentration 
of local anaesthetic is the 
primary determinant of effect 
























The authors concluded that 
intra-operative nociceptive 
blockade was more effective 
with epidural than lumbar 
plexus block. This was 
assessed by examination of 
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surgery rather than a clinical 
assessment of neural 
blockade or by pain scores / 
analgesia consumption.  
Although both groups of 
patients had catheters inserted 
for ongoing local anaesthetic 
infusion, the regimes used 
were not described, neither 
was the post-operative 
systemic analgesic regime.  
The authors found that both 
techniques were associated 
with similar technical 
difficulties, hemodynamic 
stability during the surgery and 
volume of blood loss.  Post-
operative analgesia and 












CLPB - Ropivacaine, 
0.2%, infusion (8 mL/h 
basal; 4 mL patient-
controlled bolus; 30-min 
lockout) from surgery 






This study examined longer 
term outcomes (up to 12 
months) after THA with a focus 
on health related quality of life 
as described by self-reported 
WOMAC scores (263).  Whilst 












CLPB - Ropivacaine, 
0.2%, infusion (8 mL/h 
basal; 4 mL patient-
controlled bolus; 30-min 
lockout) from surgery 
until 36 hours post-
operatively. Perineural 
saline infusion until post-





not powered for this outcome 
(this was a subsequent report 
of a study designed to assess 
shorter term outcomes after 
CLPB for THA), the authors 
concluded that the extension 
of CLPB for 4 days post-
operatively did not affect 
longer term health related 

























ropivacaine then 0.2% 
ropivacaine at 
0.15ml/kg/hr for 48 hrs). 
 
 
CLPB (local anaesthetic 














Continuous FNB was 
significantly inferior to 
continuous LPB when 
compared for: pain scores 
during physiotherapy (though 
not at rest), opioid related side 
effects, post-operative 
ambulatory distance and 
patient satisfaction. 
Continuous FNB was only 
slightly superior to the group 
receiving PCA opioids alone 
though it was noted that both 
regional anaesthetic 
techniques were associated 
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LPB with 0.4ml/kg 
Bupivacaine 0.5% with 1 
in 200,000 adrenaline. 
 








This study showed that 
ropivacaine may be associated 
with slightly lower pain scores 
than bupivacaine, though this 
was not clinically significant. 
Morphine consumption and 
adverse events were not 
different between groups. The 
study was not powered to 














CLPB with 0.4 mL/kg 
(loading dose) of 0.25% 
bupivacaine, followed by 
continuous infusion of 
0.25% bupivacaine at 










The addition of tramadol to 
0.25% bupivacaine in CLPB 
after THA neither improves the 
quality nor the duration of 
post-operative analgesia. Time 
to first-dose rescue analgesic, 
total rescue analgesic 
requirements, nausea, 






CLPB with 1.5 mg/kg of 
tramadol added to 
0.4 mL/kg loading dose 
of 0.25% bupivacaine, 
followed by continuous 
infusion of 0.15 mg/kg 
tramadol (50 mg/mL) 
added to 0.25% 
bupivacaine at 





vomiting and patient 
satisfaction were not 
























CLPB – 15ml 
mepivacaine, 2%, with 5 
µg/ml epinephrine, then 
10 ml ropivacaine, 0.5%, 
with 25 µg epinephrine in 
those with successful 
block.  0.2% 
Ropivacaine infusion at 8 
ml/hr plus patient 
controlled bolus dose of 
4 ml, lockout 30 min til 














The three primary outcomes 
related to readiness-for-
discharge; (i) adequate 
analgesia (numeric rating pain 
score), (ii) independence from 
intravenous opioids in the 
previous 12 h, and (iii) 
ambulation of at least 30 m 
without a time limit.  The 
distance walked in 6 minutes 
on the afternoon following 
surgery (6 minute walk test) 
was also a primary outcome.  
Patients given 4 days of 
perineural ropivacaine attained 
all three discharge criteria in a 
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24 GA CLPB – 15ml 
mepivacaine, 2%, with 5 
µg/ml epinephrine, then 
10 ml ropivacaine, 0.5%, 
with 25 µg epinephrine in 
those with successful 
block.  0.2% 
Ropivacaine infusion at 8 
ml/hr plus patient 
controlled bolus dose of 
4 ml lockout 30 min for 
24 hours post-op.  
Normal saline infusion at 
8 ml/hr plus patient 
controlled bolus dose of 
4 ml, lockout 30 min til 
post-op day 4. 
PNS median of 29 hours, compared 
with 51 hours for those of the 
control group (reduction of 
38%). Patients assigned to 
receive ropivacaine mobilised 
a median of 34m (9 –55m) in 6 
min compared with 20 m for 
those receiving normal saline, 
though this was not statistically 
significant.  Ten patients 
receiving the ropivacaine 
infusion required to have their 
infusion rates halved due to 
quadriceps weakness and 
three patients receiving 


















Spinal with hyperbaric 
bupivacaine 15 mg, 
fentanyl 15µg and 
morphine 100 µg. 
 
 










This small, single blinded 
study showed no significant 
difference between spinal 
opioid and LPB in terms of 
analgesia, nausea and 
vomiting and urinary retention 
in patients undergoing THA.  
The incidence of itch was 
significantly higher in the 
spinal opioid group.  This 
study was of poor 























CLPB with 3% lignocaine 
with 1 in 200,000 
adrenaline test dose, 
then 0.75% ropivacaine 
(0.4 mL/kg) via the 
catheter over 2 min. 
Thereafter, continuous 
infusion of 0.2% 
ropivacaine at 10 ml/h 
for 48 h.  Sham IV 
infusion with saline. 
 
Continuous infusion of 
morphine 0.1% and 
ketorolac 0.12% at a rate 
of 2mL/h for 48 h. Sham 
CLPB infusion catheter 












This study was only single 
blind (investigators not 
blinded).  Pain scores were 
lower over the 48 hour post-
operative period in the CLPB 
group though analgesic 
consumption was only less in 
first 24 hours.  The authors 
went on to question the value 
of continuing the infusion past 
this point. The incidence of 
nausea was significantly lower 






















Pain scores and morphine 
consumption were lower in the 
first 4 post-operative hours 
only in the LPB group. There 
was no reduction in post-
operative pain scores at rest or 
movement for other time 
points up to 48 hours. There 



























was no difference in level of 
mobility, post-operative 
nausea, sedation or length of 
stay between the three groups. 
Patients in the LPB group 
were noted to have a more 
complete sensory block in the 
proximal thigh and 
accompanying lower pain 
scores in first 4 hours than 
those in the FNB group. This 
was postulated to be due to 
the innervation provided by the 
more proximal ilioinguinal, 
iliohypogastric and 
genitofemoral nerves which 
would be covered by a more 
proximal approach to the 
lumbar plexus and missed by 
the more distal FNB. Epidural 
diffusion of LA occurred in 4 
out of 15 cases in LPB group. 
The authors concluded that 
neither FNB nor LPB should 







CLPB - Test dose 3ml 
2% lignocaine with 
epinephrine. Bolus of 20 





Only 53% of patients receiving 
CLPB had blockade of all 3 
nerves (femoral, obturator and 
lateral cutaneous nerve of 















5 ml increments via 
catheter followed by  
infusion of bupivacaine 
0.125% at 10 ml/h for 36 
hours. Catheter removed 
at 36 hours.  PCA 
morphine as below. 
 
PCA morphine 1mg 
bolus dose, lockout 6 









thigh).  Despite this, patients in 
the CLPB group used less 
morphine, had less nausea 
and had higher patient 
satisfaction scores (all 
statistically significant).  This 












IT morphine 0.1mg in 
1ml 0.9% saline 
 








Morphine consumption was 
statistically significantly lower 
in patients receiving IT 
morphine both in the PACU 
and at 24 and 48 hours post-
op.  Higher rates of urinary 
retention were noted in the IT 
morphine group though there 
was no increase in itch or 
PONV and satisfaction scores 
were generally high and 
similar between the two 
groups. Respiratory 
depression did not occur in 
either group. There were no 
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episodes of epidural spread of 
LA in the LPB group.  This 
















LPB with 0.4ml/kg 
bupivacaine and 1 in 




Skin perforation only at 
lumbar plexus injection 
site, no placebo 









Pain scores and morphine 
consumption were statistically 
significantly less in the LPB up 
to the 6 hour time point, 
though not thereafter.   Post-
operative, though not intra-
operative blood loss was also 
lower in the LPB group though 
the actual difference was only 
in the order of 166ml and 
therefore was not necessarily 
clinically significant.  Epidural 
extension of LPB occurred in 3 
patients.   
Table 8.5-1 - Study characteristics and outcomes – Lumbar Plexus Block 
CEA = continuous epidural analgesia, CFNB= continuous femoral nerve block, CLPB = continuous lumbar plexus block, FNB = femoral nerve block, , GA = general 
anaesthesia, h = hours,  IT morphine = intrathecal morphine, LA = local anaesthetic, LCNT = lateral cutaneous nerve of thigh block, LPB = lumbar plexus block, m = 
metres, PACU = post-anaesthesia care unit, PCA = patient controlled analgesia, PNS = peripheral nerve stimulator, RCT = randomised controlled trial, SAB = 
subarachnoid block, THA = total hip arthroplasty.
  
8.5.4 Lumbar plexus block - discussion 
Use of a single shot lumbar plexus block provides better short term analgesia (4-
6 hours post-operatively) in patients who have undergone THA compared with 
systemic analgesia (244;270).  However when compared with spinal opioid, 
single shot lumbar plexus block was not superior (222;267).  Continuous lumbar 
plexus block has been shown to provide good analgesia following THA when 
compared with CFNB, PCA morphine and systemic morphine infusion (248;249) 
(266;268;269).  However, this was not associated with improved health related 
quality of life at 12 months (262).  The dose of local anaesthetic rather than the 
volume or concentration were found to be the most important determinant of 
efficacy (260), and the addition of tramadol did not improve analgesia (265). 
Lumbar plexus block may be associated with significant complications including 
intrathecal and epidural placement, psoas haematoma or abscess, renal trauma 
and systemic LA toxicity.  The performance of this technique requires 
considerable expertise and may be time-consuming to perform hence limiting its 
use.   
8.6 Sciatic Nerve Block 
The sciatic nerve supplies motor and sensory innervation to the posterior aspect 
of the thigh and most of the lower leg and therefore can provide analgesia after 
hip surgery when used in combination with a lumbar plexus nerve block.  The 
sciatic nerve is formed from the anterior rami of L4 – S3, and is the largest nerve 
in the body, forming most of the sacral plexus (L4–S4).  The sciatic nerve is 
actually formed of two nerves in close proximity, the tibial and common 
peroneal nerves.  These nerves usually separate in the mid-thigh, although 
separation as proximally as the pelvis occurs in a minority of patients. The 
sciatic nerve leaves the pelvis via the greater sciatic foramen, commonly under 
the pririformis muscle, before travelling under the gluteus maximus and 
continuing distally between the greater trochanter and ischial tuberosity.  It 
supplies motor innervation to the muscles of the posterior thigh as well as all 
muscles of the leg and foot. It provides sensory innervation to the skin of the 
lateral aspect of the leg (anterolateral and posterolateral), and almost all of the 
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foot (with the exception of the medial part of the foot which is innervated by 
saphenous nerve).  Injury to the sciatic nerve typically produces: complete 
motor loss of the muscles of the posterior thigh, leg and foot and sensory loss 
over the territories described above (83).   
8.6.1 Sciatic nerve block – Technique using peripheral nerve 
stimulation 
The sciatic nerve can be blocked from several different locations along the lower 
extremity.  Labat’s sciatic nerve block is a classic approach which targets the 
nerve in the gluteal region. Other approaches to sciatic nerve blockade include 
the anterior and lateral approaches (which allow the patient to remain supine), 
and the parasacral and prone approaches. The Raj sub-gluteal approach is 
performed in the supine position with the hip flexed.   
In the Labat approach, the patient is placed in the lateral position (operative 
side up), and the leg is flexed at the knee. A line is drawn between the greater 
trochanter and the posterior superior iliac spine (PSIS). A second line is then 
drawn from the greater trochanter to the patient’s sacral hiatus.  The point of 
needle insertion is found by drawing a line perpendicular from the midpoint of 
the first line to its intersection with the second line. 
 
Figure 8.6-1 - The Labat approach to the sciatic nerve 
GT = Greater trochanter, IC = Iliac Crest, PSIS = posterior superior iliac spine, SH = sacral hiatus. 
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The anterior approach to the sciatic nerve is performed with the patient lying 
supine. This may be an advantage in patients in whom changing position will be 
associated with pain.  A line is drawn from the pubic tubercle to the anterior 
superior iliac spine (ASIS).  A second parallel line is then drawn from the greater 
trochanter.  A perpendicular line is drawn at the junction of the medial and 
lateral two thirds, to intersect the second line.  This is the point of needle 
insertion.   
The lateral approach to the sciatic nerve can again be performed with the 
patient in the supine position.  A line is drawn from the posterior edge of the 
greater trochanter along the length of the femur.  The needle is then inserted 
along this line at a point half way between the knee and greater trochanter.  
Blocking the sciatic nerve at this level will miss the posterior cutaneous nerve of 
thigh and will therefore not prevent tourniquet pain. 
The Raj approach is again performed supine but with the patient’s leg held in a 
flexed position at the knee and hip to 90º.  A line is drawn connecting the 
greater trochanter to the ischial tuberosity.  The point of needle insertion is 
around half way along this line in the groove formed by the hamstring and 
adductor muscles (271).   
 
Figure 8.6-2 - The Raj approach to the sciatic nerve. 
GT = Greater Trochanter, IT = Ischial Tuberosity 
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8.6.2 Sciatic nerve block – ultrasound guided technique 
The sciatic nerve can be blocked both in the sub-gluteal region and anteriorly 
using ultrasound guidance.  To perform the block from the sub-gluteal position, 
the patient must lie in the lateral position with the operative leg uppermost.  A 
line is drawn between the greater trochanter and ishcial tubserosity and the 
sciatic nerve presumed to lie half way down this line.  A 5Hz curvelinear 
ultrasound transducer is then applied in a parallel position with the depth set to 
around 7cm.  The bony structures can then be identified, and the sciatic nerve 
visualised below he gluteus maximus muscle.  The nerve is often seen as a thin, 
wide, lip-shaped structure in this area.  The nerve can then be anaesthetised 
using an in- or out of plane technique (272). 
To perform a sciatic nerve block from the anterior approach, the sciatic nerve is 
accessed at the level of the greater trochanter posterior to the femur.  The 
nerve sits at the posterior border of adductor magnus and behind biceps femoris.  
The patient is positioned with the hip and knee slightly flexed and the hip 
externally rotated to 45º.  A low frequency (2-5MHz) transducer is then placed 
on the thigh approximately 8cm distal to the inguinal crease.  The femur and 
sciatic nerve can then be viewed and local anaesthetic infiltrated.   
8.6.3 Literature review – sciatic nerve block 
Studies were identified using the following methodology:  MEDLINE, EMBASE and 
the Cochrane Register of Controlled Clinical Trials were searched using the 
search strategy displayed in Figure 8.6-3.  Inclusion criteria were: RCTs 
published between 1990 - 2013, performed in human adults, undergoing total hip 
arthroplasty and published in the English language.  At least one of the following 
outcomes required to be recorded for a study to be included: pain score, 
analgesia consumption or adverse effects.  Studies were excluded if they 
examined patients undergoing hip and knee arthroplasty as one group with no 
separation of results.  References of retrieved articles were for searched for 
other articles of relevance not identified in the original search.  
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1.  exp Arthroplasty, Replacement, Hip/  
2. exp Nerve Block/ 
3. exp Sciatic Nerve/ 
4. (continuous adj sciatic).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol 
supplementary concept, rare disease supplementary concept, unique 
identifier] 
5. 2 AND 3  
6. 4 OR 5 
7. 1 AND 6 
Figure 8.6-3 - Search strategy 
 
8.6.4 Results  
Ten citations were identified, of which only one met inclusion criteria (Figure 
8.6-4). Study characteristics and outcomes are displayed in Table 8.6-1.  The 
methodological quality of the included Dutch study was good with a Jadad score 
of 4.  This study had been approved by the relevant Institutional Review Board or 
local ethics committee.  The study included 45 patients. 
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Figure 8.6-4 - Consort diagram of included studies 
 
































Sciatic (10ml) and LPB 
(40ml) with total 50 mL 
levobupivacaine 3 
mg/mL with 1 in 
200,000 adrenaline. 
 
Sciatic (10ml) and LPB 
(40ml) with total 50 mL 
ropivacaine 4.5 mg/mL 
with 1 in 200,000 
adrenaline. 
 
Sciatic (10ml) and LPB 
(40ml) with total 50 mL 
bupivacaine 3 mg/mL 











11110 Patients generally had low 
pain scores and opiate use 
though there was no 
significant difference between 
groups.  The duration of motor 
blockade was found to be 
longest in the Bupivacaine 
group.  Epidural spread of LA 
was noted in 1 patient.  
 
 
Table 8.6-1- Study characteristics and outcomes – Sciatic Nerve Block 
GA = general anaesthesia, LPB = lumbar plexus block, PNS = peripheral nerve stimulator, RCT = randomised controlled trial, THA = total hip arthroplasty. 
 8.6.5 Discussion 
There is a lack of high quality, published evidence examining the use of sciatic 
nerve blockade in total hip replacement.  Consequently, there is at present no 
clear evidence to support the routine performance of a sciatic nerve block for 
hip replacement surgery.  While it is not possible to provide complete analgesia 
of the hip joint after hip replacement surgery without a sciatic nerve block, this 
is not commonly practiced due to concerns about reduced post-operative 
mobility.   
 
8.7 Fascia iliaca block 
The fascia iliaca block may be considered an anterior approach to the lumbar 
plexus which relies on proximal spread of local anaesthetic beneath the fascia 
iliaca.  The fascia iliaca is a fascial layer which connects laterally to the whole 
length of the inner lip of the iliac crest and medially to the linea terminalis of 
the lesser pelvis where it is continuous with periosteum. It is connected to the 
posterior margin of the inguinal ligament and is continuous with the transversalis 
fascia. The fascia iliaca covers the iliacus (a large, triangular shaped muscle 
which fills the ilium) and the psoas muscle (together referred to as the 
iliopsoas). The external iliac vessels lie anterior to the fascia while the nerves of 
the lumbar plexus lie posteriorly.  The fascia iliaca passes behind the femoral 
vessels which are encased within the femoral sheath.   
The femoral nerve descends through the fibres of the psoas major to exit at the 
lower portion of the lateral border of the psoas muscle.  It then passes distally 
between the psoas and iliacus muscle, deep to the fascia iliaca.  The femoral 
nerve exits the pelvis into the upper thigh, enclosed in the fascia iliaca and sits 
on top of the iliopsoas muscle and lateral to the femoral vessels.   
The lateral cutaneous nerve of thigh is a purely sensory nerve arising from the L2 
and L3 nerve roots that provides sensation from the iliac crest down the lateral 
portion of the thigh.  This nerve also emerges from the lumbar plexus and 
travels downward lateral to the psoas muscle, crossing the iliacus muscle deep 
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to the fascia iliaca.  The obturator nerve innervates a portion of the distal, 
medial thigh and is predominantly a motor nerve.  It arises from the L2-4 nerve 
roots and crosses the iliacus muscle, deep to the fascia, in the medial thigh.  
Therefore, injection of local anaesthetic beneath the fascia iliaca should result 
in anaesthesia of all three of these nerves.   
In addition, two other lumbar plexus nerves contribute sensory fibers to the 
upper part of the anterior aspect of the thigh.  These are the ilioinguinal nerve 
and the gentiofemoral nerve.  The ilioinguinal nerve emerges at the lateral 
border of the psoas muscle, before crossing the quadratus lumbarum muscle 
obliquely.  It lies immediately posterior to its covering fascia until it pierces the 
transversus abdominis and oblique muscles in the direction of the spermatic cord 
or the round ligament of the uterus.  The genitofemoral nerve perforates the 
psoas muscle, then runs on its anterior aspect posterior to the fascia iliaca.  The 
fascia iliaca block may therefore also result in anaesthesia of the genitofemoral 
nerve.  
8.7.1 Fascia ilaca block – landmark technique 
The landmarks for this block are the anterior superior iliac spine, pubic tubercle 
and inguinal ligament. The fascia iliaca block is performed in the following way:  
The patient is positioned in the supine position and a line drawn on the skin 
connecting the anterior superior iliac spine to the pubic tubercle. This is then 
divided into thirds. At the junction of the lateral and medial two thirds, a 
second line is drawn perpendicular to and intersecting the line joining the 
anterior superior iliac spine and pubic tubercle. The insertion point is 1cm along 
this second line. A block needle is then inserted perpendicular to the skin at this 
point. A “pop” or give is felt as the needle passes through the fascia lata, and a 
second “pop” felt as it passes through the fascia iliaca. The local anesthetic 
should inject without resistance.  Large volumes of local anaesthetic are 
generally used as the fascia iliaca block is a field block in which no individual 
nerve is targeted. 
The fascia iliaca block was first described by Dalens et al in 1989 after a 
randomised study comparing it with the “3 in 1” block in 120 children ranging in 
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age from 0.7 to 17 years and from 7.3 to 79kg (86).  Blockade of all 3 nerves was 
found in over 90% of patients receiving fascia iliaca block compared with levels 
of between 13% (obturator) and 100% (femoral) seen with the “3 in 1” 
technique.  This was further investigated in 100 fit adults by Capdevila et al in 
1998 (241).  In this study, the fascia iliaca block was found to provide more 
reliable blockade of both femoral and lateral cutaneous nerve of thigh than the 
“3 in 1” block.  However, neither block  produced full sensory anaesthesia in any 
more than 38% of patients and spread of local anaesthetic was variable and 
unpredictable (241).   
8.7.2 Fascia iliaca block – ultrasound guided technique 
The use of ultrasound to perform fascia iliaca block has recently been 
investigated with the hypothesis that direct visualisation of the needle and 
injectate would result in more accurate placement of local anaesthetic and 
subsequent higher success rates (10).  In this study of 80 patients undergoing 
total hip or knee replacement, patients were randomised to receive a fascia 
iliaca block performed using either a landmark or ultrasound guided technique.  
As well as sensory blockade, motor blockade of both femoral and obturator 
nerves was assessed.  Patients receiving a landmark technique fascia iliaca block 
had successful blockade of all 3 nerves in 47% of cases. This compares favourably 
with the 34% described in the study by Capdevila et al (241).  In the patients in 
whom ultrasound guidance was used for block placement, a higher rate of 
sensory block in the medial thigh (95% vs 60%, p=0.001) was seen.  Complete 
blockade of all three nerves was seen in 82% of patients (p=0.001).   
While this data is encouraging, the potential clinical benefits of this have not 
been fully investigated.   
8.7.3 Literature review – Fascia iliaca block 
Studies were identified using the following methodology; PUBMED, EMBASE and 
the Cochrane Register of Controlled Clinical Trials were searched using the 
search strategy as detailed in Figure 8.7-1.  Inclusion criteria were: RCTs 
published between 1990-2013, performed in human adults, undergoing total hip 
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arthroplasty and published in the English language.  At least one of the following 
outcomes required to be recorded for a study to be included: pain score, 
analgesia consumption or adverse effects. Studies were excluded if they 
examined patients undergoing hip and knee arthroplasty as one group with no 
separation of results.  References of retrieved articles were searched for other 
articles of relevance not identified in the original search.  
1. exp Arthroplasty, Replacement, Hip/ 
2. exp Nerve Block/ 
3. fascia iliaca block.mp. 
4. ilacus fascia.mp. 
5. 3 OR 4 
6. 2 AND 5 
7. 1 AND 6 
Figure 8.7-1 - Search strategy 
 
8.7.4 Results 
3 citations were identified, of which only one met inclusion criteria. This was an 
Australian study of 44 patients.  Study characteristics and outcomes are 
displayed in Table 8.7-1. The methodological quality of the included study was 
good with a Jadad score of 4. This study had been approved by the relevant 
Institutional Review Boards or Local Research Ethics Committee.   
 




Figure 8.7-2 - Consort diagram of included studies






























Modified fascia iliaca 
block with 30ml 0.5% 
bupivacaine with 1 in 
200,000 adrenaline plus 
150µg clonidine and 
9ml normal saline (total 
volume 40ml). SAB with 
2.5-3.5ml of 0.5% 
bupivacaine and 10-
15µg fentanyl.  PCA 
morphine. 
 
Modified fascia iliaca 
block with 40ml normal 
saline.  SAB with 2.5-
3.5ml of 0.5% 
bupivacaine and 10-













The authors hypothesised that 
making the point of needle 
insertion 1cm above the 
inguinal ligament (rather than 
0.5cm below) would result in a 
more proximal spread of LA 
and more reliable block of the 
nerves derived from L1 and 
L2.  While no difference in 
morphine consumption was 
noted at 3 or 6 hour time 
points, a statistically significant 
decrease in morphine use was 
seen at 12 hours (median 
10mg vs 26mg, p<0.01), and 
at 24 hours (22.5mg vs 
37.5mg, p<0.001).  This was 
thought to be due to improved 
LA spread to reach the nerves 
formed by the L1-2 roots 
(ilioinguinal, iliohypogastric 
and genitofemoral nerves). 
Pain scores were not different 
between groups though this 
can be explained by the fact 
that patients titrated their own 
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analgesia to effect.  The 
incidence of PONV was also 
not different between groups.  
It should be noted that the 
group receiving the active 
block received not only LA but 
clonidine within the injectate 
and it is possible that this may 
have resulted in systemic 
effects and affected the 
morphine consumption. 
 
Table 8.7-1- Study characteristics and outcomes – Fascia Iliaca Block   
PCA = patient controlled analgesia, THA = total hip arthroplasty, LA = local anaesthetic, RCT = randomised controlled trial, SAB = subarachnoid block. 
  
8.7.5 Discussion – fascia iliaca block 
There is a lack of published evidence relating to the use of the fascia iliaca block 
for analgesia after total hip replacement.  While some promising results have 
been seen with the fascia iliaca block performed using a landmark technique, 
the potential benefits of an ultrasound guided approach have not yet been fully 
examined and merit further investigation. 
We hypothesise that by increasing the success rate of the fascia iliaca block with 
ultrasound, it will be possible to achieve superior analgesia post-operatively. Our 
aim is to assess whether the use of the ultrasound guided fascia iliaca block is 
non-inferior to intrathecal morphine in the provision of post-operative analgesia 
for primary hip arthroplasty. If this is the case, opioid could be removed from 
the spinal anaesthetic. This could, in theory, have significant safety benefits, 
whilst also reducing side effects.   
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8.8 Chapter 8 Summary 
 There are a number of regional anaesthesia techniques which can be used 
for total hip arthroplasty.  Each has advantages and disadvantages. 
 Spinal morphine is a well established technique used for anaesthesia and 
analgesia in total hip replacement. 
 Ultrasound guided fascia iliaca block has not yet been investigated in the 
clinical setting as a means of providing analgesia after total hip 
arthroplasty.
 Chapter 9 
 
Spinal opioid versus ultrasound guided fascia 
iliaca plane block for analgesia after primary hip 
arthroplasty: study protocol for a randomised, 
blinded, non-inferiority controlled trial 
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The following chapter forms the basis for the study protocol which 
was published in the journal Trials; 2011:12;51.  
9.1 Background 
Hip surgery is increasingly being performed, often in elderly patients with 
significant co-morbidity (275).  Whilst the optimal anaesthetic technique is yet 
to be established (225), it is important that adverse effects are minimised to 
optimise patient safety, comfort and recovery and to facilitate rehabilitation. 
The main options for anaesthesia are general anaesthesia (GA) and regional 
anaesthesia (RA) or a combination of the two. In a recent systematic review, 
regional anaesthesia (RA) was demonstrated to reduce post-operative pain, 
morphine consumption and post-operative nausea and vomiting compared to 
systemic analgesia (224). 
Spinal anaesthesia is a RA technique commonly used in many patients undergoing 
total hip arthroplasty (THA) (276). Opioids are commonly added to the spinal 
anaesthetic in order to prolong and improve post-operative pain relief (277) and 
are associated with reduced post-operative opioid requirements in patients 
undergoing hip arthroplasty (218;219;221). However, spinal opioids are 
associated with side effects including urinary retention, nausea and vomiting, 
itch and rarely, but most seriously, respiratory depression (199).  Such adverse 
effects can be uncomfortable for the patient, delay mobilisation, recovery and 
eventual discharge and occasionally be dangerous (210;211). 
In patients undergoing THA, peripheral nerve blockade has been shown to 
improve pain scores and reduce opioid consumption (224). The fascia iliaca 
nerve block can provide sensory blockade of the main nerves which supply pain 
to the hip: the femoral nerve, obturator nerve and lateral cutaneous nerve of 
thigh (86;274). However, clinical success rates of this block when performed 
‘blindly’ using traditional landmark techniques are variable (241). Using 
ultrasound to locate nerves during peripheral nerve blockade has repeatedly 
been shown to increase success rates, reduce block onset time, increase block 
duration, reduce volumes of local anaesthetic required and increase patient 
satisfaction compared to traditional techniques (233-238;278).  Use of 
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ultrasound guidance in the performance of fascia iliaca block has been shown to 
increase success rates compared with the landmark technique (10).  In this 
study, the clinical benefits of this increased success were not further 
investigated. 
Ultrasound guided fascia iliaca block has not yet been evaluated clinically as a 
method of providing post-operative analgesia following primary THA. We 
hypothesise that by increasing the success rate of the fascia iliaca block with 
ultrasound, it will be possible to achieve superior and more reliable analgesia 
than that obtained using the landmark based technique. The aim of this study is 
to assess whether the ultrasound guided fascia iliaca block can provide 
comparable post-operative analgesia to spinal morphine for primary THA. If this 
is the case, spinal opioid could be removed from the spinal anaesthetic. This 
could potentially reduce opioid related side effects, have safety benefits and 
reduce nursing workload in terms of post-operative monitoring requirements. 
The further investigation of this technique will provide a valuable contribution 
to existing knowledge and could profoundly change current practice. 
 
9.2 Methods / Design 
9.2.1 Overview 
This is a single centre, randomised, double-blinded, placebo-controlled, non-
inferiority study (279).   This study has been approved by the West of Scotland 
Research Ethics Committee 4 (reference no. 10/S0704/43) and is registered with 
the ClinicalTrials.gov database (reference no. NCT01217294). This study will be 
performed in keeping with the requirements of the Declaration of Helsinki. 
9.2.2 Hypothesis 
Ultrasound guided fascia iliaca plane block provides post-operative analgesia 
which is not inferior to that obtained with spinal morphine in patients 
undergoing primary total hip arthroplasty. 
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9.2.3 Objectives  
This study aims to compare the efficacy and safety of ultrasound guided fascia 
iliaca block with spinal morphine in the provision of post-operative analgesia 
after primary hip arthroplasty.  
9.2.4 Primary outcome 
The primary outcome measure is post-operative intravenous morphine 
consumption in a 24 hour period as self administered using a patient controlled 
analgesia (PCA) pump.  
Patients will receive “step-down” opioid analgesics after the PCA is discontinued 
at 24 hours post-operatively.  These step down analgesics will be converted to 
intravenous  morphine equivalent when calculating 48 hour morphine 
consumption in the secondary outcomes.  This will not affect the Primary 
Outcome of 24 hour morphine consumption.   
9.2.5 Secondary outcomes 
Secondary outcomes include:  
 Pain scores at 3, 6, 12 and 24, 36 and 48 hours at rest and on movement 
as recorded post-operatively on the PCA chart where time zero is the end 
of the operation (numerical pain rating score 0 – 10 where 0 is no pain and 
10 is worst pain imaginable). 
 Time to first morphine administration in minutes from time zero. 
 Morphine consumption at 3, 6, 12, 36 and 48 hours (morphine equivalent 
will be reported at 48 hours due to the use of step-down opioid 
analgesia).  
 Episodes of respiratory depression defined as respiratory rate < 8/min or 
requiring naloxone administration in the first 48 hours post-operatively. 
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 Incidence of hypotension as defined by systolic blood pressure < 80mmHg 
or a drop of >25% from baseline systolic pressure, or requiring vasopressor 
in the first 48 hours post-operatively from time zero. 
 Incidence of post-operative nausea and vomiting as defined by nausea 
score of greater than or equal to 2 (on a PONV scale where 0 = none, 1 = 
mild, 2 = moderate, 3 = severe nausea and 4 = patient vomiting) or 
requiring the administration of an anti-emetic agent in the first 48 hours 
post-operatively. 
 Incidence of pruritus as defined by itch felt to be distressing by the 
patient on questioning after the first 48 hour period post-operatively or 
requiring treatment with naloxone. 
 Incidence of sedation as defined by sedation score of greater than or 
equal to 2 (where 0 = awake, S = normal sleep, 1 = drowsy but easy to 
rouse, 2 = sedated and difficult to rouse, and 3 = unconscious) or requiring 
naloxone administration in the first 48 hours post-operatively. 
 Incidence of urinary retention as defined by the requirement for urinary 
catheterisation due to failure to pass urine in the first 48 hours post- 
operatively. 
 Time to first mobilisation as defined by patient able to mobilise from bed 
to chair in hours from time zero as recorded by physiotherapy staff. 
 Quadriceps strength as graded by the MRC assessment of power on the 
first post-operative day as recorded by the physiotherapist. 
 Patient satisfaction as measured using a visual analogue scale (VAS) from 
0 – 100mm where 0 is absolutely not satisfied and 100 is completely 
satisfied.  
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9.2.6 Study centre 
Our centre is a tertiary referral facility for orthopaedics and trauma surgery with 
the necessary type and volume of clinical cases required for this study. There is 
a wealth of experience on the use of ultrasound guidance for regional 
anaesthetic techniques, including fascia iliaca block (10), within the 
department. 
9.2.7 Patients and enrolment 
Patients scheduled to undergo unilateral primary hip arthroplasty will be invited 
to participate in the study during their routine pre-operative assessment visit 
performed in advance of surgery. Inclusion criteria are: ASA physical status I - III, 
18 - 85 years of age, weight between 50-110 kg, and competence to consent. 
Exclusion criteria are: contraindications to fascia iliaca block or spinal 
anaesthesia such as coagulopathy, malignancy or infection in the inguinal area, 
preference for general anaesthesia, allergy to opioids, significant peripheral 
neuropathy or neurological disorder affecting the lower extremity, pregnancy, 
history of alcohol or drug dependency, history of long term strong opioid intake 
(i.e. WHO step 3 analgesics) and history of significant psychiatric conditions that 
may affect patient assessment. 
All suitable patients will be given a patient information sheet approved by the 
West of Scotland Ethics Committee. They will be given an opportunity to review 
this before written informed consent is obtained prior to surgery. 
9.2.8 Consent 
The process of consent will be in accordance with the Declaration of Helsinki. 
Patients will be fully informed that they are being asked to participate in a 
research study. The procedures involved in the study and the chances of being 
assigned randomly to one of two groups will be explained in person and via an 
information sheet. Patients will be made aware that they may receive a placebo 
injection in their groin and that this would have no clinical benefit to them.  A 
signed consent form will be obtained from each patient and retained by the 
investigators. Patients will be made aware that their case notes may be accessed 
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by relevant research staff as well as NHS ward staff and independent research 
monitors who may wish to inspect documentation.  All parties reviewing the 
patient’s records will treat the information in the strictest of confidence and 
patient confidentiality will be maintained at all times.  Patients will be made 
aware of their right to withdraw from the study at any time without adverse 
effects on their clinical care. 
9.2.9 Randomisation 
A computer generated allocation sequence (in permuted blocks) will be created 
by an independent operator who is not directly involved with the study. Once 
created, the allocation sequence will be kept in a secure locked drawer making 
it inaccessible to all study personnel. Allocation concealment will be achieved 
using sequentially numbered sealed envelopes which are opaque when held up to 
the light. When a patient is enrolled in the study, an administrator working 
within the Glasgow University Academic Unit of Anaesthesia will be contacted 
and asked to give the next numbered envelope to the anaesthetist who will 
make up the medications used in the study. The administrator will record the 
patient’s details and the number of the envelope assigned to that patient. The 
allocation sequence will be accessed only when study data collection is complete 
or in any instance where unblinding of the study is thought to be essential in the 
provision of appropriate patient care. 
Patients in the Ultrasound Guided Fascia Iliaca Group will receive: spinal 
anaesthesia with hyperbaric bupivacaine at a dose between 10 and 15 mg, 
adjusted based on patient height and weight at the discretion of the attending 
anaesthetist, with no spinal morphine.  Ultrasound guided fascia iliaca block 
using 2 mg/kg of levobupivacaine diluted to a total of 40 ml with sterile saline. 
Post-operative analgesia will include Paracetamol 1 g four times daily and 
patient controlled analgesia (PCA) with morphine (1 mg bolus, 5 minute lockout 
period).  Patients will continue on any analgesics they were taking pre-
operatively. 
Patients in the Spinal Morphine Group will receive: spinal anaesthesia with 
hyperbaric bupivacaine as above, and with the addition of spinal morphine 100 
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micrograms (0.1 ml). “Sham” ultrasound guided fascia iliaca injection with 40 ml 
of sterile saline.  Post-operative analgesia as previously described. 
9.2.10 Blinding 
This is a double blind study as both patient and investigator are blinded to the 
treatment allocation.  The injectates for the nerve blocks will be prepared by an 
independent anaesthetist who has no involvement with study design, data 
collection or analysis. This same independent anaesthetist will prepare and 
perform the spinal injections and look after the patient in theatre. The use of 
sedation with target controlled infusion propofol and the administration of fluid 
will be at the discretion of the independent anaesthetist.  Anti-emetic drugs will 
not be given in theatre unless felt to be necessary by this anaesthetist. This 
anaesthetist, who has no ongoing role within the study, will be the only person 
who is aware of the treatment allocation.   
A separate study anaesthetist will perform the ultrasound guided fascia iliaca 
blocks in a blinded fashion using the pre-prepared injectate. The patient, 
surgeon, study anaesthetist performing the ultrasound guided fascia-iliaca 
blocks, ward staff, and research nursing staff who collect and record the 
outcome data will all be blinded to the study intervention.  In the very rare 
event that a member of research nursing staff can not perform data collection, a 
study anaesthetist will be asked to perform this task.  The study anaesthetist 
will be blinded to the treatment allocation in all cases. 
The study will be unblinded only after all patients had been recruited and the 
study is declared closed to the relevant authorities.  All study data will be kept 
entirely separate from the treatment allocation key until the time of unblinding 
and analysis of results.  No member of the study team will have access to the 
allocation key at any point as this will be kept securely by a member of 
University of Glasgow secretarial staff.  
 
Chapter 9  200 
9.2.11 Intra-operative management 
The anaesthetist looking after the patient in theatre will play no part in data 
analysis and will record the intra-operative proceedings as normal. The patient’s 
participation in this study and the two possible anaesthetics that may have been 
administered will be documented on the anaesthetic chart. The randomisation 
code may be accessed if deemed necessary in the provision of optimal patient 
care. The patient may receive sedation if requested and as directed by the 
anaesthetic doctor. Fluid administration and the use of vasopressors will again 
be at the discretion of the anaesthetic doctor. All medications, with the 
exception of the medications used to perform the spinal or fascia iliaca block, 
will be detailed in the anaesthetic record. No anti-emetic will be administered 
peri-operatively unless specifically indicated. 
9.2.12 Postoperative management 
After surgery, patients will be taken to the recovery room and monitored 
according to standard hospital policy. Pain will be treated, if required, with 
intravenous morphine every 5 - 10 min as directed by nursing staff. Patients will 
be familiarised with the Patient Controlled Analagesia (PCA) device and 
discharged once recovery room discharge criteria have been met. Patients will 
remain on oxygen for at least 24 hours and whilst receiving PCA morphine as is 
routine protocol in our unit. 
Naloxone will be prescribed for sedation or respiratory depression as specified 
on the PCA protocol.  After a 48 hour period, data regarding pain scores, nausea, 
itch, sedation and hypotension will cease being collected as detailed in the 
primary and secondary outcomes. The investigator who collects the data 
(research nurse) will be blinded as to the nature of the anaesthetic 
administered. The time to first mobilisation will be assessed and the patient will 
continue to be monitored by physiotherapy staff until discharge. Any serious 
adverse events will prompt follow up. Patients will be seen routinely following 
discharge by the arthroplasty specialist nurse. Symptoms of nerve damage will 
be actively sought at this consultation. Patients will be asked to rate their level 
of satisfaction with post-operative analgesia at both 48 hour and 3 month time 
points. 
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9.2.13 Criteria for discontinuation 
Every effort will be made to retain patients in the trial and to minimise 
withdrawals. Patients may request to be withdrawn from this study at any time. 
Intention to treat and “as treated” analyses will be performed. 
9.2.14 Data Collection 
Data will be obtained from copies of the anaesthetic record, recovery room 
observation chart, PCA chart, ward observation chart and drug prescription 
chart. These charts will be reviewed after the first 48 hour post-operative period 
by an independent research nurse. The research nurse will be blinded to the 
anaesthetic technique used.  All documentation relating to the study will be 
stored in an anonymised case report file unique to each patient. These case 
report files will be archived in a locked facility for a period of 10 years. 
9.2.15 Sample Size and Statistical Considerations 
In the comparison of ultrasound guided fascia iliaca block with spinal opioid in 
patients undergoing primary hip replacement, we intend to compare an 
established technique in widespread practice (spinal morphine) with the less 
well investigated technique of ultrasound guided fascia iliaca block. The primary 
outcome of the study is 24 hour morphine consumption. This outcome is used 
commonly in trials of spinal opioid for hip arthroplasty surgery. Mean 24 hour 
morphine consumption after hip arthroplasty is reported to lie within the range 
10 mg (221) to 30 mg (219) when using 0.1 mg intrathecal morphine. From our 
own audit data of patients receiving spinal opioid for hip arthroplasty over an 8 
month period, mean 24 hour post-operative morphine consumption was 24.6mg 
(SD 17.6mg) which lies within the reported range described above (219;221). 
In order to calculate sample size, we used a method suggested for non-
inferiority trials (279;280).  For this we made the following assumptions. Type 1 
error (α) was set at 0.05; Type 2 error (β) at 0.2; and Z numbers based on one-
tailed testing. We considered a difference between groups (δ) of greater than 10 
mg of morphine to be clinically significant. 10 mg of morphine equates to one 
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subcutaneous dose of morphine commonly used in post-operative analgesia pain 
protocols (281). 
The expected difference between the Control (spinal morphine) and Treatment 
(ultrasound guided fascia iliaca) groups (δ) is more difficult to estimate. To 
date, there is only one published trial looking at 24 hour post-operative 
morphine consumption after fascia iliaca block for hip arthroplasty, although this 
was performed with the landmark technique alone and did not employ 
ultrasound (274).  In this study, mean 24 hour post-operative morphine 
consumption in the fascia iliaca group was 23 mg. Therefore, there is a 1.6 mg 
difference between the mean 24 hour morphine consumption obtained from our 
audit data of patients receiving spinal morphine, and that obtained in a study 
looking at patients receiving fascia iliaca block for hip arthroplasty (274). Thus, 
the number of patients required to adequately power this study is 108. 
The null Hypothesis (H0) for this non-inferiority study is that the experimental 
treatment (ultrasound guided fascia iliaca block) is not non-inferior to the 
established treatment (spinal morphine) by more than the clinically significant 
amount (δ). If H0 is rejected, the alternative hypothesis is that ultrasound guided 
fascia iliaca block is non-inferior to spinal opioid. 
The study will be performed using both intention to treat and “as treated” 
analyses. In the intention to treat analysis, patients will be considered failures if 
they require general anaesthesia or were unable to receive randomised 
treatment for any other reason. In the “as treated” analysis, only data from 
patients completing randomised treatment will be analysed. 
Secondary data analyses will be carried out on all secondary outcomes. These 
will be compared between groups using t-test, and Mann-Whitney, or Chi-
squared tests as appropriate. 
It is anticipated that recruitment for this study will take between 12 and 18 
months to complete if 1 to 2 patients are enrolled each week, using one surgeon 
to reduce surgical variability. Data collection for each patient will occur during 
the first 48 hours post-operatively and at a routine follow up appointment. No 
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further follow up will be routinely arranged. Any patients requiring specific 
follow up will have this arranged on an individual basis. 
We recognise that while this study is powered for the primary outcome, it is not 
powered for the secondary outcomes. However, the data we collect in this study 
will provide useful information for further studies looking specifically at these 
outcomes. 
9.2.16 Adverse Event Reporting and Safety 
Definitions: 
Adverse Event (AE) - Any untoward medical occurrence that a patient 
experiences whilst participating in the study. This includes occurrences which 
are not necessarily caused by or related to the trial treatment. 
 
Serious Adverse Event (SAE) – A Serious Adverse Event is defined as an 
untoward occurrence that: 
a. results in death 
b. is life threatening (at the time of the event)* 
c. requires hospitalisation or prolongation of existing hospitalisation**  
d. results in persistent or significant disability or incapacity 
e. consists of a congenital anomaly or birth defect. 
f. is otherwise considered medically significant by the investigator 
*Life threatening means that the patient was at immediate risk of death from the event as it 
occurred. It does not include an event that, had it occurred in a more serious form, might have 
caused death. 
**Requires in-patient hospitalisation should be defined as a hospital admission required for 
treatment of an adverse event. 
 
Full details of all AEs will be recorded in the subject's medical records and on 
the study record forms. Adverse Events will be monitored and followed up until 
satisfactory resolution or stabilisation. 
All adverse events must be assessed for seriousness, causality, expectedness and 
severity. This assessment is the responsibility of the Chief Investigator. 
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An SAE occurring to a research participant should be reported to the main 
Research Ethics Committee and Sponsor where in the opinion of the Chief 
Investigator the event was: 
● Related – resulted from administration of any of the research procedures. 
● Unexpected – type of event is not listed in the protocol as an expected 
occurrence. 
The Principal Investigators shall report any SAE arising during the study to the 
Chief Investigator and Sponsor as soon as reasonably practicable. 
Serious Adverse Events will be reported using the National Research Ethics 
Service SAE report form. This will thereafter be forwarded both to the Sponsor 
and to the Research Ethics Committee for review and assessment. 
9.3 Discussion 
9.3.1 Risk Benefit Assessment 
We expect that all patients will benefit from this study in view of the high level 
of post-operative monitoring and follow up which will be employed. In order to 
achieve blinding and improve the validity of the study, a “sham” ultrasound 
guided fascia iliaca block will be performed in patients in the Spinal Morphine 
Group. These patients will therefore receive an injection of an inactive 
substance (sterile saline) into the groin. As no local anaesthetic is being used in 
the sham block, potential risks will include: discomfort on injection, bleeding or 
bruising at the puncture site and nerve damage. Nerve damage is rare with 
fascia iliaca blocks as the needle is not directed towards the nerves themselves, 
but rather to lie in a plane between muscle layers. In the patients receiving 
fascia iliaca block with local anaesthetic, the risks are as before with the 
addition of local anaesthetic toxicity, although a pre-determined safe dose of 
local anaesthetic is being used. 
Patients in the Spinal Morphine Group will receive spinal morphine in 
combination with local anaesthetic in the spinal injection. Spinal opioids have 
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been used since 1979 to provide pain control after surgery (282). Due to its 
widespread international use, spinal morphine has been extensively investigated 
in this setting and spinal morphine in combination with systemic morphine is a 
commonly used post-operative regime for many surgical procedures including hip 
arthroplasty (209;222;283). Low dose spinal morphine can provide adequate 
analgesia whilst minimising side-effects (218;219;221).  Such side-effects 
include: delayed respiratory depression, pruritus, post- operative nausea and 
vomiting and urinary retention (277;284-286).  Although respiratory depression is 
rare with low doses of intrathecal morphine (286), it is potentially life-
threatening. Furthermore, the concomitant use of systemic opioids for post-
operative analgesia may add to this risk. Previous research has concluded that 
100 micrograms of intrathecal morphine combines analgesic efficacy whilst 
minimising the side effect profile (218;221).  Reassuringly, in a dose-finding 
study of intrathecal morphine for hip and knee surgery, there was no increased 
incidence of respiratory depression or hypoxaemia in patients receiving up to 0.3 
mg of intrathecal morphine. This included elderly patients who had also received 
“significant doses of PCA morphine” (219). 
A recent meta-analysis of 1300 patients was unable to define whether the use of 
spinal morphine increased the risk of respiratory depression (214).  Studies 
investigating the use of intrathecal opioid are generally not adequately powered 
to detect the incidence of respiratory depression. However, it is believed that 
lower doses result in a reduced risk (214;218-222).  A recent trial of 1915 
patients receiving 0.15 mg of intrathecal morphine for Caesarean section found 
the incidence of a respiratory rate of less than 10 breaths per minute to be 
0.26% and the need for naloxone 0.052% (220). However, there is no evidence 
that there is an effective dose of spinal morphine that would completely 
preclude the occurrence of respiratory depression. An accurate estimate of the 
incidence of this complication would therefore require a trial containing very 
large numbers of patients and is impractical to undertake. In keeping with other 
investigators, we cannot accurately predict the incidence of respiratory 
depression that may occur after the use of low dose spinal opioid and PCA 
morphine. 
In the planning of this study, a number of measures have been employed to 
reduce this potential risk. These include: the utilisation of the lowest dose of 
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spinal morphine thought to be effective (0.1 mg), the use of specific monitoring 
charts to ensure that the patient is monitored on an hourly basis, delivery of 
supplemental oxygen whilst receiving morphine via the PCA device, routine 
prescription of naloxone and the use of clear protocols to be followed by nursing 
staff in the management of adverse events. All nursing staff involved in post-
operative patient care are competent and experienced in the management of 
patients who have received spinal and systemic morphine, and are trained in the 
necessary monitoring procedures. 
Both spinal anaesthesia and peripheral nerve blockade are commonly performed 
for hip arthroplasty in the United Kingdom. Any possible risks must be weighed 
up against the risks of a general anaesthetic. Any adverse events relating to each 
of the procedures will be recorded by staff performing the study and any 
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10.1 Non-inferiority 
This study was originally designed as a traditional superiority study.  After 
editorial review by the editors of the Trials journal, it was considered optimal to 
adopt a non-inferiority design (11).  A non-inferiority study aims to determine 
whether a new treatment is no worse than a standard or reference treatment 
(279).  In order to meaningfully use this concept in the clinical setting, a margin 
of non-inferiority (a margin between the groups which is felt to be clinically 
significant) is sought (δ).  This is because trying to prove that two treatments 
are exactly the same is extremely difficult if not impossible.  Non-inferiority 
trials aim to show that a new treatment is at least as effective as the 
established treatment, or that it is worse by an amount less than δ (i.e. less than 
the amount considered clinically significant).  Therefore, even if a new 
treatment is found to be no better than a more established treatment, it may 
have other important advantages such as lower invasiveness, or fewer side 
effects.(279)  It follows that the question of non-inferiority is non-symmetrical in 
that the new treatment is not of interest if it is in fact worse than the 
established treatment (by greater than δ).   
10.1.1 Hypotheses in a non-inferiority trial 
A non-inferiority trial is different to the more traditional superiority trial in a 
number of ways.  One of the most fundamental differences lies within the null 
hypothesis for the study.  In a superiority study, the null hypothesis states that 
there is no difference between the two treatments and rejection of the null 
hypothesis means that the two treatments differ.  A type I error in this scenario 
occurs when the null hypothesis is rejected erroneously (i.e. a difference is 
found where there is none).  A type II error occurs when there is a difference 
between the two treatments but this is not detected.   
Conversely, in a non-inferiority study, the null hypothesis states that one 
treatment is not non-inferior (or is unacceptably worse than) the other.  The 
alternative hypothesis is that the difference between the two treatments is less 
than δ and that the new treatment is therefore non-inferior to the traditional 
treatment. Thus the null hypothesis appears to be reversed in a sense as the null 
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hypothesis is not “null” at all.  In this situation, a type I error exists if a 
genuinely inferior new treatment is accepted as being non-inferior and a type II 
error occurs when a non-inferior treatment is rejected erroneously. The use of 
the clinically significant amount (δ) is used not only in the analysis of a non-
inferiority study but in the calculation of sample size(163;279).   
10.1.2 Study design 
In order to perform a non-inferiority trial, it is necessary that the reference 
treatment’s efficacy is well established and is in common use, as is the case with 
spinal morphine.  This makes an alternative study design with a comparison 
made to a placebo or untreated control group unethical (279).  In addition, 
outcome measures and patient population should be similar to those in studies 
looking at the reference treatment.  Sample size should be calculated using the 
following equation: 








     (287)
 
Equation 10.1-1 - sample size calculation for non-inferiority study with continuous outcome 
variable 
 
A pre-stated margin of non-inferiority is often chosen as the smallest value that 
would result in a clinically important effect (288).  The value used for δ should 
generally be smaller than the difference used in a superiority trial of a similar 
outcome.  This means that non-inferiority studies often require increased 
numbers of participants in order to be adequately powered (279).  As with all 
studies, minimising drop-out and non-adherence to treatment is of high 
importance if accurate results are to be achieved. 
10.1.3 Analysis 
Intention to treat (ITT) analysis is generally recommended for a standard 
superiority study: 
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ITT  “Includes all randomised patients in the groups to which they were 
randomly assigned, regardless of their adherence with the entry criteria, 
regardless of the treatment they actually received, and regardless of 
subsequent withdrawal from treatment or deviation from the protocol (289).”  
In non-inferiority studies, ITT analysis can increase the risk of a type I error 
(falsely declaring non-inferiority when in fact there is a clinically important 
difference between the two groups) (290). For example, if two groups of 
patients randomised to different treatments in a poorly designed trial were to 
cross-over to a large extent, it would result in two groups in which large 
numbers of participants received each of the treatments.  In a superiority study, 
this would (correctly) be likely to produce a result in which there was no 
difference found between the groups.  However, in a non-inferiority study, if the 
groups were to become “blended” by significant cross-over, this might result in 
non-inferiority being erroneously declared (type I error).  Therefore, in a non-
inferiority study, the more poorly run the trial, the more likely an ITT analysis 
will show non-inferiority (290).  For this reason, non-ITT analyses are often 
considered more appropriate for non-inferiority studies as they reduce the 
chance of a type I error.  Such analyses use participants who received and 
completed allocated treatment. The term “as treated” means that when the 
data are analysed, the treatment assignment is based on the actual treatment 
the patients received, not the treatment the patients are supposed to have 
received (i.e. the treatment to which they were randomised). 
To this end, the FDA’s Guidance for Industry Non-Inferiority Clinical Trials, 
suggests using an ‘as-treated’ analysis for the primary outcome (291): 
“Intent-to-treat (ITT) analyses in superiority trials are nonetheless 
preferred because they protect against the kinds of bias that might 
be associated with early departure from the study. In non-inferiority 
trials, many kinds of problems fatal to a superiority trial, such as 
non-adherence, misclassification of the primary endpoint, or 
measurement problems more generally (i.e., “noise”), or many 
dropouts who must be assessed as part of the treated group, can bias 
toward no treatment difference (success) and undermine the validity 
of the trial, creating apparent non-inferiority where it did not really 
exist. Although an “as-treated” analysis is therefore often suggested 
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as the primary analysis for NI studies, there are also significant 
concerns with the possibility of informative censoring in an as-
treated analysis. It is therefore important to conduct both ITT and as-
treated analyses in NI studies. Differences in results using the two 
analyses will need close examination.” 
This is reinforced by the authors of the extension to the CONSORT statement for 
non-inferiority and equivalence studies who state (279): 
“In non-inferiority and equivalence trials, non-ITT analyses might be 
desirable as a protection from ITT’s increase of type I error risk 
(falsely concluding non-inferiority). There is greater confidence in 
results when the conclusions are consistent.” 
The concerns outlined above regarding the sole use of an “as treated” analysis 
for non-inferiority studies include that of ‘informative censoring”, and there is 
an argument that in a non-inferiority study, there is an even greater need to 
ensure that the study is well designed and carefully monitored.  The use of both 
ITT and “as treated” analyses is suggested by European and US authorities 
(291;292). 
10.1.4 Interpretation of results 
Non-inferiority is most easily assessed using a confidence interval (CI) approach.  
Firstly, a non-inferiority margin is specified (δ). This is the maximum difference 
tolerated between the groups before the new treatment is considered inferior.  
If the 95% confidence interval for the difference between treatment means lies 
within this margin, then non-inferiority is deemed to have been established.  In 
order to interpret confidence intervals in non-inferiority studies, the following 
statements are true: 
 When the entire CI is greater than δ, the treatment is inferior. 
 When the upper limit of the CI is less than δ, the treatment is non-
inferior. 
 When the upper limit of the CI is greater than δ, the result is 
inconclusive. 
This can be represented graphically as seen in Figure 11.1-1: 
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Figure 10.1-1- Interpretation of confidence intervals for non-inferiority studies 
 
Advantages Disadvantages 
Useful when placebo control is 
inappropriate. 
Must meet specific design and analysis 
parameters to be useful. 
Not limited to pharmaceutical therapy 
 
Requirements appear to be poorly 
understood by investigators. 
Can be used for risk-benefit analyses 
 
Not recommended when the reference 
treatment is not well established, or is 
inconsistent when compared with placebo. 
Appropriate for comparing a specific 
intervention to itself (dose vs dose or 
formulation vs formulation). 
An appropriate sample size for non-
inferiority trials is usually larger than that 
required for superiority trials. 
 Type I error may occur resulting in falsely 
declaring a treatment non-inferior.  As there 
is commonly no placebo arm (in contrast 
with a superiority study), there is no way of 
telling whether the new treatment is any 
better than no treatment. 
Table 10.1-1 - Advantages and disadvantages of non-inferiority studies 
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10.1.5 Statistical software ‘R studio’ 
Statistics for this study were performed using R studio software.  R is a computer 
language and environmental platform for statistical computing.  It is based on 
the older computer language “S” and provides a wide variety of statistical and 
graphical techniques.  R is freely available under the terms of the Free Software 
Foundation's GNU General Public License in source code form and can be run on 
a wide variety of UNIX platforms.  It is compatible with Windows and MacOS. R is 
a modular system which employs a highly effective data handling and storage 
facility.  It also has a large number of coherent, integrated tools for data 
analysis as well as sophisticated graphical facilities useful for data analysis and 
subsequent publication purposes. 
Further reasons to use R for statistical analysis include: 
 It is the main statistical environment used by researchers in areas such as 
statistics and computational mathematics.  This means that the newest 
statistical and analytic techniques will be implemented on it first. 
 It is extremely flexible and can be used for both simple and highly 
complex analyses.   
 It is freely available and costs nothing to install and use.  
 
10.1.6 Statistical considerations for the study: Spinal opioid 
versus ultrasound guided fascia iliaca plane block for 
analgesia after primary hip arthroplasty: a randomised, 
blinded, non-inferiority controlled trial. 
The primary outcome of this trial was 24 hour post-operative morphine 
consumption.  We hypothesised that there would not be a clinically meaningful 
difference between the two groups, therefore, we planned this trial with a non-
inferiority design.  From our own experience, and from examining other similar 
studies, we considered that up to a 10mg increase in morphine consumption in 
the first 24 hours post-operatively would be an acceptable clinical difference in 
establishing non-inferiority and this was therefore chosen as the non-inferiority 
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margin (δ).  A priori statistical considerations including sample size calculation 
and planned analyses are outlined in Chapter 10 and have been published in a 
journal of trial methodology (11).  
Statistical analysis for this study was performed using R studio Version 0.98.953 – 
© 2009-2013 RStudio, Inc.  Data were transferred to R studio from Microsoft 
Access and Excel programmes using appropriate import scripts.  All data sources 
were combined with the study allocation key and data were transformed to be 
readable by R, i.e. information such as dates and times were changed to the 
appropriate format where necessary.  ITT and “as treated” groups were 
separated to allow independent analysis of both groups. All data were assessed 
for normality using a Shapiro test and by displaying graphically in the form of a 
histogram.  These distributions informed the way in which the data were 
reported as well as the performance of further statistical analysis.  
10.1.6.1 Primary outcome 
The primary outcome (24 hour morphine consumption), was calculated using the 
difference between the medians and confidence intervals between the two 
groups.  We planned to declare non-inferiority of the ultrasound guided fascia 
iliaca group with respect to the spinal morphine group if the upper bound of the 
2-sided 95% confidence interval (CI) of the difference in medians in 24-hour 
opioid consumption between groups (ultrasound guided fascia iliaca group – 
spinal morphine group) was <10 mg.  The use of confidence intervals in reporting 
the results of research has increased over the past several years as this provides 
a greater amount of information than p-values alone.  This practice is now 
recommended by many editors of scientific journals (293).  
Because of the right-skewed distribution of the median 24-hour opioid 
consumption (see Figure 11.1-2), CI construction was done without distribution 
assumptions by using a bias-corrected bootstrapping technique (with 10,000 
replications) (294;295).  Bootstrapping is a statistical technique requiring 
intensive computational input which can allow a researcher to make inferences 
from their data without making strong distributional assumptions.  In other 
words, bootstrapping can provide information on the shape of the sampling 
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distribution of the outcome in question. This can then be used to calculate 
improved confidence intervals if the sampling distribution is not normal.  Due to 
the non-inferiority design, the primary outcome analysis was performed using 
both ITT and “as treated” populations.  
24 hour morphine consumption 
Figure 10.1-2 - Histogram showing right skew of data for primary outcome - 24 hour 
morphine consumption 
 
10.1.6.2 Demographic variables and secondary outcomes 
Descriptive statistics were calculated for demographic variables.  Z tests of two 
proportions were used for data relating to gender and pre-operative 
administration of paracetamol as these were simple count data.  Student’s t 
tests were used for normally distributed demographic variables such as weight, 
height, pre-operative heart rate, pre-operative systolic BP (SBP), pre-operative 
diastolic BP (DBP) and pre-operative SpO2. These data were expressed as means 
and standard deviations (SD).   
As PCA morphine was generally removed at 24 hours post-operatively, patients 
received oral opioids from this point onward if required.  Oxynorm was originally 
the oral opioid of choice though this changed to oral morphine after the study 
had been running for 4 months due to a change in hospital prescribing policy.  
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Oxynorm was converted to oral morphine by multiplying it by 1.5 (252).  Oral 
morphine was then converted to IV morphine by dividing by 3 (252).  This was 
added to the 48 hour morphine consumption for all patients to give a figure for 
total 48 hour systemic opioid consumption.   
Wilcoxon rank sum tests were used for non-normally distributed data which 
included: body mass index (BMI), fascia iliaca block time, surgery time, blood 
loss during surgery, time to first administration of morphine, morphine 
consumption at 3, 6, 12, 24, 36, 48 hours, pain scores at rest and movement at 
3, 6, 12, 24, 36, 48 hours, time to first mobilisation, quadriceps power grade 
prior to first mobilisation and patient satisfaction at 48 hours.  These data were 
expressed using median and inter-quartile range (IQR).  Again, Z tests of two 
proportions were used for data involving counts, which were: paraesthesia 
during fascia iliaca block, paraesthesia during spinal injection, intra-operative 
administration of anti-emetic, number of patients suffering respiratory 
depression, number of doses of naloxone administered for respiratory 
depression, number of patients with episodes of SBP < 80mmHg, number of 
patients with episodes of SBP > 25% below baseline, number of patients given 
post-operative vasopressor, urinary retention requiring catheterisation, number 
of patients with PONV scores >2, number of patients requiring post-operative 
anti-emetic, number of patients requiring treatment for pruritus, number of 
patients with distressing pruritus, number of patients with sedation score > 2, 
mobilisation at first attempt, number of adverse events and number of serious 
adverse events.  The tests were two sided and a p value of <0.05 was considered 
statistically significant. 
10.1.7 Linear regression 
Linear regression is a statistical tool used to model the dependence of a variable 
(y) on one or more predictor variables (x). In simple linear regression, we aim to 
predict one variable from a second variable.  In the case of simple linear 
regression, the prediction of the dependent variable (y) when plotted as a 
function of the predictor variable (x) forms a straight line.  Linear regression 
calculates an equation that minimises the distance between the fitted line and 
all of the data points (the residuals). This can be denoted as y = a + bx (i.e. the 
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equation for a straight line where ‘b’ represents the slope of the line [or 
regression coefficient], and ‘a’ represents the point at which the y axis is 
crossed [or regression constant]).  The regression coefficient represents the 
change in the dependent variable which is associated with a change of one unit 
in the predictor variable (i.e. the slope of the regression line). 
In multiple linear regression, the dependent variable is predicted by two or more 
predictor variables. This allows the investigation of the effects of a number of 
different predictor variables on the dependent variable.  Multiple linear 
regression analysis may be used to;  
 Identify factors which may affect the variable of interest (y) in order to 
improve understanding of the process. 
 Determine the extent to which the explanatory variables are linearly 
related to the dependent variable after adjusting for other variables. 
 Allow prediction of the dependent variables from explanatory variables.   
 
R2 is a statistical measure which represents the amount of variation in the data 
that is explained by the regression.  R2 has a value between 0 and 100%.  An R2 
of 0% indicates that the model explains none of the variability of the response 
data around its mean.  An R2 of 100% means that the model explains all of the 
variability of the response data around its mean.  For example, if the R2 value is 
0.88, this means that 88% of the variation in the dependent variable is explained 
by variation in the predictor variable(s). R2 is also known as the coefficient of 
determination, or the coefficient of multiple determination for multiple linear 
regression. 
 
While R2 provides useful information, it does not always give the full picture and 
has a number of limitations.  Firstly, every time a predictor variable is added to 
a model, the R2 increases, even if this is due to chance alone. R2 never decreases 
in this situation.  It therefore follows that a model with more terms may appear 
to have a better fit simply because it contains more predictor variables.  
Secondly, if a model has too many predictors, it can begin to model the random 
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noise in the data. This is known as “over-fitting” the model and it can result in 
falsely high R2 values and a decreased ability to make predictions (296). 
 
In order to address some of these issues, the adjusted R2 can be used.  This is 
adjusted for the number of predictor variables in the model and will allow an 
increase in the adjusted R2 only if the new predictor variable improves the 
model more than would be expected by chance alone. The adjusted R2 is 
therefore always lower than R2.  The adjusted R2 is used when quoting results for 
linear regression in this study. 
 
It should be noted that regression models should not be used to make predictions 
outwith the range of the original data.   
 
10.1.7.1 Linear regression for primary outcome 
A linear regression analysis was performed for the primary outcome of 24 hour 
morphine consumption as this is a continuous variable. The regression analysis 
was performed using both forward and backward step-wise approaches in order 
to try and find the optimal model. The coefficient of determination, R2, was 
calculated as an indicator of the proportion of variability explained by each 
model.  AIC values were also calculated in order to assess the quality of the 
model. 
A note on Akaike's Information Criterion (AIC) 
AIC stands for Akaike's Information Criterion. This is a measure of the relative quality of a 
statistical model for a given set of data. AIC trades off the “goodness of fit” of the model 
with the complexity of the model offering a relative estimate of the information lost when a 
given model is used to represent the process that generates the data.  As such, AIC 
provides a means for model selection. When comparing models fitted by maximum 




Chapter 10  219 
 
10.1.8 Logistic regression 
Logistic regression is used when the outcome variable of interest is binary or 
dichotomous (e.g. the presence or absence of a symptom, alive versus dead etc). 
The goal of logistic regression is to find the best fitting (yet biologically 
plausible) model to describe the relationship between the dependent (or 
outcome) variable and the independent (predictor or explanatory) variables. 
This process allows us to look at the fit of the model as well as at the 
significance of the relationships (between dependent and independent variables) 
that are being modelled.  Logistic regression estimates the probability of an 
event occurring. Therefore, rather than being able to predict a precise 
numerical value of a dependent variable from independent variables, the 
probability of an event occurring rather than an event not occurring is 
calculated. The odds ratio (OR) is used to describe this concept and is defined as 
(296);  
“The ratio of the odds of an event occurring to it not occurring”. 
A logistic regression analysis was performed for selected dichotomous secondary 
outcomes. 
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10.2 Chapter 10 Summary 
 A non-inferiority study aims to determine whether a new treatment is no 
worse than a standard or reference treatment. 
 In a non-inferiority study, the null hypothesis states that one treatment is 
not non-inferior (or is unacceptably worse than) the other.   
 Linear and logistic regression are statistical tools which can be used 
respectively to model; the dependence of a variable (y) on one or more 
predictor variables (x) and the probability of an event occurring. 
 Both intention to treat and ‘as treated’ analyses should be performed 












I am indebted to Dr Gilda Piaggio PhD (Honorary Professor Medical Statistics 
Department, London School of Hygiene and Tropical Medicine 
London, UK) and Dr Janet Wittes PhD (Statistics Collaborative, Inc., Washington 
DC) for their expert advice in the interpretation of the analyses pertaining to 
the Primary Outcome of 24 hour morphine consumption.   
11.1 Results 
From May 2011 to April 2014, 108 patients were recruited and randomised to 
either of the two study treatments.  Two patients did not undergo study 
intervention and subsequent surgery. The first was found to have cellulitis near 
the operative site and was cancelled by the operating surgeon.  The second was 
cancelled due to lack of time on the operating list.  Both of these patients were 
withdrawn from the “as treated” analysis. Three patients required general 
anaesthesia and were also withdrawn from the study as directed by the study 
protocol (11).  108 patients were analysed in the intention to treat (ITT) analysis 
and 103 in the ‘as treated’ analysis. 
                 




Patient demographics were similar between groups and are displayed in Table 
11.1-1.  As the study was randomised, any detected differences should be 
attributable to chance alone. 
 
 Spinal Morphine 
(n=54) 




Age / years 
Median (IQR) 
63.5 (55-72.75) 67 (56.25-74.75) 0 
Sex = male  
(N, %) 
22 (40.7%) 31 (57.4%) 0 
Weight / kg, 
Mean (SD) 
80.15 (13.46) 79.91 (14.29) 0 
Height / cm 
Mean (SD) 
163.8 (8.80) 165.9 (8.22) 0 
BMI  
Median (IQR) 
29.5 (27.25-32) 29(26-32.75) 0 
Pre-op HR 
Mean (SD) 
74.2 (12.39) 67.89 (10.07) 0 
Pre-op SBP / 
mmHg  
 Mean (SD) 
135.3(14.21) 134(16.00) 0 
Pre-op DBP / 
mmHg 
 Mean (SD) 




97 (96-98) 97(96-98) 2 
Table 11.1-1 - Patient demographics (intention to treat) 
BMI = body mass index, HR = heart rate, SBP = systolic blood pressure, DBP = diastolic blood 





11.1.1 Primary outcome  
For the ‘as treated’ analysis, the medians for 24 hour morphine consumption 
were calculated for each group.   
 Spinal morphine 
 (n = 51) 
Fascia Iliaca  
Block (n = 52) 
P value  
24 hour morphine 
consumption / mg 
median (IQR) 
14 (4.5 - 32.5) 39 (18 - 49.5) <0.001 
    
Table 11.1-2 - Primary outcome (as treated) 
 
The difference between the two medians was then calculated as described in 
chapter 11 (median with 95% confidence intervals - bias correcting bootstrapping 
technique with 10,000 replications).  The difference between the medians was 
25mg (95% CI 9.0 - 30.5mg).  The median is greater than the pre-specified non-
inferiority margin (δ = 10mg) though the lower end of the confidence interval 
crosses δ. The same analysis was performed for the ITT group giving a similar 
difference between medians of 24mg (95% CI 14 – 29mg). The 95% CI in this case 





                Favours USG fascia iliaca bloc              Favours spinal morphine  
 
Figure 11.1-2 - As treated and ITT analyses for 24 hour morphine consumption (primary 
outcome). 
For the ITT analysis, as the 95% CI for the difference between the medians lies 
fully outwith δ, it can be concluded that ultrasound guided fascia iliaca block is 
not non-inferior (or is inferior) to spinal morphine in providing analgesia after 
total hip arthroplasty. Therefore the null hypothesis is accepted.   
In the “as treated analysis”, the CI includes δ but is still wholly to the right of 
zero. The difference is therefore statistically significant but the result is 
technically inconclusive regarding possible inferiority of magnitude δ or worse 
(279).  
As the results of the ITT and “as treated” analyses differed slightly, we sought 
further statistical advice from two experts in the analysis of non-inferiority 
study. The first was the primary author of the CONSORT extension statement on 
reporting of non-inferiority studies (279).  Dr Piaggio gave the following 
interpretation of the Primary Outcome results:  
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“The results of the two analyses are consistent, in that the point 
estimate is to the right of δ. The ITT analysis clearly shows inferiority 
of ultrasound guided fascia iliaca block with respect to spinal 
morphine. The “as treated” analysis includes fewer subjects, 
therefore has less power to show inferiority, but still it shows that 
the new treatment is significantly worse than spinal morphine. From 
this data, I would not recommend to replace spinal morphine by USG 
fascia iliaca block”.   
Further advice was received from the author of a paper on non-inferiority 
methodology published in a journal of trial design (290).  Dr Wittes gave the 
following interpretation of the primary outcome result: 
“The conventional rule for declaring non-inferiority is that the 95% 
confidence intervals for both the ITT and the as-treated analyses 
must be fully contained in the gray area. In other words, the “bad” 
end of the confidence interval must satisfy the non-inferiority bound. 
 Your study shows: 
 ITT: the entire confidence interval is above 0, showing a statistically 
significant benefit for spinal morphine. 
As treated: again, the entire confidence interval is above 0, showing 
a statistically significant benefit for spinal morphine. The fact that 
the left end of the CI is within the non-inferiority bound does not 
change that conclusion. To have concluded non-inferiority, the right 
end of the CI would have had to have been below the NI bound.  So, 
in your case, both analyses lead to the same conclusion.”  
 
11.1.2 Secondary outcomes  
Secondary outcomes were analysed on an ‘as treated’ basis and statistically 
significant values are tabulated in Table 11.1-3 and 11.1-4. There were no 
statistically significant differences between the study groups for: ultrasound 
guided fascia iliaca block or spinal performance and associated adverse events, 
duration of surgery, blood loss during surgery, administration of pre-operative 
paracetamol, administration of intra-operative anti-emetic, time to first 
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administration of morphine, rest visual analogue pain scores (VAS) at 3, 24, 36 
and 48 hours, VAS pain scores on movement at 3, 24, 36 and 48 hours, 
respiratory depression, hypotension, sedation, nausea, vomiting, urinary 
retention, pruritus, mobilisation at 1st attempt, power grade before 
mobilisation, patient satisfaction or adverse events. 
Outcomes reaching statistical significance (p < 0.05) were: morphine 
consumption at all time points (3, 6, 12, 24, 36, and 48 hours), pain scores (VAS) 
at rest and movement at 6 and 12 hours and time to first mobilisation. Tables 























p value Missing 
data 
Time 1st morphine / 
mins  
Median (IQR) 
129(55-228) 130·5(60-240) 0·93 6 
Morphine consumption 
at 3 hours / mg  
Median (IQR) 
1(0-3) 3(0-11) 0·007 1 
Morphine consumption 
at 6 hours / mg 
Median (IQR) 
4(2-9) 13.5(5·75-20·75) <0·001 0 
Morphine consumption 
at 12 hours / mg  
Median (IQR) 
10(2·5-22·5) 24(14-35·5) <0·001 0 
Morphine consumption 
at 24 hours / mg 
Median (IQR) 
14(4·5-32·5) 39(18-49·5) <0·001 0 
Morphine consumption 
at 36 hours / mg  
Median (IQR) 
15(5-32·5) 39.5(18-55) <0·001 0 
Morphine consumption 




















p value Missing 
data 
VAS 3 hrs at rest Median 
(IQR) 
0 (0-1) 0 (0-4) 0·151 5 
VAS 6 hrs at rest Median 
(IQR) 
0 (0-2) 3 (0-5) <0·001 4 
VAS 12 hrs at rest 
Median (IQR) 
0 (0-2) 2 (0-3) 0·004 4 
VAS 24 hrs at rest 
(median, IQR) 
0 (0-4) 0.5 (0-3·75) 0·83 8 
VAS 36 hrs at rest 
Median, IQR)  
0 (0-1) 0 (0-4·75) 0·52 67 
VAS 48 hrs at rest 
(median (IQR) 
1 (0-4) 1(0-2) 0·26 15 
VAS 3 hrs on movement  
Median (IQR) 
0(0-2) 0(0-4) 0·95 0 
VAS 6 hrs on movement 
Median (IQR) 
0(0-3·5) 3(0-5·25) 0·03 8 
VAS 12 hrs on 
movement 
Median (IQR) 
0(0-2) 2(0-4) 0·03 9 
VAS 24 hrs on 
movement 
Median (IQR) 
2(0-6) 2(0-4) 0·51 12 
VAS 36 hrs on 
movement 
Median (IQR)  
0(0-2·5) 0(0-4) 0·67 68 
VAS 48 hrs on 
movement  
Median (IQR) 
4(3-7) 4(2-6) 0·58 16 
Table 11.1-4 - VAS pain scores (as treated) 
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11.1.2.1 Adverse events 
There were no episodes of respiratory depression in either group.  There was no 
statistically significant difference between groups for: patients experiencing 
hypotension (both SBP < 80mmHg and SBP < 25% under baseline reading), urinary 
retention requiring catheterisation, patients requiring an anti-emetic, patients 
experiencing pruritus requiring treatment, patients with pruritus considered to 
be distressing, ability to mobilise at first attempt, quadriceps power grade prior 
to first mobilisation attempt, patient satisfaction scores at 48 hours, presence of 
residual paraesthesia at 48 hours, occurrence of adverse events (AE) and 
occurrence of serious adverse events (SAE). 
The nature of all Adverse events and Serious Adverse Events are tabulated 
below: 
 
Nature of AE Study Group 
Post-operative pyrexia Block 
Post-operative lower respiratory tract 
infection 
Opiate 
Prolonged quadriceps motor weakness > 48 
hours but resolving within one week  
Block 
Post-operative vasovagal episode Opiate 
Post-operative blood transfusion Opiate 
Post-operative atrial fibrillation (AF) 
in a patient with known paroxysmal AF          Block 
 




Nature of SAE Study Group 
Pulmonary embolism  Opiate 
Pulmonary embolism Block 
Multiple pulmonary emboli  Block 
Wound infection resulting in multi-organ 
failure 
Opiate 
Femoral nerve palsy (resolved completely 
within 3 months)  
Block 
Late wound infection, hyponatraemia and 
confusion 
Block 
Table 11.1-6- Serious adverse events (SAE) 
All AEs and SAEs were reported to the West of Scotland Research Ethics 
Committee and NHS Greater Glasgow and Clyde Research and Development 
Department for review.  Each of these incidents was discussed by the 
appropriate parties.  No further actions were deemed necessary. 
 
11.2 Linear regression analysis 
11.2.1 Forward approach to linear regression analysis from   
all possible variables 
Linear regression analysis was performed for the primary outcome of 24 hour 
morphine consumption using both forward and backward stepwise 
methodologies.  An initial model was created by analysing each predictor 
variable separately against the primary outcome (24 hour morphine 
consumption) in a univariate unadjusted regression analysis.  Only one time 
point for variables within a time series (i.e. morphine consumption and pain 
scores) was used.  The time point of 12 hours was chosen for these variables as it 
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reached the greatest level of significance on unadjusted testing.   Any variables 
reaching statistical significance (p<0.05) in these unadjusted analyses were 
extracted and combined to create an adjusted regression model.  Factors 
reaching statistical significance on unadjusted analysis were: age, height, group, 
morphine consumption at 12 hours, pain score at rest at 12 hours, urinary 
retention requiring catheterisation, pruritus found to be distressing and 
quadriceps power grade before first mobilisation.  The coefficient of 
determination and AIC values were calculated for the adjusted regression model 
using these co-variates (R2 = 0.897, AIC 678).  
 
Variable Unadjusted univariate 
analysis for all variables 
Adjusted analysis for all 
variables 
 Estimate P value Estimate P value 
Age -0.99 <0.001   -0.10 0.34 
Weight 0.17 0.39       -    -  
Height 1.03  0.002  0.12  0.34   
BMI -0.16 0.79       -    - 
Male gender 9.92 0.07      -                           - 
Group opiate -16.96 0.002 1.71 0.433    
Pre-op HR -0.26 0.29      -     - 
Pre-op SBP -0.28 0.12      -     - 
Pre-op DBP -0.08 0.78      -     -  





-0.08 0.51       -     - 
Surgical blood 
loss 
















-19.37 0.18      -     - 
VAS at rest at 
12 hours 
6.15 <0.001 0.49 0.36   
No. episodes 
resp depression 
NA NA      -    - 
No. doses 
naloxone 
17.55  0.54      -    - 
No. episodes 
SBP<80mmHg 




-0.57 0.27      -    - 
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No. of post-op 
vasopressor 
doses 




-11.72 0.046   0.70 0.74 
No. of episodes 
of PONV 
score>2 
  0.58 0.90      -     -  
No. of post-op 
anti-emetic 
doses 
























    
- 




Time to first 
mobilisation 
0.31 0.21      -    - 
Mobilisation at 
first attempt 








0.063 0.62    -    - 
Table 11.2-1  – Unadjusted univariate and adjusted multi-variate linear regression models 
using all possible co-variates for the primary outcome (24 hour morphine consumption). 
HR = heart rate, SBP = systolic blood pressure, DBP = diastolic blood pressure, PONV = post-
operative nausea and vomiting. P values reaching statistical significance (p<0.05) are highlighted in 
yellow. 
 
11.2.1.1 Adjusted model from all possible variables  
All study variables were then combined in a full multi-variate analysis.  The R2 
for this full adjusted model was 0.899 and the AIC was 546.  However, a model 
with a large number of covariates is not desirable.  Co-variates found to be 
statistically significant in this model were extracted and used to create a new 
model.  The co-variates which reached statistical significance in this full 
adjusted analysis were: age, pre-operative SpO2, morphine consumption at 12 
hours and number of episodes of PONV score > 2.  Using these as the predictor 
variables in a new adjusted model resulted in an R2 of 0.903 and AIC of 733.  A 
backward stepwise linear regression could not be performed using all variables 




Variable Full adjusted analysis including 
all variables 
Adjusted analysis including 
only statistically significant 
variables 
 Estimate P value Estimate P value 
Age   -0.36 0.02  -0.21                   0.02 
Weight -0.01 0.99      -                         - 
Height 0.07  0.85       -                         - 
BMI -1.01 0.21       -                         - 
Male gender -4.36 0.23     -                         - 
Group opiate 2.012 0.42        -                         - 
Pre-op HR 0.023 0.80     -                         - 
Pre-op SBP 0.09 0.33     -                         - 
Pre-op DBP -0.09 0.58        -                         - 
Pre-op SpO2 -2.87 0.006   -0.49                     0.52 
Surgery 
duration 
0.06 0.37     -                         - 
Surgical blood 
loss 








0.53   
     


















4.75 0.99        -                   - 
 
VAS at rest at 
12 hours 

















-0.41 0.12     -                   - 
 
No. of post-op 
vasopressor 
doses 
-1.02 0.73     -                   - 
 






1.09 0.68  -                   - 
 
No. of episodes 
of PONV 
score>2 
  -4.67  0.03   -4.18              0.006 
No. of post-op 
anti-emetic 
doses 




















NA NA     -                   - 
 
Time to first 
mobilisation 

















-0.05 0.35     -                   - 
 
Table 11.2-2 - Backward approach adjusted multi-variable linear regression models using all 
possible co-variates for the primary outcome (24 hour morphine consumption). 
HR = heart rate, SBP = systolic blood pressure, DBP = diastolic blood pressure, PONV = post-
operative nausea and vomiting. P values reaching statistical significance (p<0.05) are highlighted in 
yellow. 
 
11.2.1.2 Unadjusted and adjusted analyses of variables available before 24 hours  
A further univariate unadjusted analysis was performed using only variables that 
would be available to a clinician prior to the outcome of interest being available 
(24 hour morphine consumption).  The included variables were: age, weight, 
height, BMI, sex, study group, pre-operative heart rate, pre-operative systolic 
and diastolic blood pressure, pre-operative SpO2, surgery duration, surgical 
blood loss, time first morphine administered, VAS pain score at rest at 12 hours, 
morphine consumption at 12 hours, intra-operative anti-emetic and pre-
operative paracetamol administered.  These will be known as the “initial 24 hour 
factors”. This was considered to be more useful if a prediction tool was to be 
used in clinical practice.  Co-variates found to be significant in this univariate 
unadjusted analysis (group, age, height, VAS at rest at 12 hours and morphine 
consumption at 12 hours) were then combined to create a new adjusted model 






Variable Univariate unadjusted 
analyses for initial 24 hour 
variables 
Adjusted analysis for initial 24 
hour variables 
 Estimate P value Estimate P value 
Age -0.99 <0.001   -0.14 0.18 
Weight 0.17 0.39       -    -  
Height 1.03  0.002  0.07  0.53   
BMI -0.16 0.79       -    - 
Male gender 9.92 0.07      -                           - 
Group opiate -16.96 0.002 0.93 0.65    
Pre-op HR -0.26 0.29      -     - 
Pre-op SBP -0.28 0.12      -     - 
Pre-op DBP -0.08 0.78      -     -  
Pre-op SpO2 -2.15 0.37      -     - 
Surgery 
duration 
-0.08 0.51       -     - 
Surgical blood 
loss 









     
 - 















-19.37 0.18      -     - 
VAS at rest at 
12 hours 
6.15 <0.001 0.57 0.57  
 
Table 11.2-3 - Unadjusted and adjusted linear regression models for co-variates available in 
the first 24 hours for the primary outcome (24 hour morphine consumption). 
HR = heart rate, SBP = systolic blood pressure, DBP = diastolic blood pressure, PONV = post-
operative nausea and vomiting. P values reaching statistical significance (p<0.05) are highlighted in 
yellow. 
 
11.2.1.3 Adjusted model for variables available before 24 hours  
An adjusted model containing all of the “initial 24 hour factors” (age, weight, 
height, BMI, sex, study group, pre-op heart rate, pre-op systolic and diastolic 
blood pressure, pre-op SpO2, surgery duration, surgical blood loss, time first 
morphine administered, VAS score at rest at 12 hours, morphine consumption at 
12 hours, intra-operative anti-emetic and pre-operative paracetamol 
administered) was then created (R2 0.908 AIC 644).  Factors which were found to 
be significant in this adjusted model (age, surgery duration and 12 hour 
morphine consumption) were analysed to give a model with an R2 of 0.898 and 




Variable Adjusted analysis for initial 24 
hour variables 
Adjusted analysis for initial 24 
hour variables reaching 
significance 
 Estimate P value Estimate P value 
Age -0.24 0.04    -0.17         0.054 
Weight -0.23 0.22       -    -  
Height 10.27 0.29        -                           - 
BMI -0.40 0.46       -    - 
Male gender -4.53 0.11      -                           - 
Group opiate 1.6 0.43      -                              - 
Pre-op HR -0.06 0.49     -     - 
Pre-op SBP -1.01 0.94      -     - 
Pre-op DBP 0.04 0.73      -     -  
Pre-op SpO2 -2.15 0.37      -     - 
Surgery 
duration 
0.11 0.03  0.03                           0.41 
Surgical blood 
loss 




0.01 0.06      -     - 














-2.11 0.64      -     - 
VAS at rest at 
12 hours 
-0.02 0.97     -                              - 
Table 11.2-4 - Multivariate adjusted linear regression model for co-variates available in the 
first 24 hours for the primary outcome (24 hour morphine consumption). 
HR = heart rate, SBP = systolic blood pressure, DBP = diastolic blood pressure, PONV = post-
operative nausea and vomiting. P values reaching statistical significance (p<0.05) are highlighted in 
yellow. 
 
11.2.1.4 Backward stepwise linear regression from variables available before 24 
hours 
A backward stepwise linear regression was then performed on all of the “initial 
24 hour” covariates.  The co-variates found to create the best model fit using 
this approach were: age, height, weight, sex, pre-operative SpO2, surgical time, 
surgical blood loss, time first morphine administered and morphine consumption 
at 12 hours.  The R2 for this model was 0.916 and the AIC was 642.  This was 






Variable Adjusted analysis for initial 24 
hour variables 
 Estimate P value 
Age -0.25 0.006 
Weight     -    - 
Height 10.27 0.009  
BMI     -     - 
Male gender -4.54 0.07 
Group opiate     -     - 
Pre-op HR     -     - 
Pre-op SBP     -     - 
Pre-op DBP     -     - 
Pre-op SpO2 -1.5 0.049 





















    -     - 
VAS at rest at 
12 hours 
    -     - 
Table 11.2-5 - Backward stepwise regression approach for co-variates available in the first 
24 hours for the primary outcome (24 hour morphine consumption). 
HR = heart rate, SBP = systolic blood pressure, DBP = diastolic blood pressure, PONV = post-
operative nausea and vomiting. P values reaching statistical significance (p<0.05) are highlighted in 
yellow. 
 
11.3 Logistic regression analysis 
Logistic regression analysis was performed on dichotomous outcomes which were 
felt to be of greatest clinical significance (i.e. those outcomes felt to relate 
most closely to a patient’s recovery and post-operative experience).   
11.3.1.1 Hypotension - SBP > 25% below baseline 
Unadjusted univariate logistic regression was performed for variables which were 
suspected clinically to have a potential effect on episodes of SBP > 25% under 
baseline.  Neither being in the spinal morphine group (p=0.49), gender (p=0.14), 
nor 3 hour morphine consumption (p=0.48) had an effect on the number of 
episodes of SBP >25% below baseline in the post-operative period. 
Morphine consumption at 6 hours was associated with decreased episodes of SBP 
>25% below baseline (p = 0.03).  OR = 0.96 (95% CI 0.92 to 0.99).  Therefore for 
every 1mg increase in morphine in a 24 hr period, the odds of having a 
hypotensive episode were reduced by 4%.  Group did not influence this (p= 0.09) 
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Similarly, morphine consumption at 12 hours (p = 0.02, OR = 0.97 [95% CI 0.95 to 
0.99]), 24 hours (p=0.009, OR = 0.98 [95% CI 0.96 to 0.99]), and 48 hours 
(p=0.008, OR = 0.98 [95% CI = 0.96 - 0.99]) were associated with decreased 
numbers of SBP >25% under baseline. Therefore for every 1mg increase in 
morphine in 24 hr period, the odds of having a hypotensive episode were 
reduced by 2%.  Group did not influence this (p= 0.098 and 0.086 respectively).   
Age was associated with an increase in the numbers of episodes of SBP>25% 
under baseline (p= 0.008). The Odds Ratio (OR) was 1.05 (95% CI 1.02 to 1.10).    
Therefore for every 1 year increase in age, the odds of having a hypotensive 
episode were increased by 5%. 
Pre-operative SBP was also associated with episodes of post-operative 
hypotension >25% under baseline (p = 0.0002, OR 1.06 [95% CI 1.03 to 1.10]).  
Therefore for every 1mmHg increase in pre-operative SBP, the odds of an 
episode of hypotension increased by 6% 
 
11.3.1.2 Urinary retention requiring catheterisation 
Factors which were considered to pose a theoretical risk of increased likelihood 
of urinary retention requiring catheterisation were analysed.  Neither study 
group (p=0.27), age (p=0.14), gender (p=0.33), BMI (p=0.09), weight (p=0.18), 
surgical blood loss (p=0.94), post-operative hypotension (SBP >25% under 
baseline, p=0.23), nor pain score at rest at 12 hours (p=0.4334) increased the 
odds of requiring catheterisation.  24 hour morphine consumption almost 
reached statistical significance with a p value of 0.052 (OR 0.98, [95% CI 0.96 to 
0.99]). 
11.3.1.3 Post-operative nausea and vomiting 
The odds of developing post-operative nausea and vomiting as defined by nausea 
score > 2 were not affected by: age (p=0.15), gender (p=0.62) weight (p=0.29), 
height (p=0.41), pre-operative systolic blood pressure (p=0.16), study group 
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(p=0.62), 24 hour morphine consumption (p=0.84), hypotension (SBP > 25% under 
baseline, p=0.45), surgical time  (p= 0.52) or surgical blood loss (p=0.22). 
Increasing BMI increased the odds of experiencing PONV (p= 0.04, OR 1.13 [95% 
CI 1.01 to 1.28]).  Therefore for every 1 unit increase in BMI, the odds of a 
patient suffering PONV increased by 13%.  VAS pain score at rest at 12 hours also 
reached statistical significance (p=0.049, OR 1.25 [95% CI 0.99 to 1.58]).  
Therefore for every 1 unit increase in the VAS pain score at rest at 12 hours, the 
odds of experiencing an episode of PONV was increased by 25%. 
 
11.3.1.4 Mobilisation 
Mobilisation at first attempt was unaffected by: age (p=0.29), sex (p=0.21), BMI 
(p=0.43), weight (p=0.72), height (p= 0.99), study group (p=0.1), pre-operative 
systolic blood pressure (p=0.2), PONV (p=0.62), urinary catheterisation (p=0.11), 
24 hour morphine consumption (p=0.20), pain scores at rest at 12 hours (p=0.85) 
and surgical time (p=0.21). 
The odds of mobilising at the first attempt was affected by the amount of blood 
lost peri-operatively (p=0.02, OR 0.99 [95% CI 0.99 to 0.99]).  Therefore for 
every 1ml additional blood loss, there was a 0.3% decreased chance of the 
patient mobilising at the first attempt.  Similarly for post-operative hypotension 
as defined by SBP > 25% below baseline (p=0.05, OR 0.92, [95% CI 0.85 to 0.99].  
Having an episode of post-operative hypotension reduced the odds of mobilising 
successfully on the first attempt by approximately 8%. 
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11.4 Chapter 11 Summary 
 For the primary outcome of 24 hour morphine consumption, the ITT 
analysis clearly shows inferiority of ultrasound guided fascia iliaca block 
with respect to spinal morphine. The “as treated” analysis includes fewer 
subjects, therefore has less power to show inferiority, but still shows that 
the new treatment is significantly worse than spinal morphine. From this 
data, we would not recommend to replace spinal morphine by USG fascia 
iliaca block”.   
 Secondary outcomes reaching statistical significance (p < 0.05) in favour 
of spinal morphine were: morphine consumption at all time points (3, 6, 
12, 24, 36, and 48 hours), pain scores (VAS) at rest and movement at 6 
and 12 hours and time to first mobilisation.  
 The factors found to create the best model for predicting 24 hour 
morphine consumption were: age, BMI, surgical time, surgical blood loss, 




























12.1.1 Study design and methodological considerations 
This study was designed following the publication by Dolan et al which showed 
the impoved reliability of fascia iliaca block when performed using ultrasound 
guidance (10).  The effects upon analgesia were not examined in this study and 
we were interested to investigate this in the setting of total hip replacement. In 
the only study examining the use of fascia iliaca block for THA, Stevens et al 
compared a modified landmark technique fascia iliaca block with placebo block 
in patients undergoing THA (274). They noted a morphine sparing effect in the 
fascia iliaca block group at 24 hours which they hypothesised may have been due 
to increased proximal spread of local anaesthetic resulting in improved 
anaesthesia in the upper third of the thigh, The duration of analgesia provided 
by ultrasound guided fascia iliaca block has not been investigated, though in a 
systematic review and meta-analysis of peripheral nerve blocks performed with 
peripheral nerve stimulation or ultrasound guidance, blocks performed using 
ultrasound were found to last around 25% longer (278).  We hypothesised that 
using ultrasound guidance to place the fascia iliaca block would result in more 
reliable placement of anaesthetic and allow for a greater degree of proximal 
spread and potentially longer duration of effect. As ultrasound guided fascia 
iliaca block had not yet been investigated as an analgesic modality for primary 
THA, we felt it important to investigate this in the first instance.   
It could be argued that the use of a fascia iliaca catheter with infusion of local 
anaesthetic might have had even greater potential for long lasting analgesia and 
would have been a suitable comparison for spinal morphine.  As this is a more 
invasive technique, we felt that it was important to investigate the less invasive 
option in the first instance. 
The study was initially designed as a traditional superiority study.  On submission 
of the protocol to the Trials journal (a journal of trial methodology edited by the 
authors of the CONSORT statements), we were advised that a non-inferiority 
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design was more appropriate.  This was because we did not think that ultrasound 
guided fascia iliaca block was likely to be superior to spinal morphine in the 
provision of analgesia after THA.  Our initial hypothesis was that ultrasound 
guided fascia iliaca block would provide analgesia which was comparable to 
spinal morphine in the provision of analgesia after THA. We were encouraged by 
the results of both Dolan et al and Stevens et al that ultrasound guided fascia 
iliaca block had the potential to provide more reliable and prolonged analgesia 
than a standard fascia iliaca block.  If the ultrasound guided block was 
associated with fewer adverse effects than spinal morphine, then it could be 
considered as a preferable option.  The non-inferiority design encompasses these 
principles in that if a new treatment option is found to be non-inferior to a more 
established treatment option, then it may be preferred if it has some other 
advantage.  The results of the study are clear in that ultrasound guided fascia 
iliaca block is inferior to spinal morphine in the provision of analgesia after THA. 
However, we could not have known this at the time of study design. 
Spinal morphine (rather than spinal diamorphine) was utilised in this study as it 
is more widely used internationally and was therefore felt to be of greater 
relevance to the international anaesthetic community. 
12.1.2 Primary outcome 
Twenty four hour morphine consumption was chosen as the primary outcome in 
this study as analgesic consumption can be used as a marker for patients’ 
experience of pain.  Pain scores themselves are difficult to interpret and while 
providing some interesting information, are highly subjective and subject to 
inter- and intra-individual variation.   
In this randomised, controlled, double blind, non-inferiority study the median 
value for 24 hour morphine consumption was 14mg (IQR 4.5 - 32.5mg) in the 
spinal morphine group and 39mg (IQR 18 – 49.5mg) in the ultrasound guided 
fascia iliaca block group (p<0.001). The difference between the two medians was 
calculated as described in chapter 11 (median with 95% confidence intervals - 
bias correcting bootstrapping technique with 10,000 replications). The 
difference between the medians for the ‘as treated’ group was 25mg (95% CI 9.0 
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- 30.5mg). The same analysis performed in the ITT analysis gave a difference 
between medians of 24mg (95% CI 14 – 29mg) which is greater than the pre-
specified non-inferiority margin (δ = 10mg).  
For the ITT analysis, it can be concluded that ultrasound guided fascia iliaca 
block is inferior to spinal morphine in providing analgesia after total hip 
arthroplasty. In the “as treated analysis”, the CI includes δ but is still to the 
right of zero.  Statistical advice from two separate experts in non-inferiority trial 
methodology was sought (see Chapter 12).  The conclusion of both authors was 
that ultrasound fascia iliaca block was not non-inferior to spinal morphine in the 
provision of analgesia after THA and could not be recommended as a 
replacement for spinal morphine. 
The values for morphine consumption seen in our study are within a similar 
range to the findings of an earlier study of 44 patients which compared a 
modified landmark-based fascia iliaca block with placebo block in patients 
receiving a spinal with fentanyl for total hip replacement (274).  In this study, 
patients who received the fascia iliaca block with local anaesthetic used a 
median of 23mg morphine in 24 hours, whereas the group receiving the placebo 
block (with 0.9% saline) received 37.5mg (p<0.001). This may indicate that the 
fascia iliaca blocks in our study were no better than placebo, though it should be 
noted that the patients in the study by Stevens et al also received fentanyl in 
their spinal injection which may have yielded some additional analgesic effects 
(274). In addition, patients in the intervention arm of this study received 150mcg 
of clonidine as part of the injectate used to perform the fascia iliaca block.  This 
may also have influenced analgesic requirements in this group as clonidine has 
analgesic as well as sedating effects (244;297). In a spinal morphine dose finding 
study by Rathmell et al, patients receiving lone spinal anaesthesia with no spinal 
opioid required around 75mg of intravenous morphine in the first 24 hours post-
operatively (226). This is significantly more than was required by patients 
receiving the ultrasound guided fascia iliaca block in this study and would 




In other studies examining femoral and “3 in 1” nerve blocks for THR (see Table 
9.4-1), 24 hour post-operative consumption of intravenous morphine (or its 
equivalent when other opioids were used) ranged from 7mg to 60mg.  However, 
these studies were very heterogeneous and mainly randomised patients to 
receive general anaesthesia in addition to nerve block or control intervention 
making direct comparison difficult (244;245;248;249;253).  When administering 
0.1mg of spinal morphine to patients undergoing THR, mean IV morphine 
consumption in 24 hours is reported to lie anywhere between 10 and 30mg 
(219;221).  Our median consumption of 14mg in the spinal morphine group would 
therefore be in keeping with this range. 
Unfortunately, not all patients received pre-operative paracetamol despite this 
being prescribed for all patients.  Reasons for this were due to availabaility of 
nursing staff to give the medication in a timely fashion.  The ward nurses who 
were responsible for administering the paracetamol had no knowledge of the 
treatment allocation and therefore any omissions were entirely random and 
should have affected each group equally. In the spinal morphine group, 64.7% of 
patients received pre-operative paracetamol while in the fascia ililaca group, 
this was slightly greater at 78.8% (p 0.17). All patients were prescribed regular 
paracetamol post-operatively.  While more patients in the fascia iliaca group 
received paracetamol pre-operatively, it seems unlikely that this one off dose of 
simple analgesia would have significantly altered the results of the study.  As 
patients in the fascia iliaca group had inferior analgesia despite the above 
theoretical advantage, this reinforces the result of the primary outcome further. 
One of the limitations of our study relates to the fact that the efficacy of the 
ultrasound guided fascia iliaca block was not confirmed prior to the 
administration of spinal anaesthesia.  This was omitted on a pragmatic level in 
view of the practicalities of undertaking this study within an NHS setting.  It 
would not have been possible to assess the efficacy of the block without 
significantly delaying the progress of the operating list due to lack of personnel 
and facilities. This would have made the continuation and completion of the 
study extremely difficult due to the significant pressures already on the 
orthopaedic service.  It would also not have been possible to assess block 
efficacy without unblinding the investigator.  As pre-operative assessment of the 
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effects of fascia iliaca block would not normally be performed prior to the 
induction of anaesthesia in patients undergoing elective THR, we considered that 
the omission of this assessment was more representative of “real life” practice. 
Our department is a tertiary referral centre for trauma and orthopaedic surgery 
and has significant expertise in the field of regional anaesthesia (10;224).  This 
includes a study comparing the efficacy of ultrasound guided versus the 
landmark technique for the performance of fascia iliaca blocks.  This study 
concluded that the ultrasound guided method was more effective in achieving 
sensory loss in the anterior, medial, and lateral aspects of the thigh from 47% to 
82% (p<0.001) as well as improving both femoral (p=0.006) and obturator motor 
block (p=0.033) (10).  Study investigators were trained by experts within the 
department in order to ensure that they were proficient in performing 
ultrasound guided fascia iliaca blocks.  The majority of the blocks were 
performed by RJK (75/108, 69.4%) with other investigators performing the 
remainder of the blocks (AG = 13/108, PH = 7/108, KP 7/108, AM = 6/108).   
Reasons for poorer analgesia in the ultrasound guided fascia iliaca block group 
can be explained by the innervation of the hip joint.  Even if a fascia iliaca block 
was entirely successful in anaesthetising the lateral cutaneous nerve of thigh, 
femoral and obturator nerves, it would still be unlikely to provide complete 
anaesthesia and hence analgesia, due to the variable innervation received from 
the sacral plexus as well as the ilioinguinal, iliohypogastric and genitofemoral 
nerves.  Sciatic nerve block is not routinely performed for total hip replacement 
due to concerns about poor post-operative mobility as well as a lack of published 
evidence.   
The paper by Stevens et al examining a landmark based fascia iliaca block 
postulated that the reason for the improved analgesia seen with their fascia 
iliaca block was due to the modified approach whereby the point of needle 
insertion was 1cm above the inguinal ligament (274).  It was hypothesised that 
this may have aided the spread of local anaesthetic towards the lumbar plexus 
hence improving the chance of anaesthetising the ilioinguinal, iliohypogastric 
and genitofemoral nerves in addition to the femoral, obturator and lateral 
cutaneous nerve of thigh. This method of block performance is unsuitable for 
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patients with previous mesh inguinal hernia repair and may carry an increased 
risk of bowel perforation or inferior gastric artery puncture.  This was a study of 
44 patients and there is no description within the paper of the methodology used 
to calculate sample size.  It is therefore unclear whether this study is adequately 
powered.  There have been no other trials to date which confirm the results of 
this study. 
12.1.2.1 A discussion of intention to treat and ‘as treated’ analyses in non-inferiority 
studies 
The use of an ITT analysis in a non-inferiority study would normally be expected 
to generate a greater risk of a type I error (declaring non-inferiority when this is 
not the case) than the “as treated” analysis.  This is why the “as treated” 
analysis has been traditionally preferred for this type of trial (279;291).  This is 
the opposite of what might be expected in a traditional superiority study where 
the ITT analysis penalises the poorly conducted trial and is considered to be at 
less risk of producing a type I error.  The erroneous rejection of the null 
hypothesis in a non-inferiority ITT analysis can thus be indicative of a poorly 
designed and / or run study and is an inherent problem with the non-inferiority 
design.  Despite these concerns, there is an argument that the ITT analysis is 
still the most valid to utilise, even in a non-inferiority study. This is on the basis 
that any trial should be conducted using rigorous methodology regardless of 
whether it is of superiority or non-inferiority design, as well as the fact that 
utilisation of ITT maintains the virtues of randomisation.  It is therefore 
considered important to apply both types of analyses to a non-inferiority study in 
order to prevent any “informative censoring” and in the recognition that both 
types of analyses have inherent strengths and weaknesses.   
There is a further argument that a third placebo arm should be utilised to ensure 
that any new treatment is in fact superior to placebo and that there is some 
within-trial validation of the value used for δ.  This is due to the phenomenon of 
“biocreep” whereby an inferior treatment, wrongly labelled as being non-
inferior in a poorly conducted non-inferiority study, erroneously becomes 
accepted as a control for other studies.  This can result in new treatments being 
compared to a treatment which may be no better than placebo (292). It was felt 
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inappropriate to include a placebo arm in this study as this would have resulted 
in patients having no analgesia in place for when the spinal anaesthetic wore off.  
This was felt to be unethical and unnecessary given the strength of evidence 
surrounding the established efficacy of spinal morphine (215;298).  
The value of δ clearly influences the results (as well as the sample size) in a non-
inferiority study.  The calculation of δ is difficult and there are a number of 
accepted methods for doing so. The value chosen for δ needs to justified by 
statistical and clinical reasoning as well as being tailored to the particular 
clinical context.  As such, it is extremely difficult to define a rule that 
adequately covers all clinical situations.  For this reason, it is vital that the 
nature of the study (be it non-inferiority or superiority) as well as the value 
chosen for δ is defined a priori.  Without this, a value for δ can easily be 
declared retrospectively in order to influence results in favour of non-inferiority. 
The protocol for this study, including a thorough description of trial methodology 
and statistical considerations including the calculation of δ, was published in a 
journal of trial methodology prior to embarking upon recruitment (11).  This 
journal is edited by the authors of the Consolidated Standards of Reporting Trials 
(CONSORT) statements (299).  The CONSORT statements are an evidence-based, 
minimum set of recommendations for reporting randomised studies. They offer a 
standardised way for authors to prepare reports of trial findings, facilitating 
their complete and transparent reporting and aiding critical appraisal and 
interpretation. The CONSORT statements are endorsed by prominent general 
medical journals, many specialty medical journals and leading editorial 
organisations. 
In this study, we have demonstrated a result which is in direct opposition to the 
methodological concerns highlighted above.  In the ITT analysis, non-inferiority 
has been rejected (i.e. the null hypothesis has been acccepted) and we can 
conclude that the ultrasound guided fascia iliaca block is in fact inferior to spinal 
morphine.  The “as treated” analysis result is technically inconclusive (and has 
fewer subjects and hence slightly less power) although again shows that the 
ultrasound guided fascia iliaca block is “significantly worse” than spinal 
morphine.  Neither type I error nor type II error (i.e. falsely rejecting a truly 
non-inferior treatment) seem likely in this situation. 
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12.1.2.2 Study withdrawals 
In reviewing the result of the primary outcome, it is of interest to consider why 
five patients (4.6%) were removed from the analysis. This non-completion rate is 
considered to be low when compared to other RCTs (300). Two patients were 
removed due to having surgery cancelled (one for cellulitis at the operative site 
and one due to lack of operating time).  Both of these patients were in the 
spinal morphine group. The reasons for cancellation and resultant withdrawal 
were entirely independent of study involvement and the surgeon making these 
decisions had no knowledge of study group allocation.  Neither patient received 
any intervention relating to the study other than randomisation.  No data other 
than demographics were available for these patients.  A further three patients 
(one from the spinal morphine group and two from the fascia iliaca group) were 
withdrawn from the analysis due to the fact they required a general anaesthetic 
(GA).  This was a pre-determined reason for withdrawal as published in the study 
protocol.  In all cases of general anaesthesia being administered, the patient had 
received the ultrasound guided fascia iliaca block (either with local anaesthetic 
or saline).  In one case, the spinal was not able to be administered by the 
anaesthetist and was therefore abandoned in favour of a GA.  In the other two 
cases, the spinal was administered, however one patient had no demonstrable 
motor block and the other developed myoclonic jerking during surgery (for which 
no sinister cause could be found) and both patients required a GA to facilitate 
surgery.  Therefore, in only one of the three cases, was there any certainty that 
the full spinal drug dose had been administered.  In addition, the drugs involved 
in the administration of a GA may have impacted upon the results and it was felt 
necessary to remove these patients from the “as treated” analysis.  As the study 
was double blind, neither patient nor investigator knew which treatment had 
been administered prior to the GA being administered.  In addition, the person 
making the decision to perform a GA was the usual anaesthetist for the theatre 
list who had no ongoing involvement with data collection and was not part of the 
study personnel.  These factors aimed to minimise bias as far as possible.  
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12.1.2.3 Linear regression modeling for the primary outcome 
The linear regression analysis found to result in the best model fit was a 
backward stepwise approach using co-variates which would be available to the 
clinician within the first 24 hours post-operatively.  This approach was 
investigated as a model using factors which were available to a clinician within 
the first 24 hours was considered more useful if a prediction tool was to be used 
in clinical practice. The co-variates found to create the best predictive model 
for 24 hour morphine consumption were: age, height, weight, sex, pre-operative 
SpO2, surgical time, surgical blood loss, time first morphine administered and 
morphine consumption at 12 hours.  The R2 for this model was 0.916 and the AIC 
was 642.   
Age is a well established predictor of analgesic requirements in the acute post-
operative setting and is negatively correlated with the dose of analgesia 
required (301;302). While weight and BMI are thought to have some influence on 
analgesic requirements, this is thought to be clinically insignificant compared 
with overall inter-individual variability (301;303).  In keeping with the findings of 
others, we found  surgical factors such as longer operating time may have an 
influence on post-operative analgesia (304;305). Prolonged surgery and/or 
greater levels of blood loss may be indicative of more difficult surgery requiring 
greater tissue manipulation and is plausible as an influencing factor on analgesia 
consumption post-operatively.  Early analgesia consumption has also been found 
to correlate with later analgesic requirements in adolescents undergoing 
scoliosis surgery (306).   An interesting systematic review of 48 studies examined 
predictors of post-operative pain and analgesic requirements after surgery.  
Factors found to be predictive of post-operative pain were: pre-existing pain, 
anxiety (or other psychological distress), age and type of surgery.  Factors 
predictive of post-operative analgesic consumption were: type of surgery, age 
and psychological distress (including anxiety).  Major orthopaedic surgery was 
found to be a risk factor for post-operative pain.  Many of the patients in our 
study would have had pre-existing pain which has precipitated the surgery and 
therefore have two inherent predictive factors for the development of pain and 
requirement for analgesia before any other considerations are made.  An 
assessment of pre-operative pain and psychological distress was not performed 
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as part of this study, though patients on strong opioid analgesia or with a 
diagnosis of chronic pain pre-operatively were excluded.  While potentially 
useful as a predictive tool, this model requires further validation before being 
employed in the clinical setting. 
 
12.1.3 Secondary outcomes 
We hypothesised that if an ultrasound guided fascia ilaca block was non-inferior 
compared with spinal morphine in the provision of analgesia after THA, that it 
may actually be advantageous if it reduced the incidence of side effects 
commonly associated with spinal morphine. These include: nausea and vomiting, 
pruritus, urinary retention, sedation and most seriously, respiratory depression. 
It should be noted that the study was not powered for all secondary outcomes. 
Secondary outcomes reaching statistical significance (p < 0.05) were: morphine 
consumption at all time points (3, 6, 12, 24, 36, and 48 hours), pain scores (VAS) 
at rest and movement at 6 and 12 hours and time to first mobilisation.  Pain 
scores at both rest and movement were not statistically significantly different at 
3 hours (when the effects of the spinal anaesthetic would be expected to be 
providing at least some analgesia) nor at 24 and 48 hours.  Morphine 
consumption has been discussed in detail under “Primary outcome”.  The other 
secondary outcomes reaching statistical significance will be discussed in turn.  
Further outcomes of interest will then be discussed (PONV, pruritus, and 
hypotension). 
12.1.3.1 VAS Pain scores  
The fact that pain scores were not significantly different after 12 hours could be 
attributable to the fact that the patients titrated their own analgesia to effect 
and is one of the reasons why pain scores can be difficult to interpret.  The fact 
that this took 12 - 24 hours to achieve may be explained by the fact that there is 
a learning curve in managing to use a patient controlled analgesia (PCA) device 
and that patients in the ultrasound guided fascia iliaca group may have had to 
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“catch up” with analgesia requirements if their pain relief was inadequate when 
the spinal anaesthetic wore off.  Whilst there was a statistically significant 
difference in VAS pain scores at 6 and 12 hours, the clinical significance of this is 
debatable.  The distinction between statistically significant and clinically 
significant differences in VAS pain scores has not been extensively studied in the 
post-operative population (307).  Pain scores were generally low (highest median 
score 3/10).  This makes differences in pain scores (when scores are generally 
within the “mild” category) difficult to quantify.  It may be that while 
differences reached statistical significance, that there was no clinically 
significant difference between groups.  On comparing patient satisfaction scores 
at 48 hours, it would seem that there was no difference between the groups and 
this may back up the assertion that there was no clinically significant difference 
in pain scores between the groups.  The subject of clinical significance between 
pain scores in the post-operative setting is one where further research is 
required.   
The first 24 hours after THR are considered to be the most painful with analgesic 
requirements reducing substantially from this point (222).  This was evident in 
our study where the majority of the morphine consumption (including oral 
morphine given once the PCA was removed) was consumed within the first 24 
hours.   
12.1.3.2 Mobilisation 
Mobilisation is a highly important aspect of the patient’s recovery and improved 
mobility is ultimately one of the main goals of THR surgery.  In this study, we 
looked at three different factors relating to post-operative mobilisation: time to 
first mobilisation, power grade of straight leg raise, and mobilisation at first 
attempt.  We defined mobilisation as the ability to mobilise from bed to chair as 
this is the initial assessment used by physiotherapy staff in our institution.  Time 
to first mobilsation in hours was statistically significantly shorter in the opioid 
group when compared to the fascia iliaca group: median 23 hours (IQR 19-25.5) 
vs 25 hours (20-42), p=0.04.  Mobility at the first attempt was slightly higher in 
the opioid group (44, 86.3%) compared with the USG fascia iliaca block group 
(38, 73%) though this was not statistically significant (p=0.16). Power grade for 
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knee extension was assessed using the MRC scale.  This was found to be the same 
between groups; median 4 (IQR 4 – 5).  This would go against the theory that any 
differences in the ability to mobilise could be attributed to the ongoing effects 
of the nerve block. 
 
0 No movement   
1  Flicker is perceptible in the muscle   
2  Movement only if gravity eliminated   
3  Can move limb against gravity   
4  Can move against gravity & some resistance exerted by examiner   
5  Normal power 
Table 12.1-1 - MRC power grade scale 
 
Comparison with other studies is difficult for this outcome due to the variety of 
ways in which mobility can be assessed.  For example, in a study of 45 patients 
undergoing THR and randomised to either PCA, CFNB or epidural, day of first 
ambulation with a walker was  (3.9 ± 1 vs 3.2 ± 0.7 vs 3.5 ± 0.7 days (p = 0.09), 
respectively (247).   In a study of 47 patients comparing CFNB and CLPB, 
distance of ambulation was assessed as a measure of mobility.  This was found to 
be significantly poorer in the CFNB group (266). In a larger study of 225 patients 
randomised to receive either PCA, CFNB or CLPB, all patients managed to 
ambulate on the first post-operative day.  However, the number of patients who 
were able to walk > 12 metres at forty-eight hours was significantly greater in 
the CLPB group compared with both the CFNB group and the PCA group (14.7%, 
1.3%, and 1.3%, respectively; p < 0.003) (248). 
On performing logistic regression analysis, mobilisation at first attempt was 
unaffected by: age (p=0.29), sex (p=0.21), BMI (p=0.43), weight (p=0.72), height 
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(p= 0.99), study group (p=0.1), pre-operative systolic blood pressure (p=0.2), 
PONV (p=0.62), urinary catheterisation (p=0.11), 24 hour morphine consumption 
(p=0.20), pain scores at rest at 12 hours (p=0.85), and surgical time (p=0.21). 
The odds of mobilising at the first attempt were affected by the amount of blood 
lost peri-operatively (p=0.02, OR 0.997 [95% CI 0.994 to 0.999]).  Therefore for 
every 1ml additional blood loss, there was a 0.3% decreased chance of the 
patient mobilising at the first attempt.  Similarly for post-operative hypotension 
as defined by SBP > 25% below baseline (p=0.05, OR 0.92, [95% CI 0.85 to 0.99].  
Having an episode of post-operative hypotension therefore reduced the odds of 
mobilising successfully on the first attempt by approximately 8%. 
12.1.3.3 Nausea and vomiting 
While not statistically significantly different between groups, the incidence of 
nausea requiring anti-emetics was relatively high in this study.  When examining 
these outcomes, it is worth noting exactly what definition of each outcome is 
being used.  For example, in this study post-operative nausea and vomiting 
PONV) as defined by a PONV score > 2 (moderate nausea) occurred in 7 patients 
(13.7%) in the spinal morphine group and 9 (17.3%) in the USG fascia iliaca 
group.  If defining nausea as the requirement for an anti-emetic to be 
administered, then the incidence of nausea was higher at 25 patients (49%) in 
the spinal morphine group, and 24 (46%) in the USG fascia iliaca group.   
0 None 
1 Mild nausea 
2 Moderate nausea 
3 Severe nausea 
4 Patient vomiting 




Many of the studies analysed in the systematic literature review in Chapter 9 
involved the patients being given nerve blocks in addition to general 
anaesthesia.  It is difficult to compare the outcome of nausea between patients 
receiving spinal and general anaesthesia as this would be a significant 
confounding factor.  
Two meta-analyses of intrathecal morphine can be used for comparison.  In a 
2009 meta-analysis of 28 RCTs (1314 patients) by Gehling et al, the incidence of 
nausea was 28% in the control group (no spinal morphine) with a relative risk 
(RR) of 1.3 in the spinal morphine group (214).  In a more recent meta-analysis 
of 65 RCTs (3338 patients) by Popping et al (215), the incidence of nausea was 
16.5% in the control group and 31.9% in the spinal morphine group.  While both 
studies included a high proportion of orthopaedic studies, it should be noted that 
they compared wide ranges of spinal morphine (25-2500mcg).  The incidence of 
PONV in our study therefore depends upon the definition used.  While examining 
reported PONV scores, the incidence appears to be within an acceptable and 
expected range.  However, the administration of anti-emetics is high indicating 
that PONV was either under-reported in terms of the performance of PONV 
scoring, or over-treated by staff eager to prevent nausea.  Rates may also be 
higher than expected due to the systemic morphine administered via PCA post-
operatively.   
We further compared our results to more specific studies involving spinal 
anaesthesia ± nerve block for THA. In a spinal morphine dose-finding study 
performed in 60 patients > 65 years of age, patients were randomised to receive, 
0, 50, 100 or 200 mcg of spinal morphine.  The incidence of nausea as defined by 
patient request for anti-emetic was 1/15 (6.7%), 5/15 (33.3%), 6/15 (40%) and 
6/15 (40%) respectively (218).  Another spinal morphine dose-finding study 
including 143 patients found the rate of PONV to be > 60% in all groups (spinal 
morphine dose 0.025mg, 0.05mg. 0.1mg, 0.2mg) (221).  In a comparison of 
landmark based modified fascia iliaca block with placebo in patients receiving 
spinal anaesthesia with local anaesthetic and fentanyl, Stevens et al recorded a 
nausea rate of 5/22 (22.7%) in each study group (274).  In a large study of 225 
patients by Marino et al (248), patients were randomised to receive either CLPB 
plus PCA, CFNB plus PCA or PCA alone.  The incidence of nausea (again definition 
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not specified) was reported as 9 (12%) in the CLPB group, 34 (45.9%) in the CFNB 
group, and 48 (64.9%) in the PCA group.  This was despite the administration of 
metoclopramide 10mg pre-operatively.  A study by Becchi et al reported an 
incidence of nausea (as defined by patient complaint) as 25/35 (71.4%) in the 
group receiving morphine and ketorolac infusion compared with 4/35 patients 
(11.4%) in the group who received CLPB (p<0.001) (268). Rates of PONV 
therefore vary significantly and are dependent upon the definition used. 
After performing logistic regression analysis on our data, the odds of developing 
post-operative nausea and vomiting as defined by nausea score > 2 were not 
affected by: age (p=0.15), gender (p=0.62) weight (p=0.29), height (p=0.41), 
pre-op systolic blood pressure (p=0.16), study group (p=0.62), 24 hour morphine 
consumption (p=0.84), hypotension (SBP > 25% under baseline, p=0.45), surgical 
time  (p= 0.52), or surgical blood loss (p=0.22). 
Increasing BMI increased the odds of experiencing PONV (p= 0.04, OR 1.13 [95% 
CI 1.01 to 1.28]).  Therefore for every 1 unit increase in BMI, the odds of a 
patient suffering PONV increase by 13%.  VAS pain score at rest at 12 hours also 
reached statistical significance (p=0.05, OR 1.25 [95% CI 0.99 to 1.58]).  
Therefore for every 1 unit increase in the VAS pain score at rest at 12 hours, the 
odds of experiencing an episode of PONV was increased by 25%. 
12.1.3.4 Pruritus 
Pruritus is considered to be major side effect of spinal opioids, can contribute to 
patient discomfort and can be difficult to treat.  Dose finding studies have 
reported a dose-related increase in pruritus with increasing doses of spinal 
morphine.  0.1mg is considered to be a dose which combines analgesic efficacy 
with an acceptable side-effect profile (218;221).   
The incidence of pruritus was not statistically significantly different between 
study groups.  The number of patients requiring treatment for itch was 2 (3.9%) 
in the opioid group and 1 (1.9%) is the USG fascia ililaca group.  This was lower 
than the number of patients who reported itch when they were asked about it 
directly by study personnel (6[11.8%] vs 3[5.8%]).  The incidence of pruritus is 
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lower than seen in other studies.  For example, Slappendel et al reported an 
incidence of around 38%, and Rathmell et al and Murphy et al reported a rate of 
40% in patients receiving 0.1mg of spinal morphine (218;219;221).  In a large 
meta-analysis examining the effects of a wide range of dose of spinal morphine, 
the incidence was reported as 12% in the control group and 37% in the spinal 
morphine group (214).  A further larger meta-analysis reported a rate of 4.4% in 
the control group and 29.2% in the spinal morphine group (215).   A dose-
response relationship was illicited in both meta-analyses.   
 
12.1.3.5 Hypotension 
The incidence of hypotension as defined by SBP < 80mmHg and SBP > 25% under 
baseline reading was not statistically significantly different between study 
groups.  Hypotension is a common side effect of spinal anaesthesia and results 
from pre-ganglionic sympathetic blockade.  Following surgery, hypotension can 
be due to a number of factors including: hypovolaemia, ongoing haemorrhage 
and sepsis and so any patient exhibiting hypotension requires medical review in 
order to make a proper assessment.  In our study, the incidence of severe 
hypotension (defined as SBP < 80mmHg) was low at 1 (1.9%) in the spinal opioid 
group and 6(1.5%) in the fascia iliaca block group.  Hypotension of SBP > 25% 
below baseline was common occurring in around half of all patients.  On 
examining the other studies in which patients received spinal anaesthesia ± 
nerve block for THR, the incidence of hypotension is not reported and therefore 
comparison is difficult.  Definitions of hypotension vary and again this makes any 
attempt at comparison difficult. Hypotension was not reported in either of the 
meta-analyses of spinal morphine (214;215).   Despite this, only one patient 
required any vasopressors and the majority of patients in our study were able to 
mobilise at the first attempt.  
From logistic regression analysis, both age and pre-operative SBP were found to 
be predictive of post-operative hypotension.  For every 1 year increase in age, 
the odds of having a hypotensive episode were increased by 5%, and for every 
1mmHg increase in pre-operative SBP, the odds of an episode of hypotension 
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increased by 6%.  Morphine consumption decreased the chances of developing 
post-operative hypotension.  This is difficult to explain as one would expect 
increasing opioid consumption to have had the opposite effect. 
12.1.3.6 Respiratory depression 
Thankfully there were no episodes of respiratory depression or sedation requiring 
treatment in this study.  This is reassuring as respiratory depression is one of the 
most feared complications of spinal opioids.  It should be noted that this study 
was not powered for this outcome (nor any of the other secondary outcomes) 
and that detecting any difference between study groups would have required a 
far higher number of patients. 
12.1.3.7 Urinary retention 
Rates of urinary retention requiring catheterisation were 20 (39.2%) in the spinal 
opioid group and 15 (28.9%) in the USG fascia iliaca block group.  Slappendel et 
al reported rates of around 70% in their spinal morphine dose finding study (221) 
while Murphy et al reported rates of 10-25% (218).  In a meta-analysis of 65 
RCTs, Popping et al found the risk of ureteric catheterisation to be 16.5% in the 
control group and 39.1% in the spinal morphine group (7 studies, wide range of 
spinal morphine doses) (215).  In the meta-analysis of 28 RCTs by Gehling et al, 
the incidence was found to be 17% in controls with no increased risk noted in the 
spinal morphine patients (214).  Only 8 studies could be included in this analysis 
however and the authors noted that a type II error could not be excluded. 
On logistic regression analysis, neither study group (p=0.27), age (p=0.14), 
gender (p=0.33), BMI (p=0.09), weight (p=0.18), surgical blood loss (p=0.94), 
post-operative hypotension (SBP >25% under baseline, p=0.23), nor pain score at 
rest at 12 hours (p=0.4334) increased the odds of requiring catheterisation.  24 
hour morphine consumption almost reached statistical significance with a p 
value of 0.052 (OR 0.98, [95% CI 0.96 to 0.99]). 
Ultrasound guided fascia iliaca block is not only inferior in the provision of 
analgesia after THA but confers no advantage in reducing the side-effect profile. 
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We do not recommend replacing spinal morphine with ultrasound guided fascia 
iliaca block for THA. 
 
12.1.4 Examination of Adverse Events and Serious Adverse 
Events  
After discussion with the operating surgeon in each case, none of the AEs or SAEs 
were felt to be directly related to the study intervention 
12.1.4.1 Femoral nerve palsy 
Symptoms and signs of femoral neuropathy vary depending on the severity and 
location of the injury.  Typical characteristics of a femoral nerve injury include 
groin or thigh pain, weakness of the iliopsoas, paralysis of the quadriceps 
femoris, loss of the knee jerk and sensory loss over the anteromedial aspect of 
the lower extremity.  There may also be swelling or haematoma noted in the 
wound or inguinal region.  Patients are usually able to walk on the flat using 
mobility assist devices, however climbing stairs is found difficult and may not be 
possible.   
 In the two instances of prolonged quadriceps motor weakness reported as an AE 
or SAE in this study, it was not possible to definitively state the nature of the 
injury as both surgery and fascia iliaca block are associated with a potential risk 
of nerve damage.   
While femoral nerve block is a theoretical complication of fascia iliaca block, 
the actual incidence is difficult to estimate as it is so uncommon.  The incidence 
of neuropathy following any peripheral nerve block was assessed in a large 
French study which found 4 cases of neurological injury and 4 cases of 
radiculopathy amongst 21,278 peripheral nerve block (0.04%) (308).  All cases of 
radiculopathy were associated either with paraesthesia during insertion or pain 
during injection, neither of which occurred in our patients.  There have been 
only two reported cases of neurological injury following fascia iliaca block.  The 
first was in a 78 year old female who had a hip replacement performed under 
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spinal anaesthesia.  The block was performed without the use of ultrasound 
guidance and at the end of the surgery (while the spinal block was still 
effective).  The patient suffered reduced sensation and weakness in the anterior 
thigh which had fully resolved by day 8 (309).  The second case occurred in a 15 
year old girl who received a fascia iliaca block without ultrasound guidance 
whilst under general anaesthesia for knee arthroscopy.  She had reduced 
sensation and mild weakness post-operatively and also complained of pain.  
These symptoms had resolved fully by 8 months (310).  
Neurological injury secondary to regional anaesthesia is thought to be related 
either to needle trauma, high pressure injection of fluid into the nerve, direct 
neurotoxicity of injected drugs or nerve ischaemia.  In the performance of the 
blocks in our patients we tried to minimise these risks as far as possible.  Firstly, 
we performed the block prior to spinal anaesthesia so that any discomfort 
experienced could be reported.  We also used ultrasound guidance to allow 
direct visualisation of the needle and to ensure that the injectate was deposited 
at a point distant to the nerve.  The injectate contained only local anaesthetic 
or normal saline and contained no potentially neurotoxic additives. 
Femoral nerve palsy is also a recognised concentration of hip arthroplasty.  A 
systematic review published in 2012 reported an incidence of femoral nerve 
palsy of 0.1-2.4% with a mean of 0.8%.  Treatment is mainly conservative and 
recovery can continue up to one year after the injury (311).  In our study, one 
patient’s neurological function had returned to normal within one week, with 
the other recovering after three months. 
12.1.4.2   Pulmonary embolism 
Three patients in this study developed pulmonary embolism post-operatively. 
Whilst this was unexpected, both deep venous thrombosis (DVT) and pulmonary 
embolism (PE) are well recognised complications of lower limb orthopaedic 
surgery.  Prior to the routine prescription of post-operative thromboprophylaxis, 
up to 60% of patients undergoing major orthopaedic surgery developed a DVT. 
Following the advent of routine thromboprophylaxis, the incidence of venous 
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thromboembolism has decreased. However, it is still considered a risk of surgery 
and as such, is included in surgical consent discussions (312). 
 
In reporting these SAEs in our study, we did not feel that the occurrence of PE 
was related to the anaesthetic technique used (i.e. the study intervention).  
Both groups in our study receive spinal anaesthesia which is known to decrease 
the incidence of DVT (and which is routinely performed in patients undergoing 
hip replacement).  From reviewing the notes and the case report file, the 
patients mobilised within an acceptable timeframe for this type of operation and 
received standard DVT prophylaxis according to hospital guidelines.  There were 
no other complications. 
 
12.1.4.3 Wound infection 
The incidence of wound infection after total hip replacement is around 1% (313).  
The operating surgeon therefore discusses this potential complication with 
patients prior to consent being obtained. The potential for post-operative 
infection, along with other post-operative complications, is also highlighted on 
patient centred websites such as “NHS choices” (314).   The incidence of 
infection has decreased over the last few decades with the routine use of 
chlorhexidine skin disinfectant, laminar flow theatres, prophylactic antibiotics, 
occlusive drapes, occlusive surgical gowns and cuffed theatre attire.  All of these 
measures were employed by the surgical team involved with this study. 
The SAEs reported in this study were discussed in detail with the operating 
surgeon. The patients’ involvement with the study was not thought to be 
causative of the infection nor have any bearing on their post-operative course.  
These incidents were felt to be due to complications of the surgical procedure, 




12.1.5 Study strengths and limitations  
 The strengths of this study lie in its a priori publication in a journal of trial 
methodology and the excellent peer review from renowned world experts in trial 
design that this entailed (11).  Peer review was also received from experts in 
regional anaesthesia representing the European Society of Regional Anaesthesia 
and Pain Medicine (ESRA) in the review and awarding of our grant funding.  The 
study methodology was judged to have scored highly on their scoring system and 
was unanimously voted as being successful (see Appendix 4).   
The calculation of the powering required for this study has been described in 
detail and we are confident that this study included sufficient patients to allow 
meaningful conclusions to be reached. 
This study was randomised using a computer generated allocation system (in 
permuted blocks).  Demographics for both groups were similar indicating 
successful randomisation.  Allocation concealment was ensured by using system 
of sealed envelopes.  The study was double blind as all patients received both a 
spinal anaesthetic and ultrasound guided fascia iliaca block injection.  The 
anaesthetist who was a trial investigator was unaware of the contents of the 
injectates and so was also blinded to the study allocation.  The only person 
aware of the treatment allocation was the anaesthetist who routinely 
anaesthetised for the operating list.  This anaesthetist was tasked with making 
up the fascia iliaca and spinal injectates, inserting the spinal anaesthetic and 
looking after the patient in theatre.  This anaesthetist had no involvement with 
study data collection or reporting.  
Any withdrawals or dropouts from the study were noted and any reasons for 
withdrawal described in detail.   
Both ITT and “as treated” analyses were performed and the pros and cons of 
each approach examined.  We received validation of our interpretation of the 
primary outcome result from two separate leading experts in the field of non-
inferiority methodology.   
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Limitations of the study mainly relate to the fact that it was performed in a non-
research setting within the NHS system.  This made it extremely difficult to 
ensure that collect all intended data were collected.  For example, data 
collected for 36 hour pain scores was limited (68 not recorded) as it was usually 
late at night and patients were generally asleep.  Nursing staff on the ward were 
informed of the study and given relevant information. However, the large 
number of nurses on the ward and frequent changes of shift meant that some 
nurses may have been more vigilant in recording data than others.  We made 
every effort to ensure that nursing and physiotherapy staff were not asked to 
perform any additional duties as a result of the study, as the majority of the 
outcomes assessed are routinely monitored after THA in our hospital.  The study 
was powered for the primary outcome but not the secondary outcomes. 
A further limitation of the study relates to the fact that ultrasound guided fascia 
iliaca block efficacy was not assessed prior to administering the spinal 
anaesthetic.  This could result in the argument that the fascia iliaca block group 
had higher analgesic requirements due to the fact that the blocks did not work.  
This is clearly a possibility though is made less likely by the fact that all study 
investigators were trained in the technique and have a high level of experience 
in performing the block within their own clinical practice. This notwithstanding, 
it is possible that some of the blocks did not work and this may clearly have 
affected the results.   
The reasons for not checking block efficacy were mainly pragmatic. We did not 
have available facilities to allow the safe insertion of a nerve block outwith the 
operating theatre and in advance of the patient going to theatre.  If we had 
done this, it would have necessitated the presence of an additional anaesthetic 
nurse and this was not possible due to staffing levels.  If we had simply 
performed the block and then waited to assess the effects before proceeding to 
administer the spinal anaesthetic, this would have resulted in a significant delay 
between patients.  This was again not possible due to pressures on theatre time.  
In addition, any assessment of the efficacy of the block would have unblinded 
the study anaesthetist and would have required an independent anaesthetist to 
perform if this was to be avoided.  Any demonstrable leg weakness would also 
have alerted the patient to their study allocation and hence the study would not 
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have been double blind.  Finally, we aimed to perform a study which would be 
representative to and relevant to usual clinical practice.  It is not our usual 
practice to check the effects of a nerve block prior to administering spinal or 
general anaesthesia and as such, it was felt appropriate that the study be 
performed in this way.   
 
12.1.6 A discussion of the use of a placebo block 
The use of placebos in RCTs is controversial and is an issue which was discussed 
at length with the West of Scotland Research and Ethics Committee prior to the 
finalisation of the study protocol and commencement of recruitment.  The 
committee concluded that the advantages of using a placebo ultrasound guided 
fascia iliaca block to ensure the internal validity of the study outweighed the 
potential risks of harm.  Placebo can be defined as: 
“an inert or innocuous substance used especially in controlled 
experiments testing the efficacy of another substance (315).” 
An alternative definition is: 
“A substance or procedure that has no inherent power to produce an 
effect that is sought or expected (316).” 
Disadvantages of using a placebo block in this study can be thought of as 
following: 
Any neuropraxia occurring post-operatively may have been caused by a 
procedure which was of no benefit to the patient.  In this study, this eventuality 
did not occur as both episodes of neuropraxia occurred in patients allocated to 
receive the fascia iliaca block with local anaesthetic.  Neuropraxia may also 
have been caused by the surgery. The exact aetiology of femoral neuropraxia 




Any adverse effects noted in the groups may have been related to either the 
spinal anaesthetic or the USG fascia iliaca block. While the injectates for each 
were different between groups, the fact that both interventions were performed 
in all patients makes assessment of adverse effects less clear.   
It is possible that the injection of saline in the fascia iliaca space may have 
exerted an effect upon the nerves via the application of pressure or the 
disruption of tissues (318).   
Use of a placebo is considered to be acceptable in certain circumstances under 
Provision 33 of the Declaration of Helsinki.  This states that: 
“The benefits, risks, burdens and effectiveness of a new intervention 
must be tested against those of the best proven intervention(s), 
except in the following circumstances:  Where no proven intervention 
exists, the use of placebo, or no intervention, is acceptable; or Where 
for compelling and scientifically sound methodological reasons the 
use of any intervention less effective than the best proven one, the 
use of placebo, or no intervention is necessary to determine the 
efficacy or safety of an intervention and the patients who receive any 
intervention less effective than the best proven one, placebo, or no 
intervention will not be subject to additional risks of serious or 
irreversible harm as a result of not receiving the best proven 
intervention.  Extreme care must be taken to avoid abuse of this 
option (319)”. 
We considered the use of placebo in this study to have scientific merit as there 
was no other way of ensuring that the study was truly double blind.  The option 
of simply performing a sonographic examination of the femoral area with the 
ultrasound probe was proposed as an option but it was felt that the patient was 
likely to realise that a block had not been performed. The performance of a 
subcutaneous injection was also considered, but this (as with the previous 
suggestion) would also have unblinded the operator who was involved in data 
analysis. The risk to the patient from an ultrasound guided fascia iliaca block 
with normal saline was felt to be low.  As fascia iliaca block is a field block and 
does not direct the injectate directly towards the nerve, this was felt to present 
a low risk for neuropraxia.  Blocks were performed using a sterile technique to 
minimise any infective risk.  Patients were fully informed of the possibility that 
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they may receive a placebo nerve block and were given the opportunity to ask 
questions regarding this.  Consent was obtained and it was emphasised to 
patients that they were entirely free to refuse study involvement in the 
knowledge that this would not impact on their care in any way.  Patients were 
also aware that they could drop out of the study at any time without having to 
give a reason.  
It has been suggested that the use of a placebo block be evaluated using the 
“SHAM tool” which aims to establish the risk of harm to the patient.  This tool 
was first published in 2011, and was therefore not available at the time of our 
study being designed and undergoing ethical review (October 2010) (320).  The 
SHAM scale suggests that the use of placebo injection for femoral nerve block is 
considered to be of moderate risk and should prompt an alternative approach by 
study designers.  We consider that fascia iliaca block is of lower risk than a 
femoral nerve block as the needle and injectate are not directed towards the 
nerve.  We were reassured that our trial design was acceptable in view of the 
advice received from the West of Scotland Research Ethics Committee and by 
the favourable peer review and feedback received from the European Society of 
Regional Anaesthesia and Pain Medicine and by the editors of the Trials journal.  
 
12.2 Conclusion 
This is an adequately powered and methodologically robust study which has 
shown that ultrasound guided fascia iliaca block is not non-inferior to spinal 
morphine in the provision of analgesia after total hip replacement.  Ultrasound 
guided fascia iliaca block is not only inferior in the provision of analgesia after 
THA but may confer no advantage in reducing the side-effect profile (although 
the study was not powered for the secondary outcomes). The incidence of 
adverse effects often attributed to spinal morphine was not different between 
groups and reassuringly, there were no incidences of respiratory depression.  
This has clear implications for practice and would suggest that spinal morphine 
remains an effective analgesic agent in this patient group.  The effect of an 
ultrasound guided fascia iliaca block administered in addition to spinal morphine 
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was not investigated in this study but would be of interest as this may result in 
morphine sparing in the post-operative period.   
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12.3 Chapter 12 Summary 
 This study has clear implications for practice. Ultrasound guided fascia 
iliaca block is not recommended as a replacement for spinal morphine 
inpatient undergoing primary total hip arthroplasty. 
 Strengths of this study include: its a priori publication and validation of 
trial methodology, strength of peer review, expert statistical advice and 
representation of real life practice.  Limitations relate to the use of 
placebo block, the lack of checking blocks for efficacy and the restrictions 
of doing research within an NHS setting. 
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13.1 Summary and future directions 
In this work, I have examined the epidemiology and pathophysiology of ageing 
recognising the challenges that this may bring to the future of healthcare 
provision.  In particular, the increasing prevalence of morbidity relating to 
musculoskeletal disease and the corresponding burden on health and social 
resources is a burgeoning problem and an area where research must be targeted 
if improvements are to be made.   
Patients admitted with fractured hip account for a large proportion of patients 
requiring emergency surgery in hospital.  This patient group is particularly frail 
with high levels of morbidity, mortality and ongoing dependence.  I have 
examined the reasons why this patient cohort represents a management 
challenge to the healthcare team, exploring the concept of frailty and the 
scoring systems that can be used to help stratify peri-operative risk.  I have 
analysed guidelines relating to the management of these patients and compared 
them for different common clinical scenarios such as the presence of anaemia or 
a heart murmur.  This work provides a useful guide to clinicians who can often 
be overwhelmed by the large volume of information available. The use of 
clinical guidelines in general has been examined and their benefits and potential 
disadvantages discussed.   
The role of large volume data collection in the form of national hip fracture 
audits has been reviewed.  These data have allowed a comparison between our 
own practice and national standards. A detailed audit of all patients admitted 
with fractured hip over a one year period in Glasgow Royal Infirmary was 
performed and data compared with that obtained from national databases.  This 
allowed us to benchmark our data against accepted standards of care and to 
identify areas for potential improvement.  The results of this audit showed our 
outcomes to compare favourably against those seen nationally. We then 
examined sub-populations identified by staff members as representing specific 
management challenges.  These were patients admitted to ICU and patients 
taking warfarin.  The results of these sub-group analyses indicate that although 
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only a small proportion of patients suffering hip fracture are admitted to critical 
care, that this number is rising.  One could make an argument that a far larger 
proportion of this frail patient group could benefit from an enhanced level of 
post-operative care, though this has clear implications for resources and is 
beyond the scope of this thesis.  The results of this work were communicated to 
anaesthetic, critical care and orthopaedic departments for further consultation.   
Patients taking warfarin and admitted with hip fracture were found to be a 
group where management was variable and inconsistent and where guidance was 
lacking.  This prompted a quality improvement initiative in the form of a 
protocol to guide management.  This was formulated in a multi-disciplinary 
setting and approved by the local Thrombosis Committee and is under ongoing 
review.  This work encouraged me to found the Glasgow Royal Infirmary Theatre 
Improvement Group.  This group includes interested staff members who are 
encouraged to propose areas where they feel care may be improved.  Using a 
collaborative approach, we aim to tackle these issues and improve patient care 
and ultimately, outcomes.  So far, projects undertaken by the group have 
included a surgical sign-out for patients undergoing emergency laparotomy and 
an intervention to prevent undetected post-operative anaemia in patients having 
surgery for hip fracture.  Feedback from other disciplines has been positive and 
some of our interventions have been translated into other areas of care by 
surgical staff.  This theatre improvement group has prompted the institution of 
similar groups both in the obstetric service and in critical care.  I hope that this 
culture of quality improvement will continue to prosper and result in meaningful 
improvements in care. 
The performance of elective orthopaedic surgery also accounts for a large 
proportion of surgical workload with total hip replacements being one of the 
most commonly performed and generally successful surgical procedures.  
Methods of anaesthesia for total hip replacement have been examined and a 
systematic review of the different types of peripheral nerve blocks performed.  
This detailed literature review allows a comprehensive comparison of the 
available techniques and highlights the lack of research performed on ultrasound 
guided fascia iliaca blocks.   I hypothesised that an ultrasound guided fascia 
iliaca block may provide analgesia which was non-inferior to that provided by 
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spinal morphine (a popular and commonly performed technique in this patient 
population).  If this was the case, the removal of spinal morphine from the 
injectate could potentially result in a reduction in unpleasant side-effects such 
as nausea, itch and potentially dangerous respiratory depression as well as 
having implications for nursing workload.  We performed a randomised, 
controlled, double blind trial of 108 patients to examine this hypothesis.  The 
trial was adequately powered and the study protocol was published a priori in a 
journal of trial methodology.  The results showed that ultrasound guided fascia 
iliaca block was not non-inferior to spinal morphine and supports the use of 
0.1mg spinal morphine as providing adequate analgesia after total hip 
replacement. 
Following on from this work, I was interested to explore the role of regional 
anaesthesia in another surgical setting.  The use of regional anaesthetic 
techniques to improve flow and potentially patency and lifespan of 
arteriovenous fistulae is an area I find interesting and I have therefore embarked 
upon a collaborative project with the Department of Vascular Surgery at the 
Western infirmary, Glasgow.  This is a further randomised controlled trial for 
which I designed the protocol with input from the vascular team.  The protocol 
has been published in a journal of trial methodology and recruitment is now 
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West of Scotland Research Ethics Service 
 West of Scotland REC 4 
 Ground floor, Tennent Institute 
 Western Infirmary 
 38 Church Street 
 Glasgow 
 G11 6NT 
 e-mail: evelyn.jackson@ggc.scot.nhs.uk 
 Telephone: 0141-211-1722  
 Facsimile: 0141-211-1847 
21 October 2010 
 
Professor John Kinsella 
Head of Section of Anaesthesia, Pain and Critical Care 
University Section of Anaesthetics 
Glasgow Royal Infirmary 





Dear Professor Kinsella 
 
REC reference number: 10/S0704/43 
Protocol number: 1 
Study Title: Intrathecal opiate versus ultrasound guided fascia iliaca 
block for analgesia after primary hip arthroplasty  
 
Thank you for your letter of 30 September 2010, responding to the Committee’s request for 
further information on the above research and submitting revised documentation. 
 
The further information was considered in correspondence by a sub-committee of the REC. 
A list of the sub-committee members is attached.   
 
Confirmation of Ethical Opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting 
documentation, as revised, subject to the conditions specified below. 
 
Ethical Review of Research Sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start of 
the study (see “Conditions of the favourable opinion” below). 
 
Conditions of the Favourable Opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start of 
the study. 
 
Management permission or approval must be obtained from each host organisation prior to 
the start of the study at the site concerned. 
 
For NHS research sites only, management permission for research (“R&D approval”) should 
be obtained from the relevant care organisation(s) in accordance with NHS research 
governance arrangements.  Guidance on applying for NHS permission for research is 
available in the Integrated Research Application System or at http://www.rdforum.nhs.uk. 
 
Where the only involvement of the NHS organisation is as a Participant Identification Centre 
(PIC), management permission for research is not required but the R&D office should be 
notified of the study and agree to the organisation’s involvement. Guidance on procedures 
for PICs is available in IRAS. Further advice should be sought from the R&D office where 
necessary. 
 
Sponsors are not required to notify the Committee of approvals from host organisations. 
 
It is the responsibility of the sponsor to ensure that all the conditions are complied 
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Statement of Compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK. 
 
After Ethical Review 
 
Now that you have completed the application process please visit the National Research 
Ethics Service website > After Review 
 
You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure.  If you wish to make your views 
known please use the feedback form available on the website. 
 
The attached document “After ethical review – guidance for researchers” gives detailed 




• Notifying substantial amendments 
• Adding new sites and investigators 
• Progress and safety reports 
• Notifying the end of the study 
 
The NRES website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures. 
 
We would also like to inform you that we consult regularly with stakeholders to improve our 
service. If you would like to join our Reference Group please email 
referencegroup@nres.npsa.nhs.uk.  
 




for Dr Brian Neilly 
Chair 
 
Enclosures: List of names and professions of members who were present at the meeting 
 “After ethical review – guidance for researchers”  
 
Copy to: Dr Steven Burke, R&D Office, Tennent Institute, Western Infirmary 
  
West of Scotland REC 4 
 
Attendance at Sub-Committee of the REC meeting on 21 October 2010 
 
  
Committee Members:  
 
Name   Profession   Present    Notes    
Dr Kenneth James (Chair) Consultant Anaesthetist  Yes  In correspondence 










Title:  Study protocol:  Intrathecal opioid versus ultrasound guided fascia iliaca 





Response to reviewer’s report 
 
 
Dear Dr Moher, 
 
 
Thank you for giving us the opportunity to revise and resubmit our manuscript entitled; 
“Intrathecal opioid versus ultrasound guided fascia iliaca plane block for analgesia 
after primary hip arthroplasty – a randomised controlled trial”. 
 
We have revised our manuscript in response to your helpful suggestions and comments. 




This is a protocol of a randomized trial comparing ultrasound block to no ultrasound 
block in 96 people receiving primary hip arthroplasty. The primary outcome is 24-hour 
post operative morphine consumption. 
Page numbering, and better still line numbering would greatly facilitate my peer review 
of the protocol 
This has now been addressed. Please see the revised manuscript.   
 
 
The protocol is registered and the investigators are seeking funds. On this latter point, can 
the investigators provide a little more detail for readers about the funding request? For 
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example, are the investigators applying for peer review funding, funding from industry, 
or a combination? 
This aspect has been expanded from line 393.  A grant application has been 
submitted to the Chief Scientist’s Office (CSO).  The CSO is part of the Scottish 
Government Health Directorate.  Its role is to support research initiated by the 
research community in Scotland and to advise the Scottish Government on how 
research contributes to improvements in health and healthcare. Grant 
applications to the CSO undergo a stringent peer review process prior to any 
award being made.  
A grant application has also been made to the European Society for Regional 
Anaesthesia and Pain Medicine.  Once again, all applications are peer reviewed 
by experts in the field of regional anaesthesia prior to funds being awarded. 
These funders have no role in study design, data collection and analysis, decision 
to publish, or preparation of the manuscript.  The decision regarding any funding 
awards remains outstanding. 
 
 
In the covering letter submitted along with the protocol the investigators consider this to 
be a pragmatic trial. I’m more used to thinking about pragmatic trials as ones involving 
several hundred participants across many different centres recruiting participants. 
The word “pragmatic” has been removed.   
 
 
In the body of the protocol (hypothesis section) the investigators state their interest in 
seeing whether ultrasound guided versus non-ultrasound block is “comparable”. When I 
read comparable in the context of a randomised trial I interpret this to mean interest in 
detecting equivalence or non-inferiority. The investigators need to clarify this point as it 
impinges upon several other aspects of the proposed trial, particularly the sample size 
section. Is the trial designed as a superiority trial or an equivalence or non-inferiority 
trial? 
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We thank the reviewer for these helpful comments.  We have altered the 
manuscript to clarify that this is a noninferiority trial. As we had not originally 
categorised the trial in this manner, the statistical calculation to obtain the 
sample size has been revised (line 259). The number of patients now required has 
altered very slightly and the statistical derivation of this number is described in 
the revised manuscript.  
 
 
First line of the “overview” section: the investigators should delete “prospective” 
and elsewhere in the text of the protocol. 
The word “prospective” has been deleted as advised. 
 
 
The consent section is rather long at about half a page. Is there something 
unusual about this trial, in terms of the intervention, safety profile that warrants 
this amount of space? 
The consent process for this trial has been reviewed and approved by the West of 
Scotland Research Ethics Committee 4.  The Research Ethics Committee did not 
feel that there was anything unusual or concerning about our trial.  This section 
of the article has therefore been shortened accordingly. Please see the revised 
manuscript (line 166). 
 
 
The randomisation section needs more clarification for readers. The investigators 
tell readers about how the generation of their sequence will be generated – 
computer generated. What’s less well described is how allocation concealment is 
be achieved and how the randomization will be implemented (e.g., Moher et al. 
CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting 
parallel group randomized trials. BMJ. 2010 Mar 23;340:c869)? 
This section has now been extended to take into account the reviewers comments, 
many of which were addressed in our protocol but unfortunately omitted from the 




Would readers find it more helpful if group 1 and group 2 were relabelled 
‘experimental’ and ‘control’? 
Group 1 has been renamed Fascia Iliaca Group and Group 2, Spinal Morphine 
Group.  See line 189. 
 
 
In the sample size and statistical considerations section the reader is not provided with 
information about the anticipated length of time the investigators will take to recruit and 
enrol the participants – how long will the trial take? Similarly, in this section, there are no 
details as to whether the investigators plan on establishing a data safety and monitoring 
committee as part of the trial conduct? 
It is anticipated that recruitment for this study will take between one and two 
years to complete if 1 to 2 patients are enrolled each week.  We wish to work only 
with one surgeon to reduce inter-operator variability.  At present he undertakes at 
least 4 total hip replacements every week.  Data collection for each patient will 
occur during the first 48 hours post-operatively and at a routine 6 week follow up 
appointment.  No further follow up will be routinely arranged.  Any patients 
requiring specific follow up will have this arranged on an individual basis. (Line 
306) 
 
We value and respect the reviewer’s question on the need for a Data Monitoring 
Committee. However, we have not proposed to have an independent data 
monitoring committee.  It is our understanding that the need for such committees 
in certain trials remains under debate.  Our understanding is that Data 
Monitoring Committees are required where the trial meets the definition of 
‘Randomised trial with mortality or major morbidity endpoints’.  Respiratory 
depression or death are the only serious adverse events we would think worthy of 
the attention of the suggested additional data monitoring committee.  These events 
are extremely rare and have not occurred in the context of intrathecal opioid use 
in our hospital in the last 5 years.  Death would be picked up routinely by the 
Scottish Audit of Surgical Mortality.  Both would be picked up at follow up in the 
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first 48 hours by investigators. In addition all serious morbidity or mortality 
would be independently audited by our institution’s cardiac arrest audit, and / or 
the anaesthetic department’s well developed morbidity and mortality review 
process.  In the event of either of these serious events, we would invite the 
Anaesthetic Clinical Governance Committee to review the results of the study up 
until that point.   
Consistent with good clinical practice, we also intend to conduct monthly safety 
meetings in order to highlight and discuss any safety concerns. Whilst we 
appreciate that these will not be independent, all adverse events will be reviewed 
at these meetings and any serious adverse events (and suspected unexpected 
serious adverse reactions) communicated to the appropriate authority as detailed 
in the protocol, namely the Pharmacovigilance Office in the Robertson Centre for 






Dr Rachel Kearns 
Dr Alan Macfarlane 
Dr Keith Anderson 
Professor John Kinsella 
 
 
Academic Unit of Anaesthesia Pain and Critical Care Medicine, 4th Floor, 
Walton Building, Glasgow Royal Infirmary, 84 Castle Street, Glasgow, G40SF  
Tel:  +44 (0)141 2114625 
Email:  rkearns@doctors.org.uk 
Appendix 5 
From: David Moher <editorial@trialsjournal.com> 
To: Dr Rachel Kearns <rkearns@doctors.org.uk> 
Date: 15 Feb 2011 09:58:47 +0000 
Subject: Your manuscript is acceptable for publication in principle. 
Authors: Rachel J Kearns Dr, Alan JR Macfarlane Dr, Keith J Anderson Dr and 
John Kinsella Professor 
Title  : Study Protocol: Intrathecal opioid versus ultrasound guided fascia iliaca 
plane block for analgesia after primary hip arthroplasty - a randomised, blinded 
noninferiority trial. 
Journal: Trials 
MS     : 1483554814464143 
 
Dear Dr Kearns, 
 
Peer review of your manuscript (above) is now complete, and we are delighted, 
in principle, to accept the manuscript for publication in Trials. 
 
However before acceptance, our editorial production team needs to check the 
format of your manuscript, to ensure that it conforms to the standards of the 
journal. They will get in touch with you shortly to request any necessary changes 
or to confirm that none are needed. 
 
Authors of study protocols published in a BMC Series medical journal or Trials 
are entitled to a 20% discount 
(http://www.biomedcentral.com/info/about/apcfaq#discount) on the article 
processing charge if the results of the trial are submitted and accepted for 
publication in one of these journals. For more information on this scheme, and to 
find out whether your protocol can be published with a discount, view the publish 
your study protocol page at BioMed Central 
(http://www.biomedcentral.com/info/authors/protocols). 
 





Editors-in-Chief: Doug Altman, Curt Furberg, Jeremy Grimshaw and Peter 
Rothwell 
 







ESRA Research Grant 2011 
      March 2011 
Dear Dr. Kearns, 
It is a pleasure to inform you that your application for the ESRA Research Grant has been 
successful.  Your submission followed the ESRA guidelines and conformed in almost all points to 
the published ESRA Grant requirements/preferences. The fact that you have not published any 
original studies on regional anaesthesia in peer-reviewed journals was the only one drawback. The 
Grant Subcommittee consisting of 3 Board Members with extensive scientific background, scored 
independently your protocol titled “Intrathecal opioid versus ultrasound-guided fascia iliaca plane 
block for analgesia after primary THA” giving it 48 out of 60 possible points. During the midterm 
ESRA Board meeting in Brussels on March 11th, 2011 the Officers of the Board unanimously voted 
to give your project one of the ESRA Research Grants.  
 
I personally congratulate you and you co-workers on your successful application. ESRA wishes your 
project all the best and hopes for its timely and effective conduct. As a Chairman of the Research 
Grant Subcommittee I would like to be informed by e-mail about the progress of your study: the 
dates of inclusion of the first and the last patient, submission of the manuscript to a peer-
reviewed journal and acceptance of the manuscript for publication. The manuscript you submit for 
publication should state that the study was sponsored by the ESRA Research Grant. Also, please do 
not forget to mention the support of the ESRA Research Grant, whenever you publicly present the 
data from your study, either partial or complete.   
Concerning the terms and conditions of transfer of Grant’s money, please contact via e-mail ESRA 
Treasurer, Dr. Harald  Rettig (hcrettig@hotmail.com).  
 
Kind regards, 
Zbigniew J. Koscielniak-Nielsen, MD, PhD, FRCA 




Version 1.4 260511 
University Department of Anaesthesia,  
Pain & Critical Care Medicine 4th Floor,  
Walton Building, Glasgow Royal Infirmary,  




Intrathecal opioid versus ultrasound guided fascia iliaca 




We would like to invite you to take part in a research study. Before you decide you need to 
understand why the research is being done and what it will involve for you. Please take time to 
read the following information carefully. Talk to others about the study if you wish. Ask us if 
there is anything that is not clear or if you would like more information.  
 
Who is conducting the research? 
The research is being carried out by Dr Rachel Kearns, Dr Alan Macfarlane, Dr Keith Anderson 
and Professor John Kinsella from the Department of Anaesthesia, Pain and Critical Care 
Medicine in Glasgow Royal Infirmary.  
 
What is the purpose of the study? 
This study is being performed in order to investigate the optimal way to provide anaesthesia and 
pain relief for patients undergoing hip surgery.  At present, there are a wide range of acceptable 
techniques each with their own advantages and disadvantages.  We wish to compare two different 
methods of providing anaesthesia and pain control after the operation to see which provides the 
best results in terms of pain control with the least side effects.   
 
Why have I been invited? 
You have been invited to take part in this study as you have been scheduled to undergo a total hip 
replacement by your surgeon.  This operation is performed commonly in our hospital and requires 
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an anaesthetic given by an anaesthetic doctor.  We propose to use two different anaesthetic 
techniques to provide anaesthesia and pain control for this operation.  Both of these techniques 
are currently being used by anaesthetic doctors for this type of operation and are known to be 
safe.  However, the two techniques have not been compared before.  We hope that by comparing 
these two techniques directly, we will be able to establish whether one is better than the other for 
patients undergoing hip surgery.   
 
Do I have to take part? 
It is up to you to decide. We will describe the study and go through this information sheet, which 
we will then be given to you. You will be asked to sign a consent form to show you have agreed 
to take part. You are free to withdraw at any time, without giving a reason. This would not affect 
the standard of care you receive or your future treatment.   If you do decide to take part, your 
General Practitioner (GP) will be informed of your involvement. 
 
What does taking part involve? 
You will be seen by your surgeon and anaesthetic doctor at the pre-operative assessment clinic as 
normal.  At this visit, a member of staff involved in the performance of this study will give you 
some information about what participation in the study involves.  Any risks and benefits will be 
discussed with you at this visit.  You will be seen again before your operation at which point any 
further questions you have will be answered.  If you decide that you would like to take part in the 
study, you will be asked to sign a consent form and will be allocated at random into one of two 
groups (this is like a coin toss).  
   
Patients in both groups will receive two injections; a nerve block (which is an injection in the 
groin), and a spinal injection (which is an injection in the back).   The nature of these injections 
will differ slightly in each group so that the two different anaesthetic techniques can be compared.  
As all patients will receive both an injection in the back and an injection in the groin, neither 
patient nor doctor will know what group they are in.  This will make the results of the study more 
reliable.   
 
Patients in Group 1 will receive a nerve block (injection in the groin) using ultrasound imaging.  
The nerve block will be performed using local anaesthetic in order to provide pain relief after the 
surgery.  Patients will then receive a spinal anaesthetic (injection in the back) which contains 
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local anaesthetic but which does not contain any morphine.  The spinal injection will make the 
patient numb from the waist down so that the surgery can be performed. 
 
Patients in Group 2 will again receive a nerve block (injection in the groin) using ultrasound 
imaging.  In this group, saline (salty water) rather than local anaesthetic will be used to perform 
the nerve block.  Patients in this group will again receive a spinal injection (injection in the back) 
which will make them numb from the waist down.  In this group, the spinal injection will also 
contain morphine to provide post-operative pain relief.   
 
The techniques described are not new and are commonly performed for this type of operation.  
The techniques described will be performed by an experienced anaesthetic doctor.  Patients will 
be offered medicine (if they wish) which will make them feel sleepy during the operation.  This 
can be discussed with the anaesthetic doctor.   
 
After the operation, both groups of patients will receive pain killers.  This will consist of 
Paracetamol as well as a pump containing morphine.  The morphine pump provides you with pain 
relief when you need it and will give you a dose of pain killer when you press a button on a 
handset.  This is a standard method of giving pain relief after major surgery.  You cannot take too 
much morphine using this pump as there are many safety features which prevent this. 
 
After the operation, you will receive oxygen through an oxygen mask while you are using the 
morphine pump.  This is routine when using this type of pain relief.  You will be monitored each 
hour initially by nursing staff on the ward.  The physiotherapy team will do exercises with you 
with the aim of getting you up onto your feet within 1 day of your operation.  Again, this is 
routine after a hip operation.  Information will also be collected by a member of the study team 
regarding your levels of pain, mobility, satisfaction with the technique and whether any other side 
effects of the pain relief occurred. This will occur while you are in hospital.  The surgeon who 
performed your operation will see you at a clinic 3 months after your operation as is routine for 
all patients having this type of surgery. 
 
What happens to the information? 
Your identity and personal information will be completely confidential and known only to the 
researchers. The information obtained will remain confidential and stored within a locked filing 
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cabinet for a period of 10 years. The data are held in accordance with the Data Protection Act, 
which means that we keep it safely and cannot reveal it to other people, without your permission.  
 
What are the possible benefits of taking part? 
It is hoped that by taking part in this research, you will be providing valuable information 
regarding the best way to provide pain relief after hip surgery.  We hope that we can help to 
identify the best way to provide pain relief while keeping any side effects to the lowest possible 
level.   
 
Are there any risks? 
As with all type of anaesthetic there are risks. Both groups will receive a spinal anaesthetic which 
is a standard and commonly used anaesthetic for hip operations. This, amongst other things, has 
the major benefit of avoiding the risks of a general anaesthetic.  
 
Spinal anaesthesia is safe but common side effects include feeling sick, fall in blood pressure and 
difficulty passing urine afterwards.  There is also a small chance of a headache. Nerve damage is 
a rare complication of a spinal anaesthetic. The symptoms include numbness or weakness.  Most 
of the time this is short lived and resolves after a few weeks to months.  In very rare cases, nerve 
damage can be permanent.  Other rare risks include infection and abscess formation.  The risk of 
permanent damage or paralysis due to spinal anaesthesia is estimated to be around 1 in 50,000 
cases).  In the patients receiving morphine in the spinal injection, additional risks include 
drowsiness and breathing problems (very rare) and itch.  It should be noted that the incidence of 
serious side effects is extremely rare and that spinal anaesthesia is currently the technique of 
choice in this hospital to provide anaesthesia for this patient group. 
 
Nerve damage, as described above, is also a rare complication of a nerve block. In the case of the 
nerve block being used in this study however, the needle is not placed near the nerve and we 
believe that this is safer than other nerve blocks as the needle should not be able to damage the 
nerve.  Other risks of a nerve block include pain or bruising at the injection site, failure to be 
effective, infection, seizures and irregular heart rate (very rare). 
 
Who has reviewed the study? 
This study has been reviewed by the West of Scotland Research Ethics Committee 4.  
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If you have any further questions? 
We will give you a copy of the information sheet and signed consent form to keep. If you would 
like more information about the study and wish to speak to someone not closely linked to the 
study, please contact;  Dr Malcolm Booth, Consultant in Anaesthesia and Intensive Care 
Medicine at Glasgow Royal Infirmary, telephone 0141 211 4225 
 
Contacts: 
Rachel Kearns, Anaesthetic Registrar, Glasgow Royal Infirmary; telephone 0141 211 4620 
Alan Macfarlane, Consultant Anaesthetist, Glasgow Royal Infirmary; telephone 0141 211 4620 
 
If you have a complaint about any aspect of the study? 
If you are unhappy about any aspect of the study and wish to make a complaint, please contact:  
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                      Your patient named above has agreed to participate in a clinical research trial titled;  
 
Intrathecal opioid versus ultrasound guided fascia iliaca block for analgesia after 
primary hip arthroplasty 
 
The research is being carried out by Dr Rachel Kearns, Dr Alan Macfarlane, Dr Keith Anderson 
and Professor John Kinsella from the Department of Anaesthesia, Pain and Critical Care 
Medicine in Glasgow Royal Infirmary.  
 
This study is being performed to investigate the optimal way to provide anaesthesia and 
pain relief for patients undergoing hip surgery.  We plan to compare a nerve block 
(ultrasound guided fascia iliaca plane block) and a spinal injection containing only local 
anaesthetic, with a sham nerve block and a spinal injection containing intrathecal 
morphine.  We hypothesise that ultrasound guided fasca iliaca plane block will provide 
analgesia equivalent to that of intrathecal morphine for primary hip arthroplasty in the 
first 48 hours after surgery and will therefore remove the need to use intrathecal opioid.  
As intrathecal opioids have some significant side effects, this may provide some benefits 
in susceptible patients.   
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Participation in this trial will involve undergoing one of the two treatment arms in a 
blinded fashion and receiving follow up by the research team on the ward for 48 hours 
post-operatively.  Patients will be reviewed 3 months after discharge at the arthroplasty 
clinic as is routine for all patients undergoing hip surgery.     
 
Risks of participation relate to spinal anaesthesia and peripheral nerve blockade.  If a 
patient who has participated in this trial consults you with any symptoms which you 
consider may be related to one of the trial procedures, we would be most grateful if you 
could contact us using the contact details below. 
 






ST6 in Anaesthesia 
Telephone:  0141 2114620 
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 Intrathecal opioid versus ultrasound guided fascia iliaca 
block for analgesia after primary hip arthroplasty 
 
Consent Form  
 
Please initial the BOX          Please initial box 
 
I confirm that I have read and understand the information sheet dated 26/05/2011 (version 
1.4) for the above study and have had the opportunity to ask questions 
 
I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights 
being affected.  
 
I understand that sections of my medical notes may be looked at by the research 
team where it is relevant to my taking part in the research. I give my permission 
for the research team to have access to my records. 
 









---------------------------------------               -----------------         ---------------------------------- 
Name of Participant           Date      Signature 
 
 
---------------------------------------               -----------------          --------------------------------- 
Name of Researcher           Date       Signature 
 
 
1 copy to the patient, 1 copy to the researcher, 1 Original for the patients’ notes 
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 University Section of Anaesthesia,  
Walton Building, Glasgow Royal Infirmary,  
91, Wishart Street, Glasgow, G31 2HT 
 
Intrathecal opioid versus ultrasound guided fascia iliaca plane block for 
analgesia after primary hip arthroplasty study. 
 
Patient Data Collection Sheet 
Version no.: 1.4 (180411)    Patient study no.___________ 
 




Inclusion criteria (all must be present) 
English-speaking  □  Competent to give consent     □ 
ASA physical status I – III □  18-85 years of age, inclusive     □ 
50-110 kg  inclusive  □  For unilateral primary hip arthroplasty  □ 
 
Exclusion criteria (none must be present) 
Infection at injection site  □  Hypovolaemia   □ 
Raised intracerebral pressure  □  Coagulopathy   □ 
Malignancy at injection site  □  Allergy to opioids / LA □ 
Pregnancy    □  Alcohol / drug dependency     □ 
Patient preference for general anaesthesia      □ 
Peripheral neuropathy or neurologic disorder affecting the lower extremity  □ 
Long term opioid intake(MST,Oramorph,oxycontin,oxynorm,sevredol,fentanyl)    □ 
Significant psychiatric conditions that may affect patient assessment  □ 
 
Consent 
Consent obtained      yes  □ no   □ 
Copy of consent form to patient / notes / research file yes  □ no   □ 
Date: 
Signature of personnel obtaining consent        ______________________ 
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Intrathecal opioid versus ultrasound guided fascia iliaca plane block for 
analgesia after primary hip arthroplasty study. 
 
Patient Data Collection Sheet 
Version no.: 1.4   (180411)    Patient study no.___________ 
 
Researcher; Dr Rachel Kearns    
 
Demographics 
Age                                                          Weight    Height 




HR   BP (baseline)    SpO2 
 
 
Fascia Iliaca Block 
Time to perform (from skin cleansing to finish): _____minutes 
 
Adverse events: 
Vessel puncture                            □ Paraesthesia  □ 






Bloody tap                                    □ Paraesthesia  □ 
Local anaesthetic toxicity             □ Pain on injection □ 




Surgeon  : 
Duration of surgery : 
Estimated blood loss : 
Time of end of surgery (ie time of leaving theatre = time zero):   
 
Requirement for GA :         yes  □ no   □ 
 
 
Paracetamol 1g administered pre-operatively yes  □ no   □ 
Anti-emetic administered intra-operatively yes  □ no   □ why……... 
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 Intrathecal opioid versus ultrasound guided fascia iliaca plane block for 
analgesia after primary hip arthroplasty study. 
 
Patient Data Collection Sheet 
Version no.: 1.4   (180411)    Patient study no.___________ 
 








IV PCA Morphine consumption (mg) from end of surgery 
 
3 hours     ______ 24 hours    _______ 
6 hours     ______  (if available) 
12 hours   ______ 48 hours    _______  (if available) 
**Total dose of oxynorm received by patient in first 48 hour period:____________ 
                                                                                                               (see kardex) 
 
  
Pain scores (VAS 0 – 10) – document at rest and on movement (R / M) –   NB.  If PCA 
discontinued at 24 hours, pain scores etc should be available from obs / MEWS chart 
           
3 hours     ___/___ 24 hours    ____/___ 
6 hours     ___/___ 36 hours    _______   




Respiratory depression in 1st 48 hours post-operatively  
Respiratory rate < 8       □    no. of readings ____ 
Naloxone administered for respiratory depression  □    no. of doses     ____ 
 
 
Hypotension in 1st 48 hours post-operatively – Baseline BP is that recorded on pre-op 
checklist 
Systolic BP < 80mmHg      □   no. of readings ____ 
Systolic BP > 25% less than baseline BP ( _____ )  □   no. of readings ____ 
Vasopressors required post-operatively    □   no. of doses     ____  
 
 
Urinary retention in 1st 48 hours post-operatively 
Urinary retention requiring catheterisation □    
 
 
PONV in 1st 48 hours post-operatively 
Nausea score > 2      □   no. of readings ____ 
Nausea requiring anti-emetic     □   no. of doses      ____ 
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Intrathecal opioid versus ultrasound guided fascia iliaca plane block for 
analgesia after primary hip arthroplasty study. 
 
Patient Data Collection Sheet 
Version no.: 1.4   (180411)    Patient study no.___________ 
 
Researcher; Dr Rachel Kearns    
 
 
Pruritus in 1st 48 hours post-operatively 
Requiring treatment with naloxone    □   no. of doses      ____ 
Itch felt to be distressing to the patient    □ 
 
 
Sedation in 1st 48 hours post-operatively 
Sedation score > 2      □   no. of readings ____ 
Sedation requiring treatment with naloxone   □   no. of doses      ____ 
 
 
Time to first mobilisation (bed to chair) from time zero (end of surgery) 
Time in hours   _______________ 
Did patient achieve mobilisation at first attempt?   yes  □ no   □ 
   
 
 
Quadriceps strength pre mobilisation as graded by physiotherapists on post-operative 
day 1 using MRC power assessment scale (0 - 5) 
 
Grade      
 
 
Patient satisfaction score (VAS 0 - 100mm) 
At 48 hours       □ 




Adverse event / serious adverse event reported?  yes  □ no   □  
 
Please refer any AE / SAE to Rachel Kearns 
 
Email:  rachel.harrison890@gmail.com 
 
Mobile:  07890524153 
 





































p value Missing 
data 




240 (180-300) 0·67 5 
FI vessel puncture  
N (%) 
0 0 NA 0 
FI paraesthesia on 
injection 
N (%) 
1 (2%) 0 0·99 0 
Spinal bloody tap  
N (%) 
0 0 NA 0 
Spinal paraesthesia on 
insertion 
N (%) 
0 3 (5·77%) 0·23 0 
Spinal pain on injection  
N (%) 
0 0 NA 0 
Table App 12-Error! No text of specified style in document.-1 - Anaesthetic procedural information (as 
treated)  






















p value Missing 
data 
Surgery time / mins 
Median (IQR) 
88 (73·5-97) 79 (60 – 91·25) 0·06 0 
Surgery blood loss / ml 
Median (IQR) 
300 (200-400) 300 (200-400) 0·84 4 
Pre-op paracetamol  
N (%) 
33(64·7%) 41(78·8%) 0·17 0 
Intra-op anti-emetic  
N (%) 
3 (2·9%) 1 (1·0%) 0·60 0 
Table App 12-2  – Surgical information (as treated) 
















guided  Fascia 
Iliaca Block 
(n=52) 
p value Missing 
data 
No. patients with 
respiratory depression < 
8 breaths per min  
N (%) 
0 0 NA 0 
No. patients with 
episodes of SBP < 
80mmHg  
N (%) 
1 (1·96%) 6 (11·54%) 0·12 0 
No. patients with 
episodes of SBP > 25% 
under baseline N (%) 
25 (49·02%) 29 (55·77%) 0·63 0 
No. patients given post-
operative vasopressor  
N (%) 





20 (39·22%) 15 (28·85%) 0·37 0 
Patients with PONV 
score >2  
N (%) 
7 (13·73%) 9 (17·3%) 0·82 0 
No. patients requiring 
anti-emetics, N (%) 
25 (49·02%) 24(46·15%) 0·93 0 
No. patients with 
pruritus requiring 
treatment, N (%) 
2 (3·92%) 1 (1·92%) 0·99 0 
Pruritus considered to 
be distressing  
N (%) 
6 (11·76%) 3 (5·77%) 0·47 0 
Patients with episodes 
of sedation score > 2  
N (%) 




0 0 NA 0 
Time of 1st mobilisation/ 
hrs Median (IQR) 
23 (19-25·5) 25 (20-42) 0·04 3 
Mobile on 1st attempt  
N (%) 
44 (86·27%) 38 (73·08%) 0·16 0 
Power grade at 1st 
mobilisation attempt 
Median (IQR) 
4 (4-5) 4(4-5) 0·06 7 
Patient satisfaction at 
48 hrs  
Median, IQR 
76(59-89) 80(50-89) 0·57 9 
Residual paraesthesia at 
48hrs  
N (%) 
1 (1·96%) 0 (0) 0·99 0 
Adverse events 
N (%) 
3 (58·82%) 3 (57·69%) 1 0 
SAE  
N (%) 
2 (3·92%) 4 (7·69%) 0·69 0 
 
Table App 12-3  – Secondary outcomes (as treated) 
SBP = systolic blood pressure, PONV = post-operative nausea and vomiting, SAE = serious adverse 
event, NA = not applicable.  P values reaching statistical significance (p<0.05) are highlighted in yellow. 
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